WO2021190425A1 - TRANSFORMING GROWTH FACTOR-β RECEPTOR INHIBITOR - Google Patents
TRANSFORMING GROWTH FACTOR-β RECEPTOR INHIBITOR Download PDFInfo
- Publication number
- WO2021190425A1 WO2021190425A1 PCT/CN2021/081965 CN2021081965W WO2021190425A1 WO 2021190425 A1 WO2021190425 A1 WO 2021190425A1 CN 2021081965 W CN2021081965 W CN 2021081965W WO 2021190425 A1 WO2021190425 A1 WO 2021190425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- alkyl
- cycloalkyl
- group
- Prior art date
Links
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 title abstract description 10
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 212
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 108091005735 TGF-beta receptors Proteins 0.000 claims abstract description 10
- -1 Gonarelin analogs Chemical compound 0.000 claims description 59
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 239000002207 metabolite Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 claims description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims description 2
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 claims description 2
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 2
- 239000002139 L01XE22 - Masitinib Substances 0.000 claims description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010062038 Lip neoplasm Diseases 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 201000005027 Lynch syndrome Diseases 0.000 claims description 2
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 2
- FOFDIMHVKGYHRU-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-4-(4-benzofuro[3,2-d]pyrimidinyl)-1-piperazinecarbothioamide Chemical compound C12=CC=CC=C2OC2=C1N=CN=C2N(CC1)CCN1C(=S)NCC1=CC=C(OCO2)C2=C1 FOFDIMHVKGYHRU-UHFFFAOYSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 claims description 2
- 108010064641 ONX 0912 Proteins 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- HZLFFNCLTRVYJG-WWGOJCOQSA-N Patidegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- 206010043276 Teratoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 239000004012 Tofacitinib Substances 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 229960001686 afatinib Drugs 0.000 claims description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 229950009447 alisertib Drugs 0.000 claims description 2
- 229950009545 amuvatinib Drugs 0.000 claims description 2
- 229960003982 apatinib Drugs 0.000 claims description 2
- 229960003005 axitinib Drugs 0.000 claims description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003736 bosutinib Drugs 0.000 claims description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960002412 cediranib Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 2
- 229950009240 crenolanib Drugs 0.000 claims description 2
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- 229960002448 dasatinib Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960001251 denosumab Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002074 flutamide Drugs 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- 229950008692 foretinib Drugs 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 229950004161 ganetespib Drugs 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960000578 gemtuzumab Drugs 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 229960001507 ibrutinib Drugs 0.000 claims description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 229950002133 iniparib Drugs 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 2
- 229960002014 ixabepilone Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 229960003784 lenvatinib Drugs 0.000 claims description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- 229950002216 linifanib Drugs 0.000 claims description 2
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims description 2
- 229950001762 linsitinib Drugs 0.000 claims description 2
- PKCDDUHJAFVJJB-VLZXCDOPSA-N linsitinib Chemical compound C1[C@](C)(O)C[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PKCDDUHJAFVJJB-VLZXCDOPSA-N 0.000 claims description 2
- 201000006721 lip cancer Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229960004655 masitinib Drugs 0.000 claims description 2
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 claims description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229950008814 momelotinib Drugs 0.000 claims description 2
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 2
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims description 2
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001346 nilotinib Drugs 0.000 claims description 2
- 229950011068 niraparib Drugs 0.000 claims description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229960002450 ofatumumab Drugs 0.000 claims description 2
- 229960000572 olaparib Drugs 0.000 claims description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229950005750 oprozomib Drugs 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 229950004941 pictilisib Drugs 0.000 claims description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000624 procarbazine Drugs 0.000 claims description 2
- 229950001626 quizartinib Drugs 0.000 claims description 2
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 229950006764 rigosertib Drugs 0.000 claims description 2
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229950004707 rucaparib Drugs 0.000 claims description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 2
- 229960000215 ruxolitinib Drugs 0.000 claims description 2
- 229960005569 saridegib Drugs 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 229950005976 tivantinib Drugs 0.000 claims description 2
- 229960001350 tofacitinib Drugs 0.000 claims description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- 229960004066 trametinib Drugs 0.000 claims description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- 229950003081 volasertib Drugs 0.000 claims description 2
- SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 1
- 229950002205 dacomitinib Drugs 0.000 claims 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960001786 megestrol Drugs 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 64
- 238000006243 chemical reaction Methods 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 238000003786 synthesis reaction Methods 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 238000005481 NMR spectroscopy Methods 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 19
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 18
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 18
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 239000012043 crude product Substances 0.000 description 14
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- OUBORTRIKPEZMG-UHFFFAOYSA-N INT-2 Chemical compound Nc1c(ncn1-c1ccc(F)cc1)C(=N)C#N OUBORTRIKPEZMG-UHFFFAOYSA-N 0.000 description 11
- 101001060278 Xenopus laevis Fibroblast growth factor 3 Proteins 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000006165 cyclic alkyl group Chemical group 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229950000456 galunisertib Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003350 kerosene Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 3
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 0 CCOC(c1c(cc(cc2)-c3c(C4CC4)[n](*)nc3-c(cc3)ccc3F)[n]2nc1)=O Chemical compound CCOC(c1c(cc(cc2)-c3c(C4CC4)[n](*)nc3-c(cc3)ccc3F)[n]2nc1)=O 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 102000049939 Smad3 Human genes 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 2
- 125000005955 1H-indazolyl group Chemical group 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- 238000003727 ADP Glo Kinase Assay Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 101000810330 Arabidopsis thaliana Eukaryotic translation initiation factor 3 subunit E Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 102000057208 Smad2 Human genes 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- PYAIUESAGBXTTQ-UHFFFAOYSA-N 1,1-difluoroethyl acetate Chemical compound CC(=O)OC(C)(F)F PYAIUESAGBXTTQ-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LKENTYLPIUIMFG-UHFFFAOYSA-N 1-cyclopentylethanone Chemical compound CC(=O)C1CCCC1 LKENTYLPIUIMFG-UHFFFAOYSA-N 0.000 description 1
- HVCFCNAITDHQFX-UHFFFAOYSA-N 1-cyclopropylethanone Chemical compound CC(=O)C1CC1 HVCFCNAITDHQFX-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- NEUWPDLMDVINSN-UHFFFAOYSA-N 1h-pyrazol-5-ylboronic acid Chemical compound OB(O)C=1C=CNN=1 NEUWPDLMDVINSN-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- ZTBGDNNRDRISQZ-UHFFFAOYSA-N 2-bromo-6-(difluoromethyl)pyridine Chemical compound FC(F)C1=CC=CC(Br)=N1 ZTBGDNNRDRISQZ-UHFFFAOYSA-N 0.000 description 1
- DOWNSQADAFSSAR-UHFFFAOYSA-N 2-bromo-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC(Br)=N1 DOWNSQADAFSSAR-UHFFFAOYSA-N 0.000 description 1
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- QGFYFOHMBDMGBZ-UHFFFAOYSA-N 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol Chemical compound C1=C(O)C(CN(CC)CC)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 QGFYFOHMBDMGBZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WQOAKXFBWOXJNG-UHFFFAOYSA-N Brc1cc2ccn[n]2cc1 Chemical compound Brc1cc2ccn[n]2cc1 WQOAKXFBWOXJNG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- BJLDVHOVNHJAOT-UHFFFAOYSA-N CC(c1c(cc(cc2)-c3c(C4CC4)[nH]nc3-c(cc3)ccc3F)[n]2nc1)=O Chemical compound CC(c1c(cc(cc2)-c3c(C4CC4)[nH]nc3-c(cc3)ccc3F)[n]2nc1)=O BJLDVHOVNHJAOT-UHFFFAOYSA-N 0.000 description 1
- PYDMJYONQKIAFL-UHFFFAOYSA-N CC(c1c(cc(cc2)Br)[n]2nc1)=O Chemical compound CC(c1c(cc(cc2)Br)[n]2nc1)=O PYDMJYONQKIAFL-UHFFFAOYSA-N 0.000 description 1
- AGKFUSKKCQLWPS-UHFFFAOYSA-N CCOC(c1c(cc(cc2)-c3c(C4CC4)[nH]nc3-c(cc3)ccc3F)[n]2nc1)=O Chemical compound CCOC(c1c(cc(cc2)-c3c(C4CC4)[nH]nc3-c(cc3)ccc3F)[n]2nc1)=O AGKFUSKKCQLWPS-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VAXJGDZVHAXVSL-UHFFFAOYSA-N Cc1nc(-c2n[nH]cc2-c2cc3ccn[n]3cc2)ccc1 Chemical compound Cc1nc(-c2n[nH]cc2-c2cc3ccn[n]3cc2)ccc1 VAXJGDZVHAXVSL-UHFFFAOYSA-N 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- NSVFUOSGXKSNDE-UHFFFAOYSA-N NC(c1c(cc(cc2)-c3c(CO)[nH]nc3-c(cc3)ccc3F)[n]2nc1)=O Chemical compound NC(c1c(cc(cc2)-c3c(CO)[nH]nc3-c(cc3)ccc3F)[n]2nc1)=O NSVFUOSGXKSNDE-UHFFFAOYSA-N 0.000 description 1
- 208000008846 Neurocytoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- GEQJAPXMQSCIFA-UHFFFAOYSA-N OCc1c(cc(cc2)-c3c(C4CC4)[nH]nc3-c(cc3)ccc3F)[n]2nc1 Chemical compound OCc1c(cc(cc2)-c3c(C4CC4)[nH]nc3-c(cc3)ccc3F)[n]2nc1 GEQJAPXMQSCIFA-UHFFFAOYSA-N 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 108700032504 Smad2 Proteins 0.000 description 1
- 108700031297 Smad3 Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000005239 aroylamino group Chemical group 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- AYABEJGGSWJVPN-UHFFFAOYSA-N methyl 6-(trifluoromethyl)pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C(F)(F)F)=N1 AYABEJGGSWJVPN-UHFFFAOYSA-N 0.000 description 1
- CYWIZMOZBTXFIL-UHFFFAOYSA-N methyl 6-methylpyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C)=N1 CYWIZMOZBTXFIL-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- IHUQJPKASFTOBM-UHFFFAOYSA-N n-(2,4-dinitrophenyl)hydroxylamine Chemical compound ONC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O IHUQJPKASFTOBM-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010922 spray-dried dispersion Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DRZYCRFOGWMEES-UHFFFAOYSA-N tert-butyl n-pyridin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=NC=C1 DRZYCRFOGWMEES-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000005403 thiohaloalkoxy group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention provides a new type of heterocyclic compound, its preparation method and its application as TGF- ⁇ receptor (especially TGF ⁇ RI) antagonist.
- Transforming growth factor- ⁇ (transforming growth factor- ⁇ , TGF- ⁇ ) is a multifunctional growth factor and cytokine. It is combined with activins, inhibitors, and Mullerian inhibitors. Substance, MIS) and bone morpho-genetic proteins (BMPs) and other related proteins form the transforming growth factor- ⁇ superfamily. It can participate in the regulation of a variety of biological processes, including cell proliferation, differentiation, development, and modification of extracellular matrix (including tumor matrix and immunosuppression, angiogenesis and fibrous tissue generation).
- MIS transforming growth factor- ⁇
- BMPs bone morpho-genetic proteins
- TGF- ⁇ RI type I
- TGF ⁇ RII type II
- TGF ⁇ RIII type III
- the signal transduction in the TGF- ⁇ signaling pathway is mainly through the combination of TGF- ⁇ ligand with the serine/threonine kinase receptor TGF ⁇ RI (ALK5) and TGF ⁇ RII on the cell surface to form a heterotetrameric complex, and then TGF ⁇ RII interacts with TGF ⁇ RI
- ALK5 serine/threonine kinase receptor
- TGF ⁇ RII TGF ⁇ RI
- the glycine/serine region phosphorylates and activates the phosphorylation of TGF ⁇ RI to the intracellular signaling protein Smad protein molecule-Smad2/Smad3 that is connected to it.
- TGF ⁇ RIII transforming growth factor- ⁇ III receptor
- TGF- ⁇ plays a key role in the occurrence and progression of fibrosis in different organ systems such as heart, liver, lung, and kidney.
- Abnormal TGF- ⁇ signaling is related to many human diseases, such as cancer, cardiovascular disease, inflammation, organ fibrotic disease, pancreatic disease, etc.
- the dysregulation of TGF- ⁇ signaling is very common, which can promote tumor cell growth and differentiation, and regulate extracellular matrix and epithelial-mesenchymal transition.
- TGF- ⁇ has been proven to play an important role in regulating anti-tumor immunity.
- TGF- ⁇ has a strong inhibitory effect on the differentiation of T lymphocytes, and has a significant negative effect on dendritic cells, CD8 + T cells and NK cells. At the same time, it can enhance immunosuppressive T reg and bone marrow-derived suppressor cells (MDSC). ), thereby providing a favorable tumor microenvironment for tumor growth and metastasis. Therefore, inhibiting the signal transduction of a certain link in the TGF- ⁇ signaling pathway may become one of the effective methods for the treatment of tumors.
- MDSC bone marrow-derived suppressor cells
- TGF ⁇ RI As an important node in the TGF- ⁇ signaling pathway, TGF ⁇ RI (ALK5) is considered to be an important target for tumor treatment. By preventing the binding of TGF ⁇ RI to ligands, it inhibits the phosphoric acid of ALK5 on its downstream signaling protein (Smad2 or Smad3). In order to prevent and treat various related diseases mediated by ALK5, it can affect or block TGF- ⁇ signal transmission.
- Cy represents a C 6 -C 10 aryl group or a 5-10 membered heteroaryl group substituted by 0, 1, 2 or 3 substituents, wherein the substituents are selected from: halogen, C 1 -C 6 alkyl , C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl, -OR a , cyano, nitro, NR a R b , -SO 2 R a , -C(O)R a ,- C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;
- R 1 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl;
- R 2 represents hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl, -OR a , cyano, Nitro, NR a R b , -SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -NR a C(O)R b , -SO 2 NR a R b , -NR a SO 2 R b ;
- R 3 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl, -OR a , cyanide Group, nitro group, NR a R b , -SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -NR a C(O)R b , -SO 2 NR a R b , -NR a SO 2 R b ;
- R 4 represents hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, halogenated C 1 -C 6 alkyl, -OR a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , hydroxyl (C 1 -C 6 alkyl);
- R 5 represents hydrogen, C 1 -C 6 alkyl, C 2- C 6 alkene Group, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl; or R 4 , R 5 together with the atoms they are connected together form a 5-8 membered saturated and unsaturated ring, and the ring can also Randomly contain 0, 1 or 2 heteroatoms selected from N, O, S;
- R a and R b each independently represent hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, or halogenated C 1 -C 6 alkyl; or R a, R b form together with the atoms to which they are attached a 5-8 membered ring which may also optionally contain 1 or 2 heteroatoms selected from N, O, S, heteroatoms;
- n 0, 1, 2 or 3.
- the compound of formula (I) has the following structure of formula (II):
- R 1, R 3, R 4 , R 5, R a, R b and n have the meanings according to claim 1;
- R 2 represents hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl;
- W represents CR L or N
- R 6 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl, -OR a , cyano, nitro, NR a R b ,- SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;
- R L represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl, -OR a , cyano, nitro, NR a R b ,- SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;
- o 0, 1, 2 or 3.
- the compound of the present invention is selected from the following structures:
- the compounds of the present invention can also be prepared in the form of pharmaceutically acceptable salts, which can be formed using, for example, the following inorganic or organic acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid , Lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxyl Benzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid or toluenesulfonic acid.
- inorganic or organic acids hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid , Lactic acid,
- the pharmaceutically acceptable salt of the present invention can be prepared by conventional methods, for example, by dissolving the compound of the present invention in an organic solvent miscible with water (such as acetone, methanol, ethanol, and acetonitrile), and adding an excessive amount of organic acid or An aqueous inorganic acid solution is used to precipitate the salt from the resulting mixture, the solvent and remaining free acid are removed therefrom, and then the precipitated salt can be separated.
- an organic solvent miscible with water such as acetone, methanol, ethanol, and acetonitrile
- the compound of the present invention may include a solvate form, preferably, the solvate is a hydrate.
- the present invention also provides the use of the compound of the present invention in the preparation of a medicine for preventing or treating diseases that can be regulated by inhibiting the activity of ALK5.
- the disease is selected from cancer, tumor, inflammatory disease, autoimmune disease and immune-mediated disease.
- the present invention provides a pharmaceutical composition for preventing or treating cancer, tumor, inflammatory disease, autoimmune disease, neurodegenerative disease, attention-related disease or immune-mediated disease, which comprises the formula of the present invention (I) Compound as active ingredient.
- the present invention provides a method for preventing or treating cancer, tumor, inflammatory disease, autoimmune disease, neurodegenerative disease, attention-related disease or immune-mediated disease, which includes Of mammals administer the compounds of the invention.
- cancer or tumors may include, but are not limited to, skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, pancreatic cancer, prostate cancer, colon cancer, lung cancer, bone cancer, brain cancer, neurocytoma, rectal cancer , Colon cancer, familial adenomatous polyposis cancer, hereditary non-polyposis colorectal cancer, esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, gastric cancer, adenocarcinoma, medullary thyroid cancer, Papillary thyroid cancer, kidney cancer, renal parenchymal cancer, ovarian cancer, cervical cancer, uterine body cancer, endometrial cancer, choriocarcinoma, testicular cancer, urinary cancer, melanoma, brain tumors such as glioblastoma, Astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodg
- the compound of the present invention or a pharmaceutically acceptable salt thereof when administered in combination with another anticancer agent or checkpoint inhibitor for the treatment of cancer or tumor, the compound of the present invention or a pharmaceutically acceptable salt thereof can provide an enhanced anticancer effect.
- anticancer agents for the treatment of cancer or tumors may include, but are not limited to, cell signal transduction inhibitors, chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carbohydrate Mustine, lomustine, streptozotocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, Mercaptopurine, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectidine, dactinomycin, doxorubicin , Epirubicin, daunomycin, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxi
- inflammatory diseases may include, but are not limited to, arthritis, rheumatoid arthritis, spondyloarthritis, gouty arthritis, osteoarthritis, juvenile arthritis , Other arthritic conditions, lupus, systemic lupus erythematosus (SLE), skin-related diseases, psoriasis, eczema, dermatitis, allergic dermatitis, pain, lung disease, lung inflammation, adult respiratory distress syndrome (ARDS) , Pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, atherosclerosis, myocardial infarction, congestive heart failure, myocardial ischemia reperfusion injury, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, asthma, Sjogren's syndrome, autoimmune thyroid disease, urticaria (rubella), multiple sclerosis,
- the compound of the present invention or a pharmaceutically acceptable salt thereof when administered in combination with another therapeutic agent for the treatment of inflammatory diseases, autoimmune diseases and immune-mediated diseases, the compound of the present invention or a pharmaceutically acceptable salt thereof can provide enhanced Therapeutic effect.
- therapeutic agents for the treatment of inflammatory diseases, autoimmune diseases, and immune-mediated diseases may include, but are not limited to, steroid drugs (e.g., prednisone, hydroprednisolone, methylhydroprednisolone) Pine, cortisone, hydroxycortisone, betamethasone, dexamethasone, etc.), methotrexate, leflunomide, anti-TNF ⁇ agents (e.g., Etanercept, Infliximab, Adali Monoclonal antibodies, etc.), calcineurin inhibitors (e.g., tacrolimus, pimecrolimus, etc.) and antihistamines (e.g., diphenhydramine, hydroxyzine, loratadine, ebas , Ketotifen, cetirizine, levocetirizine, fexofenadine, etc.), and at least one therapeutic agent selected from them may be included in the pharmaceutical composition of the present invention.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be administered orally or parenterally as an active ingredient, and its effective amount ranges from 0.1 to 2,000 mg/kg body weight/day in the case of mammals including humans (body weight of about 70 kg). It is preferably 1 to 1,000 mg/kg body weight/day, and administered in a single or 4 divided doses per day, or following/not following a predetermined time.
- the dosage of the active ingredient can be adjusted according to a number of relevant factors (such as the condition of the subject to be treated, the type and severity of the disease, the rate of administration, and the doctor's opinion). In some cases, an amount less than the above dosage may be appropriate. If it does not cause harmful side effects, an amount larger than the above dose can be used and the amount can be administered in divided doses per day.
- the pharmaceutical composition of the present invention can be formulated into dosage forms for oral administration or parenteral administration (including intramuscular, intravenous and subcutaneous routes) according to any of the conventional methods, such as tablets, granules, powders, capsules, syrups , Emulsion, microemulsion, solution or suspension.
- the pharmaceutical composition of the present invention for oral administration can be prepared by mixing the active ingredient with a carrier such as the following: cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, hard Magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers and diluents.
- a carrier such as the following: cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, hard Magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers and diluents.
- carriers used in the injection composition of the present invention are water, salt solution, glucose solution, glucose-like solution, alcohol, glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester,
- the compounds of the present invention can be prepared in a variety of ways known to those skilled in the field of organic synthesis, and the compounds of the present invention can be synthesized using synthetic methods known in the field of organic synthetic chemistry or through variations known to those skilled in the art. .
- the desired reaction can be carried out in a solvent or solvent mixture suitable for the kit materials used and suitable for the transformation achieved.
- the present invention describes the cis- and trans- (or E- and Z-) geometric isomers of the compounds of the present invention, and they can be separated into a mixture of isomers or separate isomer forms.
- the compounds of the present invention can be isolated in optically active or racemic form.
- the compounds of the present invention may exist in a variety of tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecule and the chemical bonds between the atoms of the molecule are thus rearranged. It should be understood that all tautomeric forms that may exist are included in the present invention.
- substituent is selected from, for example, the following substituents such as alkyl, cycloalkyl, aryl, heterocyclyl, halogen, hydroxy, Alkoxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amine groups (two of the amino substituents are selected (From alkyl, aryl or arylalkyl), alkanoylamino, aroylamino, aralkanoylamino, substituted alkanoylamino, substituted arylamino, substituted aralkanoylamino, thio, alkyl Thio, arylthio, arylalkylthio, arylthiocarbonyl, arylalkylthiocarbonyl, alkylsul
- substituents such as alkyl, cycloalkyl,
- alkyl or "alkylene” as used herein is intended to include branched or straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- C 1 -C 6 alkyl means an alkyl group having 1 to 6 carbon atoms.
- alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl) and Pentyl (e.g., n-pentyl, isopentyl, neopentyl).
- Preferred alkyl groups are C 1 -C 6 alkyl groups, and more preferred alkyl groups are C 1 -C 4 alkyl groups.
- alkenyl refers to a straight or branched hydrocarbon group containing one or more double bonds and usually having a length of 2 to 20 carbon atoms.
- C 2 -C 8 alkenyl contains two to eight carbon atoms.
- Alkenyl includes, but is not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl, and the like.
- a preferred alkenyl group is a C 2 -C 8 alkenyl group, and a more preferred alkenyl group is a C 2 -C 6 alkenyl group.
- alkynyl means a straight or branched hydrocarbon group containing one or more triple bonds and usually having a length of 2 to 20 carbon atoms.
- C 2 -C 8 alkynyl contains two to eight carbon atoms.
- a preferred alkynyl group is a C 2 -C 8 alkynyl group, and a more preferred alkenyl group is a C 2 -C 6 alkynyl group.
- Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and the like.
- alkoxy refers to -O-alkyl.
- C 1 -C 6 alkoxy (or alkyloxy) is intended to include C 1 , C 2 , C 3 , C 4 , C 5 and C 6 alkoxy.
- a preferred alkoxy group is a C 1 -C 6 alkoxy group, and a more preferred alkoxy group is a C 1 -C 4 alkoxy group.
- alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (such as n-propoxy and isopropoxy), and tert-butoxy.
- alkylthio or “thioalkoxy” means an alkyl group, as defined above, with the specified number of carbon atoms connected via a sulfur bridge; for example, methyl-S- and ethyl-S-.
- aryl alone or as part of a larger part such as “aralkyl”, “aralkoxy” or “aryloxyalkyl”, refers to a monocyclic ring having a total of 5 to 12 ring members , A bicyclic or tricyclic ring system, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
- a monocyclic aromatic group refers to a phenyl group
- a bicyclic or more aromatic group refers to naphthyl, anthracenyl, etc.
- the aryl bicyclic ring can also be a benzene ring fused with a cycloalkyl group or a ring Alkenyl, or fused with a cycloalkynyl group.
- the preferred aryl group is a C 6 -C 12 aryl group.
- "aryl" refers to an aromatic ring system, which includes, but is not limited to, phenyl, biphenyl, indanyl, 1-naphthyl, 2-naphthyl, and tetrahydronaphthalene base.
- aralkyl or "arylalkyl” refers to an alkyl residue attached to an aryl ring. Non-limiting examples include benzyl, phenethyl, and the like.
- the fused aryl group may be connected to another group at a suitable position on the cycloalkyl ring or aromatic ring.
- Example The arrow line drawn from the ring system indicates that the bond can be connected to any suitable ring atom.
- cycloalkyl refers to a monocyclic or bicyclic cyclic alkyl group.
- the monocyclic cyclic alkyl group refers to a C 3 -C 8 cyclic alkyl group, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornanyl.
- Branched cycloalkyl groups such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl”.
- the bicyclic cyclic alkyl group includes a bridged ring, a spiro ring, or a fused ring cycloalkyl group.
- the preferred cycloalkyl group is a C 3 -C 6 cycloalkyl group.
- cycloalkenyl refers to a monocyclic or bicyclic cyclic alkenyl.
- the monocyclic cyclic alkenyl group refers to a C 3 -C 8 cyclic alkenyl group, including but not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and norbornenyl.
- Branched cycloalkenyl groups such as 1-methylcyclopropenyl and 2-methylcyclopropenyl are included in the definition of "cycloalkenyl”.
- the bicyclic cyclic alkenyl group includes a bridged ring, a spiro ring, or a fused ring cyclic alkenyl group.
- hydroxyalkyl refers to a branched and straight chain saturated aliphatic hydrocarbon group with the specified number of carbon atoms and at least one -OH is attached to the carbon atom of the hydrocarbon group.
- hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl.
- Halo or halogen includes fluorine, chlorine, bromine and iodine.
- Haloalkyl is intended to include branched and straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms and substituted with one or more halogens.
- haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoromethyl Propyl and heptachloropropyl.
- haloalkyl groups also include "fluoroalkyl groups” intended to include branched and straight chain saturated aliphatic hydrocarbon groups having a designated number of carbon atoms and substituted with one or more fluorine atoms.
- Haloalkoxy or "haloalkyloxy” means a haloalkyl group as defined above with the specified number of carbon atoms connected via an oxygen bridge.
- C 1 -C 6 haloalkoxy is meant to include C 1 , C 2 , C 3 , C 4 , C 5 and C 6 haloalkoxy.
- Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluoroethoxy.
- haloalkylthio or “thiohaloalkoxy” means a haloalkyl group as defined above that has the specified number of carbon atoms connected by a sulfur bridge; for example, trifluoromethyl-S- and pentafluoroethyl -S-.
- heteroaryl means a stable 3-membered, 4-membered, 5-membered, 6-membered, or 7-membered aromatic monocyclic or aromatic bicyclic ring or 7-membered, 8-membered, 9-membered, 10-membered, 11-membered, 12-membered , 13-membered or 14-membered aromatic polycyclic heterocyclic ring, which is fully unsaturated, partially unsaturated, and contains carbon atoms and 1, 2, 3 or 4 independently selected from N, O and S And includes any of the following polycyclic groups in which any heterocyclic ring as defined above is fused with a benzene ring. Nitrogen and sulfur heteroatoms can optionally be oxidized.
- the nitrogen atom is substituted or unsubstituted (ie N or NR, where R is H or another substituent if defined).
- the heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. If the resulting compound is stable, the heterocyclic group described herein may be substituted on a carbon or nitrogen atom.
- the nitrogen in the heterocyclic ring can optionally be quaternized.
- the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to each other.
- the total number of S and O atoms in the heterocyclic ring is not more than one.
- Preferred heteroaryl groups are 5-12 membered heteroaryl groups.
- heteroaryl groups include, but are not limited to, acridinyl, azetidinyl, azetidinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothienyl, benzoxazole Group, benzoxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH -Carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3 -b] Tetrahydrofuryl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H
- heterocycloalkyl refers to a monocyclic heterocycloalkyl system, or a bicyclic heterocycloalkyl system, and also includes spiro heterocycles or bridged heterocycloalkyls.
- the monocyclic heterocycloalkyl refers to a 3-8 membered, and at least one saturated or unsaturated but not aromatic cyclic alkyl system selected from O, N, S, and P.
- the bicyclic heterocycloalkyl system refers to a heterocycloalkyl group fused to a phenyl group, or a cycloalkyl group, or a cycloalkenyl group, or a heterocycloalkyl group, or a heteroaryl group.
- a preferred heterocycloalkyl group is a 3-12 membered heterocycloalkyl group.
- substitution means that at least one hydrogen atom is replaced by a non-hydrogen group, provided that the normal valence is maintained and the substitution results in a stable compound.
- nitrogen atoms such as amines
- these nitrogen atoms can be converted into N-oxides by treatment with an oxidizing agent (such as m-CPBA and/or hydrogen peroxide) to obtain the present invention
- an oxidizing agent such as m-CPBA and/or hydrogen peroxide
- any variable occurs more than once in any composition or formula of a compound, its definition at each occurrence is independent of its definition at every other occurrence.
- the group may be optionally substituted with up to three R groups, and R is independently selected from R at each occurrence. definition.
- substituents and/or variables are only allowed if the above-mentioned combinations produce stable compounds.
- solvate means the physical association of a compound of the invention with one or more solvent molecules (whether organic or inorganic). This physical association includes hydrogen bonding. In some cases, such as when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid, the solvate will be able to be separated.
- the solvent molecules in the solvate can be arranged in regular and/or disordered arrangements.
- Solvates may contain stoichiometric or non-stoichiometric solvent molecules.
- “Solvate” encompasses both solution-phase and isolatable solvates. Exemplary solvates include, but are not limited to, hydrate, ethanolate, methanolate, and isopropanolate. Solvation methods are well known in the art.
- patient refers to an organism that is treated by the method of the present invention.
- organisms preferably include, but are not limited to, mammals (e.g., murine, ape/monkey, horse, cow, pig, dog, cat, etc.) and most preferably refer to humans.
- an effective amount means the amount of a drug or agent (ie, a compound of the present invention) that will elicit a biological or medical response of a tissue, system, animal, or human sought by, for example, a researcher or clinician.
- therapeutically effective amount means an amount that results in an improved treatment, cure, prevention, or alleviation of a disease, disorder, or side effect, or reduction in disease, compared to a corresponding subject who has not received the above-mentioned amount. Or the rate of progression of the disease.
- the effective amount can be given in one or more administrations, administrations or doses and is not intended to be limited by a particular formulation or route of administration. The term also includes within its scope an effective amount for enhancing normal physiological functions.
- treatment includes any effect that leads to amelioration of a condition, disease, disorder, etc., such as alleviation, reduction, regulation, amelioration or elimination, or amelioration of its symptoms.
- a certain compound or pharmaceutical composition can improve a certain disease, symptom or condition after administration, especially its severity is improved, the onset is delayed, the progression of the disease is slowed, or the duration of the disease is reduced. Regardless of fixed administration or temporary administration, continuous administration or intermittent administration, it can be attributed to or related to the administration.
- prevention refers to preventing, blocking, eliminating the occurrence of a disease or interfering with or slowing the development of a disease before the occurrence of a disease or symptom.
- composition refers to a combination of an active agent and an inert or active carrier, so that the composition is particularly suitable for in vivo or ex vivo diagnosis or treatment.
- bases include, but are not limited to, alkali metal (e.g., sodium) hydroxide, alkaline earth metal (e.g., magnesium) hydroxide, ammonia, and the like.
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium hydroxide
- ammonia e.g., sodium
- salt of the compound of the present invention is intended for therapeutic use, and the salt of the compound of the present invention is expected to be pharmaceutically acceptable.
- salts of non-pharmaceutical acids and bases can also be used, for example, in the preparation or purification of pharmaceutical compounds.
- immediate is used herein to refer to the following compounds, substances, compositions and/or dosage forms: within the scope of reasonable medical judgment, they are suitable for use in contact with human and animal tissues without excessive toxicity or irritation Sex, allergic reactions, and/or other problems or complications, and are commensurate with a reasonable benefit/risk ratio.
- phrases "pharmaceutically acceptable carrier” and “pharmaceutically acceptable carrier” mean pharmaceutical substances, compositions or vehicles, such as liquid or solid fillers, diluents, excipients, manufacturing aids (e.g. Lubricants, talc, magnesium stearate, calcium stearate or zinc stearate or stearic acid) or solvent encapsulated substances, which involve carrying or transporting the active compound from one organ or part of the body to another organ or Parts of the body.
- manufacturing aids e.g. Lubricants, talc, magnesium stearate, calcium stearate or zinc stearate or stearic acid
- solvent encapsulated substances which involve carrying or transporting the active compound from one organ or part of the body to another organ or Parts of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient.
- acceptable refers to a prescription component or active ingredient that does not have undue harmful effects on the health of the general treatment target.
- cancer refers to an abnormal growth of cells that cannot be controlled and which can metastasize (spread) under certain conditions.
- This type of cancer includes, but is not limited to, solid tumors (such as bladder, intestine, brain, chest, uterus, heart, kidney, lung, lymphoid tissue (lymphoma), ovary, pancreas or other endocrine organs (such as thyroid), prostate , Skin (melanoma) or hematoma (such as non-leukemic leukemia).
- co-administration refers to administering several selected therapeutic drugs to a patient in the same or different modes of administration at the same or different times.
- an “enhance” or “enhance”, as used herein, means that the expected result can be increased or prolonged in terms of potency or duration. Therefore, in terms of enhancing the therapeutic effect of a drug, the term “enhanced” refers to the ability of the drug to increase or extend the potency or duration of the drug in the system. "Synergy value” as used herein refers to the ability of another therapeutic drug to be maximized in an ideal system.
- immune disease refers to a disease or symptom that produces an adverse or deleterious reaction to an endogenous or exogenous antigen. The result is usually cell dysfunction, or destruction and dysfunction, or destruction of organs or tissues that may produce immune symptoms.
- subject or “subject” includes mammals and non-mammals.
- Mammals include, but are not limited to, mammals: humans, non-human primates such as orangutans, apes and monkeys; agricultural animals such as cows, horses, goats, sheep, pigs; domestic animals such as rabbits and dogs; laboratory animals include rodents, Such as rats, mice and guinea pigs.
- Non-mammalian animals include, but are not limited to, birds, fish, etc.
- the selected mammal is a human.
- Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transdermal, vaginal, and otic administration , Nasal administration and local administration.
- parenteral administration includes intramuscular injection, subcutaneous injection, intravenous injection, intramedullary injection, ventricular injection, intraperitoneal injection, intralymphatic injection, and intranasal injection.
- the mode of administration of the compounds described herein is a local rather than a systemic mode of administration.
- the long-acting formulation is administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
- the drug is administered through a targeted drug delivery system.
- liposomes encapsulated by organ-specific antibodies In this specific embodiment, the liposomes are selectively targeted to specific organs and absorbed.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of the present invention formulated together with one or more pharmaceutical carriers (additives) and/or diluents, and optionally one One or more of the above-mentioned other therapeutic agents.
- the compound of the present invention can be administered by any suitable means for any of the above-mentioned purposes, for example, oral administration, such as tablets, pills, powders, granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions, spray-dried Dispersions), syrups and emulsions; sublingually; buccal; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (for example, in a sterile injectable aqueous or non-aqueous solution or suspension Liquid form); nasal, including administration to the nasal membranes, such as by inhalation spray; topical, such as in the form of creams or ointments; or transrectally, such as in the form of suppositories. They can be administered alone, but are usually administered using a pharmaceutical carrier selected based on the chosen route of administration and standard pharmaceutical practice.
- the pharmaceutical carrier is formulated according to many factors within the scope of those skilled in the art. These factors include, but are not limited to: the type and nature of the active agent formulated; the subject to whom the composition containing the active agent is to be administered; the expected route of administration of the composition; and the targeted therapeutic indication.
- Pharmaceutical carriers include aqueous and non-aqueous liquid media and various solid and semi-solid dosage forms.
- the above-mentioned carrier may include many different ingredients and additives in addition to the active agent, and the above-mentioned other ingredients are included in the formulation for various reasons known to those skilled in the art, such as stabilizing active agents, binders, and the like.
- suitable pharmaceutical carriers and the factors involved in the selection of carriers please refer to many easily available sources, such as Allen LVJr.et al. Remington: The Science and Practice of Pharmacy(2Volumes), 22nd Edition (2012) ), Pharmaceutical Press.
- the dosage regimen of the compound of the present invention varies depending on known factors, such as the pharmacodynamic properties of the specific agent and its administration mode and route; the species, age, sex, health status, medical condition and weight of the recipient. ; The nature and degree of symptoms; the types of simultaneous treatment; the frequency of treatment; the route of administration, the patient's renal and liver function, and the desired effect.
- the daily oral dose of each active ingredient should be about 0.001 mg/day to about 10-5000 mg/day, preferably about 0.01 mg/day to about 1000 mg/day, and most preferably The ground is about 0.1 mg/day to about 250 mg/day.
- the most preferred intravenous dose should be about 0.01 mg/kg/min to about 10 mg/kg/min.
- the compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses of two, three or four times daily.
- the compound is usually selected as a suitable pharmaceutical diluent, excipient or carrier (herein Administered in the form of a mixture of drugs collectively referred to as drug carriers).
- a dosage form (pharmaceutical composition) suitable for administration may contain about 1 mg to about 2000 mg of active ingredient per dosage unit.
- the active ingredient will usually be present in an amount of about 0.1-95% by weight based on the total weight of the composition.
- a typical capsule for oral administration contains at least one compound of the present invention (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture was passed through a 60-mesh screen and packed into No. 1 gelatin capsules.
- a typical injectable preparation can be prepared by aseptically placing at least one compound of the present invention (250 mg) in a bottle, aseptically lyophilizing and sealing. For use, the contents of the bottle are mixed with 2 mL of physiological saline to produce an injectable preparation.
- the scope of the present invention includes (alone or in combination with a pharmaceutical carrier) pharmaceutical compositions containing a therapeutically effective amount of at least one compound of the present invention as an active ingredient.
- the compound of the present invention may be used alone, in combination with other compounds of the present invention, or in combination with one or more other therapeutic agents (e.g., anticancer agents or other pharmaceutically active substances).
- the compound of the present invention (which can be used in a suitable hydrated form) and/or the pharmaceutical composition of the present invention is formulated into a pharmaceutical dosage form by conventional methods known to those skilled in the art.
- the actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be changed, so as to obtain the amount of the active ingredient that is effective for realizing the desired therapeutic response, composition, and administration mode of a specific patient without being toxic to the patient.
- the selected dosage level will depend on many factors, including the activity of the particular compound of the invention or its ester, salt or amide used; route of administration; time of administration; excretion rate of the particular compound used; rate and extent of absorption The duration of treatment; other drugs, compounds and/or substances used in combination with the specific compound used; the age, sex, weight, condition, general health and previous medical history of the patient being treated and other factors well known in the medical field.
- a doctor or veterinarian with ordinary skill in the art can easily determine and prescribe an effective amount of the required pharmaceutical composition.
- the physician or veterinarian can start a competition of the compound of the present invention used in the pharmaceutical composition at a level lower than the required level, and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of the compound of the invention will be the amount of the compound that is the lowest dose effective to produce a therapeutic effect.
- Such effective doses usually depend on the above-mentioned factors.
- oral, intravenous, intracerebroventricular, and subcutaneous doses of the compound of the present invention for patients range from about 0.01 to about 50 mg/kg body weight/day.
- the effective daily dose of the active compound can be administered separately in two, three, four, five, six or more sub-doses at appropriate intervals throughout the day, optionally in unit dosage form.
- the medication is administered once a day.
- the compound of the present invention can be administered alone, it is preferable to administer the compound in the form of a pharmaceutical preparation (composition).
- kits/product packaging is also described here.
- kits can be composed of a conveyor, a medicine pack or a container box.
- the container box can be divided into multiple compartments to accommodate one or more containers, such as vials, test tubes, and the like.
- Each container contains all A single component in the method described. Suitable containers include bottles, vials, syringes and test tubes.
- the container is made of acceptable materials such as glass or plastic.
- the container may contain one or more of the compounds described herein.
- the compounds may exist in the form of pharmaceutical components, or they may exist as a mixture with other ingredients described herein.
- the container may have a sterile outlet (for example, the container may be an intravenous infusion bag or a bottle, and the stopper may be pierced by a hypodermic syringe needle).
- kits may contain a compound, and instructions, labels, or operating instructions for the method of use described herein.
- a typical kit may include one or more containers.
- each container contains one or more materials (such as reagents, or concentrated mother liquor, and/ Or equipment).
- materials include, but are not limited to, buffers, diluents, filters, needles, syringes, conveyors, bags, containers, bottles and/or test tubes, with a list of contents and/or instructions for use, and instructions for the built-in packaging. The entire set of instructions must be included.
- the label can be displayed on the container or closely related to the container.
- the appearance of a label on a container means that the label letters, numbers or other features are pasted, molded, or engraved on the container; the label can also appear in a container box or shipping box containing a variety of containers, such as in a product insert.
- a label can be used to indicate a specific therapeutic use of the contents.
- the label may also indicate instructions for use of the content, such as described in the above method.
- the unit of weight-volume percentage in the present invention is well known to those skilled in the art, for example, refers to the weight of the solute in a 100 ml solution. Unless otherwise defined, all professional and scientific terms used in the text have the same meaning as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to the content described can be applied to the method of the present invention. The preferred implementation methods and materials described in this article are for demonstration purposes only.
- the relevant intermediates are commercially available (for example from Sigma Aldrich, Alfa).
- the LC-MS experiment is measured under the following conditions:
- Preparative HPLC usually uses an acidic method (gradient of acetonitrile and water, each containing 0.1% formic acid) with Thermo U3000 AFC-3000; column: Globalsil C-18 12nm, 250x 20mm, 10 ⁇ m, or equivalent; flow rate: 20mL/min, Separate.
- N-bromosuccinimide (549 mg, 3.1 mmol) was added to N, N-dimethylformamide (5 mL) in which compound INT-1a (500 mg, 3.1 mmol) was dissolved, The resulting reaction liquid was stirred at the same temperature for 1.5 hours.
- the reaction solution was poured into water (50 mL), and extracted with ethyl acetate (50 mL ⁇ 3); the combined organic phase was washed with water and saturated brine (100 mL each), dried over anhydrous sodium sulfate, and concentrated.
- the reaction solution was quenched with a little water, poured into water (50mL), and extracted with ethyl acetate (50mL ⁇ 3); the combined organic phase was washed with water and saturated brine (100mL each), dried over anhydrous sodium sulfate, and concentrated .
- Cyclopropyl methyl ketone (160mg, 1.9mmol) was added to a solution of sodium hydrogen (37mg, 1.6mmol, 60% w/w in kerosene) in tetrahydrofuran (10mL), and the resulting reaction solution was stirred at room temperature for half an hour After heating, it was raised to reflux; then, a solution of 4-fluoroacetophenone (250 mg, 1.6 mmol) in tetrahydrofuran (3 mL) was added dropwise. The resulting reaction solution was further stirred for half an hour under reflux.
- 2,4-Dinitrophenylhydroxylamine (3.1g, 15.4mmol) was added to a solution of 4-(tert-butoxycarbonylamino)pyridine (3.0g, 15.4mmol) in 2-methyltetrahydrofuran (15mL); The resulting reaction solution was stirred at 40°C for 4 hours, then cooled to room temperature and stirred overnight. The reaction solution was filtered to obtain a yellow solid INT-4a (6.1 g, yield: 99.6%).
- Diethyl oxalate (554mg, 3.8mmol) was added to a tetrahydrofuran (20mL) solution mixed with sodium hydrogen (74mg, 3.2mmol, 60% w/w in kerosene), and the resulting reaction solution was stirred at room temperature for half an hour. Heat to reflux; then add dropwise a solution of 4-fluoroacetophenone (500 mg, 3.6 mmol) in tetrahydrofuran (6 mL) previously dissolved. The resulting reaction solution was further stirred for half an hour under reflux.
- Aqueous sodium hydroxide solution (3M, 1 mL) was added to a solution of compound 1a (147 mg, 0.31 mmol) in methanol (5 mL); the resulting reaction solution was stirred at 60° C. for 2 hours. After the reaction solution was cooled to room temperature, the pH was adjusted to 3-4 with 1M aqueous hydrochloric acid, and extracted with ethyl acetate (20 mL ⁇ 2). The combined organic phase was washed with saturated sodium bicarbonate and saturated brine (30 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil 3a (122 mg, yield: 88.1%). MS(ESI): m/z 453.2(M+H) + .
- TGF ⁇ RI kinase was purchased from Carna (Cat#09-141). Add 2 ⁇ l of enzyme solution prepared with kinase buffer (40mM Tris PH 7.5, 20mM MgCl 2 , 1mM DTT, 1mg/ml BSA) into a 384-well plate (Greiner, Cat#784075) (TGF ⁇ RI kinase is 25nM in the final reaction system) ). For the negative control, 2 ⁇ l kinase buffer was added. The compound was prepared as a 10 mM stock solution with DMSO, and the compound was diluted twice with DMSO according to the requirement of the initial concentration before the compound was detected.
- p38 ⁇ kinase was purchased from SignalChem (Cat#M39-10BG). Add 2 ⁇ l of enzyme solution (p38 ⁇ kinase in the final reaction system) prepared with kinase buffer (40mM Tris PH 7.5, 20mM MgCl 2 , 0.05mM DTT, 0.1mg/ml BSA) into a 384-well plate (Greiner, Cat#784075) 0.8ng/ul). For the negative control, 2 ⁇ l kinase buffer was added. The compound was prepared as a 10 mM stock solution with DMSO, and the compound was diluted twice with DMSO according to the requirement of the initial concentration before the compound was detected.
- HEK-Blue TGF ⁇ cells (Invivogen, Cat#hkb-tgfb), adjust the cell density to 1.25 ⁇ 10 6 cells/ml with 10% FBS DMEM, and add 40 ⁇ l per well to a 96-well plate.
- the compound was prepared as a 10 mM stock solution with DMSO, and the compound was diluted twice with DMSO according to the requirement of the initial concentration before the compound was detected. Add 2.5 ⁇ l of the compound to 1 ml of complete medium, mix by pipetting, and dilute the compound 3-fold with DMEM medium containing 0.25% DMSO (the DMSO concentration in a 100 ⁇ l system is 0.1%).
- SEAP detection uses Great EscApe SEAP chemiluminescence KIT (Clontech, Cat#631738) for detection, and cell viability detection uses CellTiter-Glo Luminescent Cell Viability Assay (Promega, Cat#G7573) for detection.
- CellTiter-Glo Luminescent Cell Viability Assay Promega, Cat#G7573
- Use Molecular Devices, SpectraMax i3x. to read the final chemiluminescence signal.
- XLFIT data obtained using the 4-parameter curve fitting is performed aggregated IC 50.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A compound of formula (I) and a pharmaceutical composition comprising same. The compound of formula (I) can be used as a TGF-β receptor inhibitor, especially a TGFβRI inhibitor, and can be used for preventing or treating, for example, various related diseases mediated by TGFβRI(ALK5). <img file="dest_path_image001.jpg" he="38.89" img-content="drawing" img-format="jpg" inline="yes" orientation="portrait" wi="41.28"/>
Description
本申请要求于2020年03月24日提交中国专利局、申请号为202010212752.X、发明名称为“转化生长因子-β受体抑制剂”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。This application claims the priority of a Chinese patent application filed with the Chinese Patent Office, the application number is 202010212752.X, and the invention title is "Transforming Growth Factor-β Receptor Inhibitor" on March 24, 2020, the entire content of which is incorporated by reference In this application.
本发明提供了一类新型杂环化合物,其制备方法及其作为TGF-β受体(特别是TGFβRI)拮抗剂的应用。The present invention provides a new type of heterocyclic compound, its preparation method and its application as TGF-β receptor (especially TGFβRI) antagonist.
转化生长因子-β(transforming growth factor-β,TGF-β)是一种多功能的生长因子和细胞因子,与活化素(activins)、抑制素(inhibins)、缪勒氏管抑制质(Mullerian inhibitor substance,MIS)和骨形成蛋白(bone morpho-genetic proteins,BMPs)等多种相关蛋白组成转化生长因子-β超家族。它能够参与调节多种生物过程,包括细胞的增殖、分化、发育以及细胞外基质的修饰(包括肿瘤基质和免疫抑制、血管生成和纤维组织生成)。Transforming growth factor-β (transforming growth factor-β, TGF-β) is a multifunctional growth factor and cytokine. It is combined with activins, inhibitors, and Mullerian inhibitors. Substance, MIS) and bone morpho-genetic proteins (BMPs) and other related proteins form the transforming growth factor-β superfamily. It can participate in the regulation of a variety of biological processes, including cell proliferation, differentiation, development, and modification of extracellular matrix (including tumor matrix and immunosuppression, angiogenesis and fibrous tissue generation).
TGF-β主要有三种细胞受体,分别是I型(TGFβRI)、II型(TGFβRII)和III型(TGFβRIII)。TGF-β信号通路中的信号传导主要是通过TGF-β配体与细胞表面的丝氨酸/苏氨酸激酶受体TGFβRI(ALK5)和TGFβRII结合形成一个异源四聚体复合物,然后TGFβRII对TGFβRI的甘氨酸/丝氨酸区域(GS region)进行磷酸化并激活TGFβRI磷酸化与其连接的细胞内信号传导蛋白Smad蛋白分子——Smad2/Smad3。磷酸化的Smad2和Smad3蛋白与Smad4结合形成的复合物转移到细胞核,结合不同的转录因子和转录共激活剂或共抑制剂,来调节靶基因的转录,引起各种各样的转录反应,从而导致基因表达的改变。而转化生长因子-βIII型受体(TGFβRIII)则本身不能传递信号,但它能通过结合TGF-β并将其传递给TGFβRII来增强TGF-β配体与TGF-βII型受体的结合,从而间接的影响信号的传导。在生物体内,细胞因子、生长因子、微环境条件、激素、磷酸化和去磷酸化激酶等都能影响和控制TGF-β信号通路中的信号传导。There are three main cell receptors for TGF-β, namely type I (TGFβRI), type II (TGFβRII) and type III (TGFβRIII). The signal transduction in the TGF-β signaling pathway is mainly through the combination of TGF-β ligand with the serine/threonine kinase receptor TGFβRI (ALK5) and TGFβRII on the cell surface to form a heterotetrameric complex, and then TGFβRII interacts with TGFβRI The glycine/serine region (GS region) phosphorylates and activates the phosphorylation of TGFβRI to the intracellular signaling protein Smad protein molecule-Smad2/Smad3 that is connected to it. The complex formed by the combination of phosphorylated Smad2 and Smad3 protein and Smad4 is transferred to the nucleus, combined with different transcription factors and transcription co-activators or co-inhibitors, to regulate the transcription of target genes and cause various transcriptional responses, thereby Lead to changes in gene expression. The transforming growth factor-βIII receptor (TGFβRIII) itself cannot transmit signals, but it can enhance the binding of TGF-β ligand and TGF-βII receptor by binding to TGF-β and transmitting it to TGFβRII. Indirectly affect signal transmission. In organisms, cytokines, growth factors, microenvironmental conditions, hormones, phosphorylation and dephosphorylation kinases, etc. can affect and control the signal transduction in the TGF-β signaling pathway.
研究表明,TGF-β在心、肝、肺、肾等不同器官系统纤维化的发生和进展中起着关键作用。异常的TGF-β信号和许多人类疾病有关,比如癌症、心血管疾病、炎症、器官纤维化疾病、胰腺疾病等。在人的肿瘤中,TGF-β信号的失调很常见,能促进肿瘤细胞生长和分化、调节细胞外基质和上皮间质转换。目前,随着肿瘤免疫疗法研究的不断深入,TGF-β已经被证实对调节抗肿瘤免疫 有重要作用。TGF-β对T淋巴细胞的分化有很强的抑制作用,对树状细胞、CD8
+T细胞和NK细胞有明显的负影响,同时它能增强免疫抑制T
reg和骨髓源性抑制细胞(MDSC)的活性,从而为肿瘤生长和转移提供有利的肿瘤微环境。因此,抑制TGF-β信号通路中某个环节的信号传导有可能成为治疗肿瘤的有效方法之一。
Studies have shown that TGF-β plays a key role in the occurrence and progression of fibrosis in different organ systems such as heart, liver, lung, and kidney. Abnormal TGF-β signaling is related to many human diseases, such as cancer, cardiovascular disease, inflammation, organ fibrotic disease, pancreatic disease, etc. In human tumors, the dysregulation of TGF-β signaling is very common, which can promote tumor cell growth and differentiation, and regulate extracellular matrix and epithelial-mesenchymal transition. At present, with the continuous deepening of tumor immunotherapy research, TGF-β has been proven to play an important role in regulating anti-tumor immunity. TGF-β has a strong inhibitory effect on the differentiation of T lymphocytes, and has a significant negative effect on dendritic cells, CD8 + T cells and NK cells. At the same time, it can enhance immunosuppressive T reg and bone marrow-derived suppressor cells (MDSC). ), thereby providing a favorable tumor microenvironment for tumor growth and metastasis. Therefore, inhibiting the signal transduction of a certain link in the TGF-β signaling pathway may become one of the effective methods for the treatment of tumors.
TGFβRI(ALK5)作为TGF-β信号通路中的一个重要节点被认为是治疗肿瘤的一个重要靶点,通过阻止TGFβRI与配体的结合,来抑制ALK5对其下游信号蛋白(Smad2或Smad3)的磷酸化,从而影响或者阻断TGF-β信号的传导,以实现预防和治疗各种由ALK5介导的相关疾病。As an important node in the TGF-β signaling pathway, TGFβRI (ALK5) is considered to be an important target for tumor treatment. By preventing the binding of TGFβRI to ligands, it inhibits the phosphoric acid of ALK5 on its downstream signaling protein (Smad2 or Smad3). In order to prevent and treat various related diseases mediated by ALK5, it can affect or block TGF-β signal transmission.
目前,国际专利申请公开号WO2000/061576、WO2002/066462、WO2004/111036、WO2004/048382、WO2009/087224、WO2009/013335、WO2012/002680、WO2016/057278、WO2017/015425、WO2017/215506、WO2018/017633等和中国专利申请公开号CN107663206A等公开了用作TGF-β受体拮抗剂的化合物。然而,仍需要对TGF-β受体,尤其是对TGFβRI(ALK5)具有更好抑制效果的抑制剂;特别地,能够选择性抑制ALK5的拮抗剂具有重要的临床价值和治疗意义,但是目前对其报道很少。现有技术中迫切需要具有更好抑制效果的ALK5抑制剂,特别是能够选择性抑制ALK5的新型拮抗剂化合物。Currently, international patent application publication numbers WO2000/061576, WO2002/066462, WO2004/111036, WO2004/048382, WO2009/087224, WO2009/013335, WO2012/002680, WO2016/057278, WO2017/015425, WO2017/215506, WO2018/017633 Et al. and Chinese Patent Application Publication No. CN107663206A etc. disclose compounds used as TGF-β receptor antagonists. However, there is still a need for inhibitors that have a better inhibitory effect on TGF-β receptors, especially on TGFβRI (ALK5); in particular, antagonists that can selectively inhibit ALK5 have important clinical value and therapeutic significance, but are currently There are very few reports. In the prior art, there is an urgent need for ALK5 inhibitors with better inhibitory effects, especially new antagonist compounds capable of selectively inhibiting ALK5.
发明内容Summary of the invention
经过长期而深入的研究,我们意外地发现了一类具有良好的ALK5抑制活性的杂环化合物。After long-term and in-depth research, we unexpectedly discovered a class of heterocyclic compounds with good ALK5 inhibitory activity.
基于上述发现,在本发明的第一个方面,提供了式(I)化合物或其药学上可接受的盐、前药、同位素衍生物、异构体、溶剂化物、或其代谢产物,Based on the above findings, in the first aspect of the present invention, a compound of formula (I) or a pharmaceutically acceptable salt, prodrug, isotope derivative, isomer, solvate, or metabolite thereof is provided,
其中:in:
Cy表示被0、1、2或3个取代基所取代的C
6-C
10芳基或者5-10元杂芳基,其中所述的取代基选自:卤素、C
1-C
6烷基、C
3-C
6环烷基、卤代C
1-C
6烷基、-OR
a、氰基、硝基、NR
aR
b、-SO
2R
a、-C(O)R
a、-C(O)OR
a、-C(O)NR
aR
b、-P(O)R
aR
b;
Cy represents a C 6 -C 10 aryl group or a 5-10 membered heteroaryl group substituted by 0, 1, 2 or 3 substituents, wherein the substituents are selected from: halogen, C 1 -C 6 alkyl , C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl, -OR a , cyano, nitro, NR a R b , -SO 2 R a , -C(O)R a ,- C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;
R
1表示氢、卤素、C
1-C
6烷基、C
3-C
6环烷基、羟基(C
1-C
6烷基)、卤代C
1-C
6烷基;
R 1 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl;
R
2表示氢、C
1-C
6烷基、C
3-C
6环烷基、羟基(C
1-C
6烷基)、卤代C
1-C
6烷基、-OR
a、氰基、硝基、NR
aR
b、-SO
2R
a、-C(O)R
a、-C(O)OR
a、-C(O)NR
aR
b、-NR
aC(O)R
b、-SO
2NR
aR
b、-NR
aSO
2R
b;
R 2 represents hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl, -OR a , cyano, Nitro, NR a R b , -SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -NR a C(O)R b , -SO 2 NR a R b , -NR a SO 2 R b ;
R
3表示氢、卤素、C
1-C
6烷基、C
3-C
6环烷基、羟基(C
1-C
6烷基)、卤代C
1-C
6烷基、-OR
a、氰基、硝基、NR
aR
b、-SO
2R
a、-C(O)R
a、-C(O)OR
a、-C(O)NR
aR
b、-NR
aC(O)R
b、-SO
2NR
aR
b、-NR
aSO
2R
b;
R 3 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl, -OR a , cyanide Group, nitro group, NR a R b , -SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -NR a C(O)R b , -SO 2 NR a R b , -NR a SO 2 R b ;
R
4表示氢、C
1-C
6烷基、C
2-C
6烯基、C
3-C
6环烷基、卤代C
1-C
6烷基、-OR
a、-C(O)R
a、-C(O)OR
a、-C(O)NR
aR
b、羟基(C
1-C
6烷基);R
5表示氢、C
1-C
6烷基、C
2-C
6烯基、C
3-C
6环烷基、卤代C
1-C
6烷基;或者R
4、R
5连同其共同相连的原子一起形成5-8元饱和和不饱和环,该环中还可以任意地含有0、1或2个选自N、O、S的杂原子;
R 4 represents hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, halogenated C 1 -C 6 alkyl, -OR a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , hydroxyl (C 1 -C 6 alkyl); R 5 represents hydrogen, C 1 -C 6 alkyl, C 2- C 6 alkene Group, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl; or R 4 , R 5 together with the atoms they are connected together form a 5-8 membered saturated and unsaturated ring, and the ring can also Randomly contain 0, 1 or 2 heteroatoms selected from N, O, S;
其中,R
a、R
b分别各自独立地表示氢、C
1-C
6烷基、C
2-C
6烯基、C
3-C
6环烷基、卤代C
1-C
6烷基;或者R
a、R
b与其所连接的原子一起形成5-8元环,该环中还可以任意地含有0、1或2个选自N、O、S的杂原子;
Wherein, R a and R b each independently represent hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, or halogenated C 1 -C 6 alkyl; or R a, R b form together with the atoms to which they are attached a 5-8 membered ring which may also optionally contain 1 or 2 heteroatoms selected from N, O, S, heteroatoms;
其中n表示0、1、2或3。Where n represents 0, 1, 2 or 3.
优选地,所述式(I)化合物具有以下式(II)结构:Preferably, the compound of formula (I) has the following structure of formula (II):
其中:in:
R
1、R
3、R
4、R
5、R
a、R
b和n具有如权利要求1所述的定义;
R 1, R 3, R 4 , R 5, R a, R b and n have the meanings according to claim 1;
R
2表示氢、C
1-C
6烷基、C
3-C
6环烷基、羟基(C
1-C
6烷基)、卤代C
1-C
6烷基;
R 2 represents hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl;
W表示CR
L或者N;
W represents CR L or N;
R
6表示氢、卤素、C
1-C
6烷基、C
3-C
6环烷基、卤代C
1-C
6烷基、-OR
a、氰基、硝基、NR
aR
b、-SO
2R
a、-C(O)R
a、-C(O)OR
a、-C(O)NR
aR
b、-P(O)R
aR
b;
R 6 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl, -OR a , cyano, nitro, NR a R b ,- SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;
R
L表示氢、卤素、C
1-C
6烷基、C
3-C
6环烷基、卤代C
1-C
6烷基、-OR
a、氰基、硝基、NR
aR
b、-SO
2R
a、-C(O)R
a、-C(O)OR
a、-C(O)NR
aR
b、-P(O)R
aR
b;
R L represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl, -OR a , cyano, nitro, NR a R b ,- SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;
o表示0、1、2或3。o represents 0, 1, 2 or 3.
优选地,本发明的化合物选自以下结构:Preferably, the compound of the present invention is selected from the following structures:
本发明的化合物也可制备成可药用盐的形式,所述可药用盐可以使用例如以下的无机酸或有机酸而形成:盐酸、氢溴酸、硫酸、磷酸、硝酸、乙酸、乙 醇酸、乳酸、丙酮酸、丙二酸、琥珀酸、戊二酸、富马酸、苹果酸、扁桃酸、酒石酸、柠檬酸、抗坏血酸、棕榈酸、马来酸、羟基马来酸、苯甲酸、羟基苯甲酸、苯乙酸、肉桂酸、水杨酸、甲磺酸、苯磺酸或甲苯磺酸。The compounds of the present invention can also be prepared in the form of pharmaceutically acceptable salts, which can be formed using, for example, the following inorganic or organic acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid , Lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxyl Benzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid or toluenesulfonic acid.
本发明的可药用盐可通过常规方法制备,例如通过将本发明的化合物溶解于与水可混溶的有机溶剂(例如丙酮、甲醇、乙醇和乙腈)中,向其中添加过量的有机酸或无机酸水溶液,以使得盐从所得混合物中沉淀,从中除去溶剂和剩余的游离酸,然后分离所沉淀的盐即可。The pharmaceutically acceptable salt of the present invention can be prepared by conventional methods, for example, by dissolving the compound of the present invention in an organic solvent miscible with water (such as acetone, methanol, ethanol, and acetonitrile), and adding an excessive amount of organic acid or An aqueous inorganic acid solution is used to precipitate the salt from the resulting mixture, the solvent and remaining free acid are removed therefrom, and then the precipitated salt can be separated.
本发明化合物(或其可药用盐)可包括溶剂化物形式,优选地,所述溶剂化物为水合物。The compound of the present invention (or a pharmaceutically acceptable salt thereof) may include a solvate form, preferably, the solvate is a hydrate.
本发明还提供了本发明的化合物在制备用于预防或治疗可通过抑制ALK5活性来调节之疾病的药物中的用途。优选地,所述疾病选自癌症、肿瘤、炎症性疾病、自身免疫性疾病和免疫介导性疾病。The present invention also provides the use of the compound of the present invention in the preparation of a medicine for preventing or treating diseases that can be regulated by inhibiting the activity of ALK5. Preferably, the disease is selected from cancer, tumor, inflammatory disease, autoimmune disease and immune-mediated disease.
此外,本发明提供了用于预防或治疗癌症、肿瘤、炎症性疾病、自身免疫性疾病、神经退行性疾病、注意力相关疾病或免疫介导性疾病的药物组合物,其包含本发明的式(I)化合物作为活性成分。In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer, tumor, inflammatory disease, autoimmune disease, neurodegenerative disease, attention-related disease or immune-mediated disease, which comprises the formula of the present invention (I) Compound as active ingredient.
此外,本发明提供了一种用于预防或治疗癌症、肿瘤、炎症性疾病、自身免疫性疾病、神经退行性疾病、注意力相关疾病或免疫介导性疾病的方法,其包括向有此需要的哺乳动物施用本发明的化合物。In addition, the present invention provides a method for preventing or treating cancer, tumor, inflammatory disease, autoimmune disease, neurodegenerative disease, attention-related disease or immune-mediated disease, which includes Of mammals administer the compounds of the invention.
癌症或肿瘤的代表性实例可包括但不限于,皮肤癌、膀胱癌、卵巢癌、乳腺癌、胃癌、胰腺癌、前列腺癌、结肠癌、肺癌、骨癌、脑癌、神经细胞瘤、直肠癌、结肠癌、家族性腺瘤性息肉性癌、遗传性非息肉性结直肠癌、食管癌、唇癌、喉癌、下咽癌、舌癌、唾液腺癌、胃癌、腺癌、甲状腺髓样癌、乳头状甲状腺癌、肾癌、肾实质癌、卵巢癌、宫颈癌、子宫体癌、子宫内膜癌、绒毛膜癌、睾丸癌、泌尿癌、黑素瘤、脑肿瘤诸如成胶质细胞瘤、星形细胞瘤、脑膜瘤、成神经管细胞瘤和外周神经外胚层肿瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、伯基特淋巴瘤、急性淋巴性白血病(ALL)、慢性淋巴性白血病(CLL)、急性骨髓性白血病(AML)、慢性粒细胞白血病(CML)、成人T细胞白血病淋巴瘤、弥漫性大B细胞淋巴瘤(DLBCL)、肝细胞癌、胆囊癌、支气管癌、小细胞肺癌、非小细胞肺癌、多发性骨髓瘤、基底细胞瘤、畸胎瘤、成视网膜细胞瘤、脉络膜黑素瘤、精原细胞瘤、横纹肌肉瘤、颅咽管瘤、骨肉瘤、软骨肉瘤、肌肉瘤、脂肪肉瘤、纤维肉瘤、尤因肉瘤或浆细胞瘤。Representative examples of cancer or tumors may include, but are not limited to, skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, pancreatic cancer, prostate cancer, colon cancer, lung cancer, bone cancer, brain cancer, neurocytoma, rectal cancer , Colon cancer, familial adenomatous polyposis cancer, hereditary non-polyposis colorectal cancer, esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, gastric cancer, adenocarcinoma, medullary thyroid cancer, Papillary thyroid cancer, kidney cancer, renal parenchymal cancer, ovarian cancer, cervical cancer, uterine body cancer, endometrial cancer, choriocarcinoma, testicular cancer, urinary cancer, melanoma, brain tumors such as glioblastoma, Astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, acute lymphocytic leukemia (ALL), chronic lymphoma Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myeloid Leukemia (CML), Adult T-Cell Leukemia Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hepatocellular Carcinoma, Gallbladder Carcinoma, Bronchial Carcinoma, Small Cell lung cancer, non-small cell lung cancer, multiple myeloma, basal cell tumor, teratoma, retinoblastoma, choroidal melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, Sarcoma, liposarcoma, fibrosarcoma, Ewing's sarcoma, or plasmacytoma.
当将本发明化合物或其可药用盐与另外的用于治疗癌症或肿瘤的抗癌剂或检查点抑制剂组合施用时,本发明化合物或其可药用盐可提供增强的抗癌作用。When the compound of the present invention or a pharmaceutically acceptable salt thereof is administered in combination with another anticancer agent or checkpoint inhibitor for the treatment of cancer or tumor, the compound of the present invention or a pharmaceutically acceptable salt thereof can provide an enhanced anticancer effect.
用于治疗癌症或肿瘤的抗癌剂的代表性实例可包括但不限于细胞信号转导抑制剂、苯丁酸氮芥、美法仑、环磷酰胺、异环磷酰胺、白消安、卡莫司汀、洛莫司汀、链脲佐菌素、顺铂、卡铂、奥沙利铂、达卡巴嗪、替莫唑胺、丙卡巴肼、甲氨蝶呤、氟尿嘧啶、阿糖胞苷、吉西他滨、巯基嘌呤、氟达拉滨、长春碱、长春新碱、长春瑞滨、紫杉醇、多西紫杉醇、拓扑替康、伊立替康、依托泊苷、曲贝替定、更生霉素、多柔比星、表柔比星、道诺霉素、米托蒽醌、博来霉素、丝裂霉素C、伊沙匹隆、他莫昔芬、氟他胺、戈那瑞林类似物、甲地孕酮、强的松、地塞米松、甲泼尼龙、沙利度胺、干扰素α、亚叶酸钙、西罗莫司、西罗莫司脂化物、依维莫司、阿法替尼、alisertib、amuvatinib、阿帕替尼、阿西替尼、硼替佐米、波舒替尼、布立尼布、卡博替尼、西地尼布、crenolanib、克卓替尼、达拉菲尼、达可替尼、达努塞替、达沙替尼、多维替尼、厄洛替尼、foretinib、ganetespib、吉非替尼、依鲁替尼、埃克替尼、伊马替尼、iniparib、拉帕替尼、lenvatinib、linifanib、linsitinib、马赛替尼、momelotinib、莫替沙尼、来那替尼、尼罗替尼、niraparib、oprozomib、olaparib、帕唑帕尼、pictilisib、普纳替尼、quizartinib、瑞格菲尼、rigosertib、rucaparib、鲁索利替尼、塞卡替尼、saridegib、索拉非尼、舒尼替尼、替拉替尼、tivantinib、替沃扎尼、托法替尼、曲美替尼、凡德他尼、维利帕尼、威罗菲尼、维莫德吉、volasertib、阿仑单抗、贝伐单抗、贝伦妥单抗维多汀、卡妥索单抗、西妥昔单抗、地诺单抗、吉妥珠单抗、伊匹单抗、尼妥珠单抗、奥法木单抗、帕尼单抗、利妥昔单抗、托西莫单抗、曲妥珠单抗;检查点抑制剂,包括但不局限于抗PD-1抗体、抗PD-L1抗体、LAG3抗体、TIM-3抗体以及抗CTLA-4抗体或它们的任意组合。Representative examples of anticancer agents for the treatment of cancer or tumors may include, but are not limited to, cell signal transduction inhibitors, chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carbohydrate Mustine, lomustine, streptozotocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, Mercaptopurine, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectidine, dactinomycin, doxorubicin , Epirubicin, daunomycin, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide, gonarelin analogs, meth Progesterone, prednisone, dexamethasone, methylprednisolone, thalidomide, interferon alpha, leucovorin, sirolimus, sirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brinib, cabotinib, cediranib, crenolanib, crizotinib, darafenib, Cotinib, Danusitin, Dasatinib, Dovetinib, Erlotinib, Foretinib, Ganetespib, Gefitinib, Ibrutinib, Icotinib, Imatinib, Iniparib, La Patinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motisanib, lenatinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, punatinib, quizartinib , Rigofini, rigosertib, rucaparib, ruxolitinib, secatinib, saridegib, sorafenib, sunitinib, tilatinib, tivantinib, tivozani, tofacitinib, Trametinib, vandetanib, velipanib, veirofenib, vemodedil, volasertib, alemtuzumab, bevacizumab, berentuzumab vedotine, catuxomab Antibody, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, rituximab, tosimol Monoclonal antibodies, trastuzumab; checkpoint inhibitors, including but not limited to anti-PD-1 antibodies, anti-PD-L1 antibodies, LAG3 antibodies, TIM-3 antibodies, and anti-CTLA-4 antibodies or any combination thereof.
炎症性疾病、自身免疫性疾病和免疫介导性疾病的代表性实例可包括但不限于,关节炎、类风湿性关节炎、脊柱关节炎、痛风性关节炎、骨关节炎、幼年型关节炎、其他关节炎性病症、狼疮、系统性红斑狼疮(SLE)、皮肤相关疾病、银屑病、湿疹、皮炎、过敏性皮肤炎、疼痛、肺病、肺部炎症、成人呼吸窘迫综合征(ARDS)、肺结节病、慢性肺部炎症性疾病、慢性阻塞性肺病(COPD)、心血管疾病、动脉粥样硬化、心肌梗塞、充血性心力衰竭、心肌缺血再灌注损伤、炎性肠病、克罗恩病、溃疡性结肠炎、肠易激综合征、哮喘、干燥综合征、自身免疫甲状腺疾病、荨麻疹(风疹)、多发性硬化、硬皮症、器官移植排斥、异种移植、特发性血小板减少性紫癜(ITP)、帕金森病、阿尔兹海默病、糖尿病相关疾病、炎症、盆腔炎性疾病、过敏性鼻炎、过敏性支气管炎、过敏性鼻窦炎、白血病、淋巴瘤、B细胞淋巴瘤、T细胞淋巴瘤、骨髓瘤、急性淋巴性白血病(ALL)、慢性淋巴性白血病(CLL)、急性髓性白血病(AML)、慢性髓性白血病(CML)、毛细胞白血病、何杰金氏病、非何杰金淋巴瘤、多发性骨髓瘤、 骨髓增生异常综合征(MDS)、骨髓增生性肿瘤(MPN)、弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤。Representative examples of inflammatory diseases, autoimmune diseases, and immune-mediated diseases may include, but are not limited to, arthritis, rheumatoid arthritis, spondyloarthritis, gouty arthritis, osteoarthritis, juvenile arthritis , Other arthritic conditions, lupus, systemic lupus erythematosus (SLE), skin-related diseases, psoriasis, eczema, dermatitis, allergic dermatitis, pain, lung disease, lung inflammation, adult respiratory distress syndrome (ARDS) , Pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, atherosclerosis, myocardial infarction, congestive heart failure, myocardial ischemia reperfusion injury, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, asthma, Sjogren's syndrome, autoimmune thyroid disease, urticaria (rubella), multiple sclerosis, scleroderma, organ transplant rejection, xenotransplantation, idiopathic Thrombocytopenic purpura (ITP), Parkinson's disease, Alzheimer's disease, diabetes-related diseases, inflammation, pelvic inflammatory disease, allergic rhinitis, allergic bronchitis, allergic sinusitis, leukemia, lymphoma, B Cell Lymphoma, T Cell Lymphoma, Myeloma, Acute Lymphatic Leukemia (ALL), Chronic Lymphatic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Hairy Cell Leukemia, He Jie King’s disease, non-Hodgkin’s lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), myelodysplastic tumor (MPN), diffuse large B-cell lymphoma, and follicular lymphoma.
当将本发明化合物或其可药用盐与另外的用于治疗炎症性疾病、自身免疫性疾病和免疫介导性疾病的治疗剂组合施用时,本发明化合物或其可药用盐可提供增强的治疗作用。When the compound of the present invention or a pharmaceutically acceptable salt thereof is administered in combination with another therapeutic agent for the treatment of inflammatory diseases, autoimmune diseases and immune-mediated diseases, the compound of the present invention or a pharmaceutically acceptable salt thereof can provide enhanced Therapeutic effect.
用于治疗炎症性疾病、自身免疫性疾病和免疫介导性疾病的治疗剂的代表性实例可包括但不限于,甾体药物(例如,强的松、氢化波尼松、甲基氢化波尼松、可的松、羟基可的松、倍他米松、地塞米松等)、甲氨蝶呤、来氟米特、抗TNFα剂(例如,依那西普、英夫利昔单抗、阿达利单抗等)、钙调神经磷酸酶抑制剂(例如,他克莫司、吡美莫司等)和抗组胺药(例如,苯海拉明、羟嗪、氯雷他定、依巴斯汀、酮替芬、西替利嗪、左西替利嗪、非索非那定等),并且选自其中的至少一种治疗剂可包含于本发明药物组合物中。Representative examples of therapeutic agents for the treatment of inflammatory diseases, autoimmune diseases, and immune-mediated diseases may include, but are not limited to, steroid drugs (e.g., prednisone, hydroprednisolone, methylhydroprednisolone) Pine, cortisone, hydroxycortisone, betamethasone, dexamethasone, etc.), methotrexate, leflunomide, anti-TNFα agents (e.g., Etanercept, Infliximab, Adali Monoclonal antibodies, etc.), calcineurin inhibitors (e.g., tacrolimus, pimecrolimus, etc.) and antihistamines (e.g., diphenhydramine, hydroxyzine, loratadine, ebas , Ketotifen, cetirizine, levocetirizine, fexofenadine, etc.), and at least one therapeutic agent selected from them may be included in the pharmaceutical composition of the present invention.
本发明的化合物或其可药用盐可作为活性成分通过口服或肠胃外施用,其有效量的范围为在哺乳动物包括人(体重约70kg)的情况下0.1至2,000mg/kg体重/天、优选1至1,000mg/kg体重/天,并且每天以单次或4次分次剂量,或者遵循/不遵循预定时间施用。活性成分的剂量可根据多个相关因素(例如待治疗对象的情况、疾病类型和严重性、施用速率和医生意见)进行调整。在某些情况下,小于以上剂量的量可能是合适的。如果不引起有害的副作用则可使用大于以上剂量的量并且该量可以每天以分次剂量施用。The compound of the present invention or a pharmaceutically acceptable salt thereof can be administered orally or parenterally as an active ingredient, and its effective amount ranges from 0.1 to 2,000 mg/kg body weight/day in the case of mammals including humans (body weight of about 70 kg). It is preferably 1 to 1,000 mg/kg body weight/day, and administered in a single or 4 divided doses per day, or following/not following a predetermined time. The dosage of the active ingredient can be adjusted according to a number of relevant factors (such as the condition of the subject to be treated, the type and severity of the disease, the rate of administration, and the doctor's opinion). In some cases, an amount less than the above dosage may be appropriate. If it does not cause harmful side effects, an amount larger than the above dose can be used and the amount can be administered in divided doses per day.
可根据常规方法中的任何一种将本发明药物组合物配制成用于口服施用或肠胃外施用(包括肌内、静脉内和皮下途径)的剂型,例如片剂、颗粒、粉末、胶囊、糖浆、乳剂、微乳剂、溶液或混悬液。The pharmaceutical composition of the present invention can be formulated into dosage forms for oral administration or parenteral administration (including intramuscular, intravenous and subcutaneous routes) according to any of the conventional methods, such as tablets, granules, powders, capsules, syrups , Emulsion, microemulsion, solution or suspension.
用于口服施用的本发明药物组合物可通过将活性成分与例如以下的载体混合来制备:纤维素、硅酸钙、玉米淀粉、乳糖、蔗糖、右旋糖、磷酸钙、硬脂酸、硬脂酸镁、硬脂酸钙、明胶、滑石、表面活性剂、助悬剂、乳化剂和稀释剂。在本发明的注射组合物中采用的载体的实例是水、盐溶液、葡萄糖溶液、葡萄糖样溶液、醇、二醇、醚(例如,聚乙二醇400)、油、脂肪酸、脂肪酸酯、甘油酯、表面活性剂、助悬剂和乳化剂。The pharmaceutical composition of the present invention for oral administration can be prepared by mixing the active ingredient with a carrier such as the following: cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, hard Magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers and diluents. Examples of carriers used in the injection composition of the present invention are water, salt solution, glucose solution, glucose-like solution, alcohol, glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester, Glycerides, surfactants, suspending agents and emulsifiers.
本发明描述示例性实施方案的过程中,本发明的其它特征将变得显而易见,给出所述实施方案用于说明本发明而不意欲成为其限制,以下实施例使用本发明所公开的方法制备、分离和表征。In the process of describing exemplary embodiments of the present invention, other features of the present invention will become apparent. The embodiments are given to illustrate the present invention and are not intended to be limitations. The following examples are prepared using the method disclosed in the present invention , Separation and characterization.
可以用有机合成领域的技术人员已知的多种方式来制备本发明的化合物,可使用有机合成化学领域中已知的合成方法或通过本领域技术人员所了解的其 变化形式来合成本发明化合物。可以在适用于所使用试剂盒材料和适用于所实现转变的溶剂或溶剂混合物中实施所需反应。The compounds of the present invention can be prepared in a variety of ways known to those skilled in the field of organic synthesis, and the compounds of the present invention can be synthesized using synthetic methods known in the field of organic synthetic chemistry or through variations known to those skilled in the art. . The desired reaction can be carried out in a solvent or solvent mixture suitable for the kit materials used and suitable for the transformation achieved.
本发明人经过长期而深入的研究,发现了一类具有TGF-β受体抑制活性、尤其是ALK5抑制活性的如式(I)所示的杂环化合物。基于上述发现,发明人完成了本发明。After long-term and in-depth research, the inventors discovered a class of heterocyclic compounds represented by formula (I) with TGF-β receptor inhibitory activity, especially ALK5 inhibitory activity. Based on the above findings, the inventor completed the present invention.
术语the term
如果无另外说明,用于本发明申请,包括说明书和权利要求书中的术语,定义如下。必须注意,在说明书和所附的权利要求书中,如果文中无另外清楚指示,无数词修饰的名词通常包括其复数意义。如果无另外说明,使用质谱、核磁、HPLC、蛋白化学、生物化学、重组DNA技术和药理的常规方法。Unless otherwise stated, the terms used in the application of the present invention, including the specification and claims, are defined as follows. It must be noted that in the specification and appended claims, if there is no other clear indication in the text, nouns modified by countless words usually include their plural meanings. If not otherwise specified, conventional methods of mass spectrometry, nuclear magnetism, HPLC, protein chemistry, biochemistry, recombinant DNA technology and pharmacology are used.
在说明书和权利要求书中,给定化学式或名称应涵盖所有立体和光学异构体及其中存在上述异构体的外消旋物。除非另外指明,否则所有手性(对映异构体和非对映异构体)和外消旋形式均在本发明范围内。所述化合物中还可存在C=C双键、C=N双键、环系统等的许多几何异构体,且所有上述稳定异构体均涵盖于本发明内。本发明描述了本发明化合物的顺式-和反式-(或E-和Z-)几何异构体,且其可分离成异构体的混合物或分开的异构体形式。本发明化合物可以光学活性或外消旋形式加以分离。用于制备本发明化合物和其中制备的中间体的所有方法均视为本发明的部分。在制备对映异构体或非对映异构体产物时,其可通过常规方法(例如通过色谱或分段结晶)进行分离。取决于方法条件,以游离(中性)或盐形式获得本发明的终产物。这些终产物的游离形式和盐均在本发明的范围内。如果需要的话,则可将化合物的一种形式转化成另一种形式。可将游离碱或酸转化成盐;可将盐转化成游离化合物或另一种盐;可将本发明异构体化合物的混合物分离成单独的异构体。本发明化合物、其游离形式和盐可以多种互变异构体形式存在,其中氢原子转置到分子的其它部分上且由此分子的原子之间的化学键发生重排。应当理解的是,可存在的所有互变异构体形式均包括在本发明内。In the specification and claims, the given chemical formula or name shall cover all stereo and optical isomers and the racemates in which the above isomers exist. Unless otherwise indicated, all chirals (enantiomers and diastereomers) and racemic forms are within the scope of the present invention. Many geometric isomers such as C=C double bonds, C=N double bonds, ring systems, etc. may also exist in the compound, and all the above stable isomers are encompassed in the present invention. The present invention describes the cis- and trans- (or E- and Z-) geometric isomers of the compounds of the present invention, and they can be separated into a mixture of isomers or separate isomer forms. The compounds of the present invention can be isolated in optically active or racemic form. All methods used to prepare the compounds of the invention and the intermediates prepared therein are considered part of the invention. In the preparation of enantiomeric or diastereomeric products, they can be separated by conventional methods (for example, by chromatography or fractional crystallization). Depending on the process conditions, the final product of the invention is obtained in free (neutral) or salt form. The free forms and salts of these end products are within the scope of the present invention. If desired, one form of the compound can be converted into another form. The free base or acid can be converted into a salt; the salt can be converted into a free compound or another salt; the mixture of isomer compounds of the present invention can be separated into individual isomers. The compounds of the present invention, their free forms and salts may exist in a variety of tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecule and the chemical bonds between the atoms of the molecule are thus rearranged. It should be understood that all tautomeric forms that may exist are included in the present invention.
除非另有定义,否则当取代基被标注为“任选取代的”时,所述取代基选自例如以下取代基,诸如烷基、环烷基、芳基、杂环基、卤素、羟基、烷氧基、氧 代、烷酰基、芳基氧基、烷酰基氧基、氨基、烷基氨基、芳基氨基、芳基烷基氨基、二取代的胺基团(其中2个氨基取代基选自烷基、芳基或芳基烷基)、烷酰基氨基、芳酰基氨基、芳烷酰基氨基、取代的烷酰基氨基、取代的芳基氨基、取代的芳烷酰基氨基、硫基、烷基硫基、芳基硫基、芳基烷基硫基、芳基硫羰基、芳基烷基硫羰基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、磺酰氨基例如-SO
2NH
2、取代的磺酰氨基、硝基、氰基、羧基、氨基甲酰基例如-CONH
2、取代的氨基甲酰基例如-CONH烷基、-CONH芳基、-CONH芳基烷基或在氮上具有两个选自烷基、芳基或芳基烷基的取代基的情况、烷氧基羰基、芳基、取代的芳基、胍基、杂环基,例如吲哚基、咪唑基、呋喃基、噻吩基、噻唑基、吡咯烷基、吡啶基、嘧啶基、吡咯烷基、哌啶基、吗啉基、哌嗪基、高哌嗪基等和取代的杂环基。
Unless otherwise defined, when a substituent is marked as "optionally substituted", the substituent is selected from, for example, the following substituents such as alkyl, cycloalkyl, aryl, heterocyclyl, halogen, hydroxy, Alkoxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amine groups (two of the amino substituents are selected (From alkyl, aryl or arylalkyl), alkanoylamino, aroylamino, aralkanoylamino, substituted alkanoylamino, substituted arylamino, substituted aralkanoylamino, thio, alkyl Thio, arylthio, arylalkylthio, arylthiocarbonyl, arylalkylthiocarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, sulfonylamino such as -SO 2 NH 2 , substituted sulfonylamino, nitro, cyano, carboxyl, carbamoyl such as -CONH 2 , substituted carbamoyl such as -CONH alkyl, -CONH aryl, -CONH arylalkyl or in When there are two substituents selected from alkyl, aryl or arylalkyl on the nitrogen, alkoxycarbonyl, aryl, substituted aryl, guanidyl, heterocyclic group, such as indolyl, imidazolyl , Furyl, thienyl, thiazolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, homopiperazinyl, etc. and substituted heterocyclic groups.
本文使用的术语“烷基”或“亚烷基”意欲包括具有指定碳原子数的支链或直链饱和脂族烃基团。例如,“C
1-C
6烷基”表示具有1个至6个碳原子的烷基。烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(例如正丙基和异丙基)、丁基(例如正丁基、异丁基、叔丁基)和戊基(例如正戊基、异戊基、新戊基)。优选的烷基是C
1-C
6烷基,更优选的烷基是C
1-C
4烷基。
The term "alkyl" or "alkylene" as used herein is intended to include branched or straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, "C 1 -C 6 alkyl" means an alkyl group having 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl) and Pentyl (e.g., n-pentyl, isopentyl, neopentyl). Preferred alkyl groups are C 1 -C 6 alkyl groups, and more preferred alkyl groups are C 1 -C 4 alkyl groups.
术语“烯基”表示含一个或多个双键且通常长度为2至20个碳原子的直链或支链的烃基。例如,“C
2-C
8烯基”含有两个至八个碳原子。烯基包括但不限于例如乙烯基、丙烯基、丁烯基、1-甲基-2-丁烯-1-基、庚烯基、辛烯基等。优选的烯基是C
2-C
8烯基,更优选的烯基是C
2-C
6烯基。
The term "alkenyl" refers to a straight or branched hydrocarbon group containing one or more double bonds and usually having a length of 2 to 20 carbon atoms. For example, "C 2 -C 8 alkenyl" contains two to eight carbon atoms. Alkenyl includes, but is not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl, and the like. A preferred alkenyl group is a C 2 -C 8 alkenyl group, and a more preferred alkenyl group is a C 2 -C 6 alkenyl group.
术语“炔基”表示含一个或多个叁键且通常长度为2至20个碳原子的直链或支链的烃基。例如,“C
2-C
8炔基”含有两个至八个碳原子。优选的炔基是C
2-C
8炔基,更优选的烯基是C
2-C
6炔基。代表性炔基包括但不限于例如乙炔基、1-丙炔基、1-丁炔基、庚炔基、辛炔基等。
The term "alkynyl" means a straight or branched hydrocarbon group containing one or more triple bonds and usually having a length of 2 to 20 carbon atoms. For example, "C 2 -C 8 alkynyl" contains two to eight carbon atoms. A preferred alkynyl group is a C 2 -C 8 alkynyl group, and a more preferred alkenyl group is a C 2 -C 6 alkynyl group. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and the like.
术语“烷氧基”或“烷基氧基”是指-O-烷基。“C
1-C
6烷氧基”(或烷基氧基)意欲包括C
1、C
2、C
3、C
4、C
5和C
6烷氧基。优选的烷氧基是C
1-C
6烷氧基,更优选的烷氧基是C
1-C
4烷氧基。烷氧基的实例包括但不限于甲氧基、乙氧基、丙氧基(例如正丙氧基和异丙氧基)和叔丁氧基。类似地,“烷基硫基”或“硫代烷氧基”表示具有指定数量碳原子的经硫桥连接的如上文所定义的烷基;例如甲基-S-和乙基-S-。
The term "alkoxy" or "alkyloxy" refers to -O-alkyl. "C 1 -C 6 alkoxy" (or alkyloxy) is intended to include C 1 , C 2 , C 3 , C 4 , C 5 and C 6 alkoxy. A preferred alkoxy group is a C 1 -C 6 alkoxy group, and a more preferred alkoxy group is a C 1 -C 4 alkoxy group. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (such as n-propoxy and isopropoxy), and tert-butoxy. Similarly, "alkylthio" or "thioalkoxy" means an alkyl group, as defined above, with the specified number of carbon atoms connected via a sulfur bridge; for example, methyl-S- and ethyl-S-.
术语“羰基”是指由碳和氧两种原子通过双键连接而成的有机官能团(C=O)。The term "carbonyl" refers to an organic functional group (C=O) formed by connecting two atoms of carbon and oxygen through a double bond.
术语“芳基”,单独或作为较大部分诸如“芳烷基”、“芳烷氧基”或“芳基氧基 烷基”的部分,是指具有总计5至12个环成员的单环、二环或三环的环系统,其中所述系统中的至少一个环为芳族的且其中所述系统中的每个环含有3至7个环成员。单环的芳香基指的是苯基,二环及二环以上的芳香基指萘基、蒽基等,同时此芳基二环也可为苯环融合了一个环烷基、或融合一个环烯基、或融合一个环炔基。优选的芳基是C
6-C
12芳基。在本发明的某些实施方案中,“芳基”是指芳族环系统,其包括但不限于苯基、联苯基、茚满基、1-萘基、2-萘基和四氢萘基。术语“芳烷基”或“芳基烷基”是指连接至芳基环的烷基残基。非限制性实例包括苄基、苯乙基等。稠合的芳基可在环烷基环或芳族环的合适位置上连接至另一基团。例从环系统中画出的箭头线表明键可连接至任意合适的环原子。
The term "aryl", alone or as part of a larger part such as "aralkyl", "aralkoxy" or "aryloxyalkyl", refers to a monocyclic ring having a total of 5 to 12 ring members , A bicyclic or tricyclic ring system, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. A monocyclic aromatic group refers to a phenyl group, and a bicyclic or more aromatic group refers to naphthyl, anthracenyl, etc. At the same time, the aryl bicyclic ring can also be a benzene ring fused with a cycloalkyl group or a ring Alkenyl, or fused with a cycloalkynyl group. The preferred aryl group is a C 6 -C 12 aryl group. In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, which includes, but is not limited to, phenyl, biphenyl, indanyl, 1-naphthyl, 2-naphthyl, and tetrahydronaphthalene base. The term "aralkyl" or "arylalkyl" refers to an alkyl residue attached to an aryl ring. Non-limiting examples include benzyl, phenethyl, and the like. The fused aryl group may be connected to another group at a suitable position on the cycloalkyl ring or aromatic ring. Example The arrow line drawn from the ring system indicates that the bond can be connected to any suitable ring atom.
术语“环烷基”是指单环或二环的环状烷基。单环的环状烷基指C
3-C
8的环状烷基,包括但不限于环丙基、环丁基、环戊基、环己基和降莰烷基。支化环烷基诸如1-甲基环丙基和2-甲基环丙基包括在“环烷基”的定义中。二环的环状烷基包括桥环、螺环或融合环的环烷基。优选的环烷基是C
3-C
6环烷基。
The term "cycloalkyl" refers to a monocyclic or bicyclic cyclic alkyl group. The monocyclic cyclic alkyl group refers to a C 3 -C 8 cyclic alkyl group, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornanyl. Branched cycloalkyl groups such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl". The bicyclic cyclic alkyl group includes a bridged ring, a spiro ring, or a fused ring cycloalkyl group. The preferred cycloalkyl group is a C 3 -C 6 cycloalkyl group.
术语“环烯基”是指单环或二环的环状烯基。单环的环状烯基指C
3-C
8的环状烯基,包括但不限于环丙烯基、环丁烯基、环戊烯基、环己烯基和降莰烯基。支化环烯基诸如1-甲基环丙烯基和2-甲基环丙烯基包括在“环烯基”的定义中。二环的环状烯基包括桥环、螺环或融合环的环状烯基。
The term "cycloalkenyl" refers to a monocyclic or bicyclic cyclic alkenyl. The monocyclic cyclic alkenyl group refers to a C 3 -C 8 cyclic alkenyl group, including but not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and norbornenyl. Branched cycloalkenyl groups such as 1-methylcyclopropenyl and 2-methylcyclopropenyl are included in the definition of "cycloalkenyl". The bicyclic cyclic alkenyl group includes a bridged ring, a spiro ring, or a fused ring cyclic alkenyl group.
术语“羟基烷基”是指具有指定碳原子数的支链和直链饱和脂族烃基团且烃基的碳原子上至少连接一个-OH。羟基烷基的实例包括但不限于羟甲基、羟乙基、1-羟基丙基、2-羟基丙基。The term "hydroxyalkyl" refers to a branched and straight chain saturated aliphatic hydrocarbon group with the specified number of carbon atoms and at least one -OH is attached to the carbon atom of the hydrocarbon group. Examples of hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl.
“卤代”或“卤素”包括氟、氯、溴和碘。“卤代烷基”意欲包括具有指定碳原子数且取代有1个或多个卤素的支链和直链饱和脂族烃基团。卤代烷基的实例包括但不限于氟甲基、二氟甲基、三氟甲基、三氯甲基、五氟乙基、五氯乙基、2,2,2-三氟乙基、七氟丙基和七氯丙基。卤代烷基的实例还包括意欲包括具有指定碳原子数且取代有1个或多个氟原子的支链和直链饱和脂族烃基团的“氟烷基”。"Halo" or "halogen" includes fluorine, chlorine, bromine and iodine. "Haloalkyl" is intended to include branched and straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms and substituted with one or more halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoromethyl Propyl and heptachloropropyl. Examples of haloalkyl groups also include "fluoroalkyl groups" intended to include branched and straight chain saturated aliphatic hydrocarbon groups having a designated number of carbon atoms and substituted with one or more fluorine atoms.
“卤代烷氧基”或“卤代烷基氧基”表示具有指定数量碳原子的经氧桥连接的如上文所定义的卤代烷基。例如,“C
1-C
6卤代烷氧基”意欲包括C
1、C
2、C
3、C
4、C
5和C
6卤代烷氧基。卤代烷氧基的实例包括但不限于三氟甲氧基、2,2,2-三氟乙氧基和五氟乙氧基。类似地,“卤代烷基硫基”或“硫代卤代烷氧基”表示具有指定数量碳原子的经硫桥连接的如上文所定义的卤代烷基;例如三氟甲基-S-和五氟乙基-S-。
"Haloalkoxy" or "haloalkyloxy" means a haloalkyl group as defined above with the specified number of carbon atoms connected via an oxygen bridge. For example, "C 1 -C 6 haloalkoxy" is meant to include C 1 , C 2 , C 3 , C 4 , C 5 and C 6 haloalkoxy. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluoroethoxy. Similarly, "haloalkylthio" or "thiohaloalkoxy" means a haloalkyl group as defined above that has the specified number of carbon atoms connected by a sulfur bridge; for example, trifluoromethyl-S- and pentafluoroethyl -S-.
术语“杂芳基”意指稳定的3元、4元、5元、6元、或7元芳香单环或芳香二环或7元、8元、9元、10元、11元、12元、13元或14元芳香多环杂环,其为完全不饱和的、部分不饱和的,且其含有碳原子和1个、2个、3个或4个独立地选自N、O和S的杂原子;且包括任何以下多环基团,其中上文所定义的任意杂环与苯环稠合。氮和硫杂原子可任选地被氧化。氮原子为取代的或未取代的(即N或NR,其中R为H或如果被定义,则为另一取代基)。杂环可在得到稳定结构的任何杂原子或碳原子处连接至其侧基。如果所得化合物是稳定的,则本文所述的杂环基可在碳或氮原子上被取代。杂环中的氮可任选地被季铵化。优选地,当杂环中S和O原子的总数超过1时,则这些杂原子彼此不相邻。优选地,杂环中S和O原子的总数不大于1。优选的杂芳基是5-12元杂芳基。杂芳基的实例包括但不限于吖啶基、氮杂环丁基、吖辛因基、苯并咪唑基、苯并呋喃基、苯并硫代呋喃基、苯并噻吩基、苯并噁唑基、苯并噁唑啉基、苯并噻唑基、苯并三唑基、苯并四唑基、苯并异噁唑基、苯并异噻唑基、苯并咪唑啉基、咔唑基、4aH-咔唑基、咔啉基、色满基、色烯基、噌啉基、十氢喹啉基、2H,6H-1,5,2-二噻嗪基、二氢呋喃并[2,3-b]四氢呋喃基、呋喃基、呋咱基、咪唑烷基、咪唑啉基、咪唑基、1H-吲唑基、咪唑并吡啶基、假吲哚基(indolenyl)、二氢吲哚基、吲嗪基、吲哚基、3H-吲哚基、靛红酰基(isatinoyl)、异苯并呋喃基、异色满基、异吲唑基、异二氢吲哚基、异吲哚基、异喹啉基、异噻唑基、异噻唑并吡啶基、异噁唑基、异噁唑并吡啶基、亚甲基二氧基苯基、吗啉基、二氮杂萘基、八氢异喹啉基、噁二唑基、1,2,3-噁二唑基、1,2,4-噁二唑基、1,2,5-噁二唑基、1,3,4-噁二唑基、噁唑烷基、噁唑基、噁唑并吡啶基、噁唑烷基、萘嵌间二氮杂苯基、羟吲哚基、嘧啶基、菲啶基、菲咯啉基、吩嗪基、吩噻嗪基、吩噁噻基、吩噁嗪基、酞嗪基、哌嗪基、哌啶基、哌啶酮基、4-哌啶酮基、胡椒基、喋啶基、嘌呤基、吡喃基、吡嗪基、吡唑烷基、吡唑啉基、吡唑并吡啶基、吡唑基、哒嗪基、吡啶并噁唑基、吡啶并咪唑基、吡啶并噻唑基、吡啶基、嘧啶基、吡咯烷基、吡咯啉基、2-吡咯烷酮基、2H-吡咯基、吡咯基、喹唑啉基、喹啉基、4H-喹嗪基、喹喔啉基、奎宁环基、四唑基、四氢呋喃基、四氢异喹啉基、四氢喹啉基、6H-1,2,5-噻二嗪基、1,2,3-噻二唑基、1,2,4-噻二唑基、1,2,5-噻二唑基、1,3,4-噻二唑基、噻蒽基、噻唑基、噻吩基、噻唑并吡啶基、噻吩并噻唑基、噻吩并噁唑基、噻吩并咪唑基、噻吩基、三嗪基、1,2,3-三唑基、1,2,4-三唑基、1,2,5-三唑基、1,3,4-三唑基和呫吨基、喹啉基、异喹啉基、酞嗪基、喹唑啉基、吲哚基、异吲哚基、二氢吲哚基、1H-吲唑基、苯并咪唑基、1,2,3,4-四氢喹啉基、1,2,3,4-四氢异喹啉基、5,6,7,8-四氢-喹啉基、2,3-二氢-苯并呋喃基、色满基、1,2,3,4-四氢-喹喔啉基和1,2,3,4-四氢-喹唑啉基。本发明还包括含有例 如上述杂环的稠环和螺环化合物。The term "heteroaryl" means a stable 3-membered, 4-membered, 5-membered, 6-membered, or 7-membered aromatic monocyclic or aromatic bicyclic ring or 7-membered, 8-membered, 9-membered, 10-membered, 11-membered, 12-membered , 13-membered or 14-membered aromatic polycyclic heterocyclic ring, which is fully unsaturated, partially unsaturated, and contains carbon atoms and 1, 2, 3 or 4 independently selected from N, O and S And includes any of the following polycyclic groups in which any heterocyclic ring as defined above is fused with a benzene ring. Nitrogen and sulfur heteroatoms can optionally be oxidized. The nitrogen atom is substituted or unsubstituted (ie N or NR, where R is H or another substituent if defined). The heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. If the resulting compound is stable, the heterocyclic group described herein may be substituted on a carbon or nitrogen atom. The nitrogen in the heterocyclic ring can optionally be quaternized. Preferably, when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to each other. Preferably, the total number of S and O atoms in the heterocyclic ring is not more than one. Preferred heteroaryl groups are 5-12 membered heteroaryl groups. Examples of heteroaryl groups include, but are not limited to, acridinyl, azetidinyl, azetidinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothienyl, benzoxazole Group, benzoxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH -Carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3 -b] Tetrahydrofuryl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, imidazopyridyl, indolenyl, indolinyl, indole Azinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolyl, isoindolyl, isoquine Linyl, isothiazolyl, isothiazolopyridyl, isoxazolyl, isoxazolopyridyl, methylenedioxyphenyl, morpholinyl, naphtholinyl, octahydroisoquinolinyl , Oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, Oxazolidinyl, oxazolyl, oxazolopyridyl, oxazolidinyl, perimidine phenyl, oxindole, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, Phenothiazinyl, phenoxathiyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidinone, 4-piperidinone, piperonyl, pteridine, purinyl, pyridine Pyridyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolopyridyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, Pyrimidyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidinone, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinazinyl, quinoxalinyl, quinuclidinyl, four Azolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiol Diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thiaanthryl, thiazolyl, thienyl, thiazolopyridyl, thienothiazolyl, thienooxazole Group, thienoimidazolyl, thienyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4- Triazolyl and xanthenyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indoline, 1H-indazolyl, benzimidazole Group, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydro-quinolinyl, 2,3- Dihydro-benzofuranyl, chromanyl, 1,2,3,4-tetrahydro-quinoxalinyl and 1,2,3,4-tetrahydro-quinazolinyl. The present invention also includes condensed ring and spiro ring compounds containing, for example, the aforementioned heterocyclic ring.
本文使用的术语“杂环烷基”指的是一个单环杂环烷基体系,或为一个二环杂环烷基体系,同时还包括螺杂环或桥杂环烷基。单环的杂环烷基指的是3-8元、且至少含一个选自O、N、S、P的饱和或不饱和但不为芳香性的环状烷基体系。二环杂环烷基体系指的是一个杂环烷基融合到一个苯基、或一个环烷基、或一个环烯基、或一个杂环烷基、或一个杂芳基。优选的杂环烷基是3-12元杂环烷基。The term "heterocycloalkyl" as used herein refers to a monocyclic heterocycloalkyl system, or a bicyclic heterocycloalkyl system, and also includes spiro heterocycles or bridged heterocycloalkyls. The monocyclic heterocycloalkyl refers to a 3-8 membered, and at least one saturated or unsaturated but not aromatic cyclic alkyl system selected from O, N, S, and P. The bicyclic heterocycloalkyl system refers to a heterocycloalkyl group fused to a phenyl group, or a cycloalkyl group, or a cycloalkenyl group, or a heterocycloalkyl group, or a heteroaryl group. A preferred heterocycloalkyl group is a 3-12 membered heterocycloalkyl group.
本文中所用的术语“取代”意指至少一个氢原子被非氢基团替代,条件是维持正常化合价且所述取代得到稳定的化合物。本文所用的环双键为在两个相邻环原子之间形成的双键(例如C=C、C=N或N=N)。The term "substitution" as used herein means that at least one hydrogen atom is replaced by a non-hydrogen group, provided that the normal valence is maintained and the substitution results in a stable compound. The ring double bond used herein is a double bond formed between two adjacent ring atoms (for example, C=C, C=N, or N=N).
在本发明化合物上存在氮原子(例如胺)的情形下,可通过使用氧化剂(例如m-CPBA和/或过氧化氢)进行处理来将这些氮原子转化成N-氧化物以获得本发明的其它化合物。因此,所显示和要求保护的氮原子视为均涵盖所显示氮及其N-氧化物以获得本发明衍生物。In the case where nitrogen atoms (such as amines) are present on the compounds of the present invention, these nitrogen atoms can be converted into N-oxides by treatment with an oxidizing agent (such as m-CPBA and/or hydrogen peroxide) to obtain the present invention Other compounds. Therefore, the shown and claimed nitrogen atoms are considered to encompass both the shown nitrogen and its N-oxides to obtain the derivatives of the present invention.
当任何变量在化合物的任何组成或式中出现一次以上时,其每次出现时的定义均独立于其在其它每种情况下出现时的定义。因此,例如如果显示基团取代有0、1、2或3个R,则所述基团可任选地取代有至多三个R基团,且在每次出现时R独立地选自R的定义。此外,取代基和/或变量的组合仅在上述组合可产生稳定的化合物时才容许存在。When any variable occurs more than once in any composition or formula of a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0, 1, 2, or 3 R, then the group may be optionally substituted with up to three R groups, and R is independently selected from R at each occurrence. definition. In addition, combinations of substituents and/or variables are only allowed if the above-mentioned combinations produce stable compounds.
术语“溶剂化物”意指本发明化合物与一个或多个溶剂分子(无论有机的还是无机的)的物理缔合。该物理缔合包括氢键。在某些情形中,例如当一个或多个溶剂分子纳入结晶固体的晶格中时,溶剂化物将能够被分离。溶剂化物中的溶剂分子可按规则排列和/或无序排列存在。溶剂化物可包含化学计量或非化学计量的溶剂分子。“溶剂合物”涵盖溶液相和可分离的溶剂化物。示例性溶剂化物包括但不限于水合物、乙醇合物、甲醇合物和异丙醇合物。溶剂化方法是本领域公知的。The term "solvate" means the physical association of a compound of the invention with one or more solvent molecules (whether organic or inorganic). This physical association includes hydrogen bonding. In some cases, such as when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid, the solvate will be able to be separated. The solvent molecules in the solvate can be arranged in regular and/or disordered arrangements. Solvates may contain stoichiometric or non-stoichiometric solvent molecules. "Solvate" encompasses both solution-phase and isolatable solvates. Exemplary solvates include, but are not limited to, hydrate, ethanolate, methanolate, and isopropanolate. Solvation methods are well known in the art.
本文使用的术语“患者”是指通过本发明的方法进行治疗的有机体。这类有机体优选包括但不限于哺乳动物(例如鼠类、猿/猴、马、牛、猪、犬、猫等)且最优选是指人类。The term "patient" as used herein refers to an organism that is treated by the method of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murine, ape/monkey, horse, cow, pig, dog, cat, etc.) and most preferably refer to humans.
本文使用的术语“有效量”意指将会引起例如研究人员或临床医师所寻求的组织、系统、动物或人的生物学或医学响应的药物或药剂(即本发明化合物)的量。此外,术语“治疗有效量”意指这样的量:与未接受上述量的相应受试者相比,所 述量导致改善的治疗、治愈、预防或减轻疾病、病症或副作用,或降低在疾病或病症的进展速度。有效量可以一个或多个给药、施用或剂量给予且不意欲被特定的制剂或给药途径限制。该术语还包括在其范围内的增强正常生理机能的有效量。The term "effective amount" as used herein means the amount of a drug or agent (ie, a compound of the present invention) that will elicit a biological or medical response of a tissue, system, animal, or human sought by, for example, a researcher or clinician. In addition, the term "therapeutically effective amount" means an amount that results in an improved treatment, cure, prevention, or alleviation of a disease, disorder, or side effect, or reduction in disease, compared to a corresponding subject who has not received the above-mentioned amount. Or the rate of progression of the disease. The effective amount can be given in one or more administrations, administrations or doses and is not intended to be limited by a particular formulation or route of administration. The term also includes within its scope an effective amount for enhancing normal physiological functions.
本文使用的术语“治疗”包括导致改善病症、疾病、障碍等的任何效果,例如减轻、减少、调节、改善或消除,或改善其症状。如本文所用,某一化合物或药物组合物,在给药后可以使某一疾病、症状或情况得到改善,尤指其严重度得到改善,延迟发病,减缓病情进展,或减少病情持续时间。无论固定给药或临时给药、持续给药或断续给药,可以归因于或与给药有关的情况。本文使用的术语“预防”是指在疾病或症状发生之前防止、阻断、消除疾病发生或者干扰或减缓病程发展。The term "treatment" as used herein includes any effect that leads to amelioration of a condition, disease, disorder, etc., such as alleviation, reduction, regulation, amelioration or elimination, or amelioration of its symptoms. As used herein, a certain compound or pharmaceutical composition can improve a certain disease, symptom or condition after administration, especially its severity is improved, the onset is delayed, the progression of the disease is slowed, or the duration of the disease is reduced. Regardless of fixed administration or temporary administration, continuous administration or intermittent administration, it can be attributed to or related to the administration. The term "prevention" as used herein refers to preventing, blocking, eliminating the occurrence of a disease or interfering with or slowing the development of a disease before the occurrence of a disease or symptom.
本文使用的术语“药物组合物”是指活性剂与惰性或活性的载体的组合,使得所述组合物尤其适用于体内或离体诊断或治疗。碱的实例包括但不限于碱金属(例如钠)氢氧化物、碱土金属(例如镁)氢氧化物、氨等。对于治疗用途,本发明化合物的盐对于治疗用途,本发明化合物的盐预期为是药用的。然而,非药用的酸和碱的盐也可用于例如药用化合物的制备或纯化中。The term "pharmaceutical composition" as used herein refers to a combination of an active agent and an inert or active carrier, so that the composition is particularly suitable for in vivo or ex vivo diagnosis or treatment. Examples of bases include, but are not limited to, alkali metal (e.g., sodium) hydroxide, alkaline earth metal (e.g., magnesium) hydroxide, ammonia, and the like. For therapeutic use, the salt of the compound of the present invention is intended for therapeutic use, and the salt of the compound of the present invention is expected to be pharmaceutically acceptable. However, salts of non-pharmaceutical acids and bases can also be used, for example, in the preparation or purification of pharmaceutical compounds.
术语“药用”在本文中用于指如下那些化合物、物质、组合物和/或剂型:在合理医学判断的范围内,其适于与人类和动物的组织接触使用而无过高毒性、刺激性、过敏反应和/或其它问题或并发症,并与合理的益处/风险比相称。The term "medicinal" is used herein to refer to the following compounds, substances, compositions and/or dosage forms: within the scope of reasonable medical judgment, they are suitable for use in contact with human and animal tissues without excessive toxicity or irritation Sex, allergic reactions, and/or other problems or complications, and are commensurate with a reasonable benefit/risk ratio.
本文使用的短语“药学上可接受的载体”、“可药用载体”意指药用物质、组合物或媒介物,诸如液体或固体填充剂、稀释剂、赋形剂、制造助剂(例如润滑剂、滑石、硬脂酸镁、硬脂酸钙或硬脂酸锌或硬脂酸)或溶剂包囊物质,其涉及将活性化合物从一个器官或身体的部分携带或运送至另一个器官或身体的部分。每种载体在与制剂的其它成分相容和对患者无害的意义上必须是“可接受的”。As used herein, the phrases "pharmaceutically acceptable carrier" and "pharmaceutically acceptable carrier" mean pharmaceutical substances, compositions or vehicles, such as liquid or solid fillers, diluents, excipients, manufacturing aids (e.g. Lubricants, talc, magnesium stearate, calcium stearate or zinc stearate or stearic acid) or solvent encapsulated substances, which involve carrying or transporting the active compound from one organ or part of the body to another organ or Parts of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient.
特定药学及医学术语Specific pharmacy and medical terms
术语“可接受的”,如本文所用,指一个处方组分或活性成分对一般治疗目标的健康没有过分的有害影响。The term "acceptable", as used herein, refers to a prescription component or active ingredient that does not have undue harmful effects on the health of the general treatment target.
术语“癌症”,如本文所用,指一种不能控制的细胞的异常生长,并且在某种条件下能够转移(传播)。这种类型的癌症包括但不限于,实体肿瘤(如膀胱、肠、脑、胸、子宫、心脏、肾、肺、淋巴组织(淋巴瘤)、卵巢、胰腺或其它内分泌器官(如甲状腺)、前列腺、皮肤(黑色素瘤)或血液瘤(如非白血性白血病)。The term "cancer", as used herein, refers to an abnormal growth of cells that cannot be controlled and which can metastasize (spread) under certain conditions. This type of cancer includes, but is not limited to, solid tumors (such as bladder, intestine, brain, chest, uterus, heart, kidney, lung, lymphoid tissue (lymphoma), ovary, pancreas or other endocrine organs (such as thyroid), prostate , Skin (melanoma) or hematoma (such as non-leukemic leukemia).
术语“联合给药”或其类似术语,如本文所用,指将几种所选的治疗药物给一个病人用药,以相同或不同的给药方式在相同或不同的时间给药。The term "co-administration" or its analogous terms, as used herein, refers to administering several selected therapeutic drugs to a patient in the same or different modes of administration at the same or different times.
术语“增强”或“能增强”,如本文所用,指预期的结果能够在效价或是持续时间方面都有增加或延长。因此,在增强药物的治疗效果方面,术语“能增强”指药物在系统中有提高或延长效价或持续时间的能力。本文所用的“增效值”,指在理想的系统中,能够最大限度地的增强另外一个治疗药物的能力。The term "enhance" or "enhance", as used herein, means that the expected result can be increased or prolonged in terms of potency or duration. Therefore, in terms of enhancing the therapeutic effect of a drug, the term "enhanced" refers to the ability of the drug to increase or extend the potency or duration of the drug in the system. "Synergy value" as used herein refers to the ability of another therapeutic drug to be maximized in an ideal system.
术语“免疫性疾病”指对内源性或外源性抗原产生的不良或有害反应的疾病或症状。结果通常会造成细胞的功能障碍、或因此而破坏并造成机能障碍、或破坏可能产生免疫症状的器官或组织。The term "immune disease" refers to a disease or symptom that produces an adverse or deleterious reaction to an endogenous or exogenous antigen. The result is usually cell dysfunction, or destruction and dysfunction, or destruction of organs or tissues that may produce immune symptoms.
术语“试剂盒”与“产品包装”是同义词。The terms "kit" and "product packaging" are synonymous.
术语“受试者”或“对象”包括哺乳动物和非哺乳动物。哺乳动物包括但不限于,哺乳类:人、非人灵长类如猩猩、猿及猴类;农业动物如牛、马、山羊、绵羊、猪;家畜如兔、狗;实验动物包括啮齿类,如大鼠、小鼠及豚鼠等。非哺乳类动物包括但不限于,鸟、鱼等。在一优选例中,所选哺乳动物是人。The term "subject" or "subject" includes mammals and non-mammals. Mammals include, but are not limited to, mammals: humans, non-human primates such as orangutans, apes and monkeys; agricultural animals such as cows, horses, goats, sheep, pigs; domestic animals such as rabbits and dogs; laboratory animals include rodents, Such as rats, mice and guinea pigs. Non-mammalian animals include, but are not limited to, birds, fish, etc. In a preferred example, the selected mammal is a human.
给药途径Route of administration
适合的给药途径包括但不限于,口服、静脉注射、直肠、气雾剂、非肠道给药、眼部给药、肺部给药、经皮给药、阴道给药、耳道给药、鼻腔给药及局部给药。此外,仅作举例说明,肠道外给药,包括肌肉注射、皮下注射、静脉注射、髓内注射、心室注射、腹膜内注射、淋巴管内注射、及鼻内注射。Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transdermal, vaginal, and otic administration , Nasal administration and local administration. In addition, for example only, parenteral administration includes intramuscular injection, subcutaneous injection, intravenous injection, intramedullary injection, ventricular injection, intraperitoneal injection, intralymphatic injection, and intranasal injection.
在一方面,此处描述的化合物给药方式是局部的而不是全身性的给药方式。在特定的具体实施例中,长效制剂通过植入给药(例如皮下或肌肉)或通过肌肉注射。此外,在另一具体化实施例中,药物通过靶向药物给药系统来给药。例如,由器官特异性抗体包裹的脂质体。在这种具体实施例中,所述脂质体被选择性的导向特定器官并吸收。In one aspect, the mode of administration of the compounds described herein is a local rather than a systemic mode of administration. In certain embodiments, the long-acting formulation is administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. In addition, in another embodiment, the drug is administered through a targeted drug delivery system. For example, liposomes encapsulated by organ-specific antibodies. In this specific embodiment, the liposomes are selectively targeted to specific organs and absorbed.
药物组合物和剂量Pharmaceutical composition and dosage
本发明还提供药用组合物,其包含治疗有效量的与一种或多种药用载体(添加剂)和/或稀释剂一起配制的一种或多种本发明的化合物,和任选的一种或多种上述其它治疗剂。可通过任意合适方式给予本发明化合物以用于任意上述用途,例如口服,诸如片剂、丸剂、粉剂、颗粒剂、酏剂、酊剂、悬浮液(包括纳米悬 浮液、微悬浮液、喷雾干燥的分散液)、糖浆和乳液;经舌下;含服;经肠胃外,诸如通过皮下、静脉内、肌内或胸骨内注射或输注技术(例如以无菌可注射水性或非水性溶液或悬浮液形式);经鼻,包括向鼻膜给药,诸如通过吸入喷雾;局部,诸如以乳膏剂或软膏剂形式;或经直肠,诸如以栓剂形式。它们可单独给药,但通常使用基于所选给药途径和标准药学实践选择的药物载体给药。The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of the present invention formulated together with one or more pharmaceutical carriers (additives) and/or diluents, and optionally one One or more of the above-mentioned other therapeutic agents. The compound of the present invention can be administered by any suitable means for any of the above-mentioned purposes, for example, oral administration, such as tablets, pills, powders, granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions, spray-dried Dispersions), syrups and emulsions; sublingually; buccal; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (for example, in a sterile injectable aqueous or non-aqueous solution or suspension Liquid form); nasal, including administration to the nasal membranes, such as by inhalation spray; topical, such as in the form of creams or ointments; or transrectally, such as in the form of suppositories. They can be administered alone, but are usually administered using a pharmaceutical carrier selected based on the chosen route of administration and standard pharmaceutical practice.
根据本领域技术人员认识范围内的诸多因素来调配药用载体。这些因素包括,但不限于:所调配活性剂的类型和性质;含有活性剂的组合物所要给药的受试者;组合物的预期给药途径;及所靶向的治疗适应症。药用载体包括水性和非水性液体介质及各种固体和半固体剂型。The pharmaceutical carrier is formulated according to many factors within the scope of those skilled in the art. These factors include, but are not limited to: the type and nature of the active agent formulated; the subject to whom the composition containing the active agent is to be administered; the expected route of administration of the composition; and the targeted therapeutic indication. Pharmaceutical carriers include aqueous and non-aqueous liquid media and various solid and semi-solid dosage forms.
上述载体可包括除活性剂外的诸多不同成分和添加剂,上述其它成分出于本领域技术人员公知的各种原因包括于制剂中,例如稳定活性剂、粘合剂等。关于合适的药用载体和载体选择中所涉及的因素的描述可参见多个容易获得的来源,例如Allen L.V.Jr.et al.Remington:The Science and Practice of Pharmacy(2 Volumes),22nd Edition(2012),Pharmaceutical Press。The above-mentioned carrier may include many different ingredients and additives in addition to the active agent, and the above-mentioned other ingredients are included in the formulation for various reasons known to those skilled in the art, such as stabilizing active agents, binders, and the like. For descriptions of suitable pharmaceutical carriers and the factors involved in the selection of carriers, please refer to many easily available sources, such as Allen LVJr.et al. Remington: The Science and Practice of Pharmacy(2Volumes), 22nd Edition (2012) ), Pharmaceutical Press.
当然,本发明化合物的剂量方案取决于已知因素而有所变化,诸如具体药剂的药效学特性及其给药模式和途径;接受者的物种、年龄、性别、健康状况、医学病状和重量;症状的性质和程度;同时治疗的种类;治疗频率;给药途径、患者的肾和肝功能及期望效应。根据一般指导,当用于指定效应时,各活性成分的日口服剂量应为约0.001mg/天至约10-5000mg/天,优选地为约0.01mg/天至约1000mg/天,且最优选地为约0.1mg/天至约250mg/天。在恒速输注期间,静脉内最优选剂量应为约0.01mg/kg/分钟至约10mg/kg/分钟。本发明化合物可以单一日剂量给药,或可以每日两次、三次或四次的分开剂量给药总日剂量。Of course, the dosage regimen of the compound of the present invention varies depending on known factors, such as the pharmacodynamic properties of the specific agent and its administration mode and route; the species, age, sex, health status, medical condition and weight of the recipient. ; The nature and degree of symptoms; the types of simultaneous treatment; the frequency of treatment; the route of administration, the patient's renal and liver function, and the desired effect. According to general guidelines, when used for a given effect, the daily oral dose of each active ingredient should be about 0.001 mg/day to about 10-5000 mg/day, preferably about 0.01 mg/day to about 1000 mg/day, and most preferably The ground is about 0.1 mg/day to about 250 mg/day. During constant rate infusion, the most preferred intravenous dose should be about 0.01 mg/kg/min to about 10 mg/kg/min. The compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses of two, three or four times daily.
所述化合物通常以与根据预期给药形式(例如口服片剂、胶囊剂、酏剂和糖浆剂)适当地选择且与常规药学实践相符合的合适药物稀释剂、赋形剂或载体(在本文中统称为药物载体)的混合物形式进行给药。The compound is usually selected as a suitable pharmaceutical diluent, excipient or carrier (herein Administered in the form of a mixture of drugs collectively referred to as drug carriers).
适于给药的剂型(药物组合物)可含有约1毫克至约2000毫克活性成分/剂量单位。在这些医药组合物中,以组合物的总重量计,活性成分通常将以约0.1-95重量%的量存在。A dosage form (pharmaceutical composition) suitable for administration may contain about 1 mg to about 2000 mg of active ingredient per dosage unit. In these pharmaceutical compositions, the active ingredient will usually be present in an amount of about 0.1-95% by weight based on the total weight of the composition.
用于口服给药的典型胶囊剂含有至少一种本发明化合物(250mg)、乳糖(75mg)和硬脂酸镁(15mg)。使该混合物穿过60目网筛,并包装成1号明胶胶囊。A typical capsule for oral administration contains at least one compound of the present invention (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture was passed through a 60-mesh screen and packed into No. 1 gelatin capsules.
典型的可注射制剂可如下制备:以无菌方式将至少一种本发明化合物(250mg)置于瓶中、以无菌方式冻干并密封。为进行使用,将瓶内容物与2mL生 理盐水混合,以产生可注射制剂。A typical injectable preparation can be prepared by aseptically placing at least one compound of the present invention (250 mg) in a bottle, aseptically lyophilizing and sealing. For use, the contents of the bottle are mixed with 2 mL of physiological saline to produce an injectable preparation.
本发明范围包括(单独或与药物载体组合)包含治疗有效量的至少一种本发明化合物作为活性成分的药物组合物。任选地,本发明化合物可单独使用、与本发明其它化合物组合使用或与一种或多种其它治疗剂(例如抗癌剂或其它药学活性物质)组合使用。The scope of the present invention includes (alone or in combination with a pharmaceutical carrier) pharmaceutical compositions containing a therapeutically effective amount of at least one compound of the present invention as an active ingredient. Optionally, the compound of the present invention may be used alone, in combination with other compounds of the present invention, or in combination with one or more other therapeutic agents (e.g., anticancer agents or other pharmaceutically active substances).
不考虑所选择的给药路径,通过本领域技术人员已知的常规方法来将本发的化合物(其可以合适的水合形式使用)和/或本发明的药物组合物配制成药用剂量形式。Regardless of the chosen route of administration, the compound of the present invention (which can be used in a suitable hydrated form) and/or the pharmaceutical composition of the present invention is formulated into a pharmaceutical dosage form by conventional methods known to those skilled in the art.
可改变活性成分在本发明的药物组合物中的实际剂量水平,从而获得对于实现特定患者的期望的治疗响应、组成和给药模式有效的而对患者无毒的活性成分量。The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be changed, so as to obtain the amount of the active ingredient that is effective for realizing the desired therapeutic response, composition, and administration mode of a specific patient without being toxic to the patient.
选定的剂量水平会取决于多种因素,包括所用的本发明的特定化合物或其酯、盐或酰胺的活性;给药路径;给药时间;所用的特定化合物的排泄速率;吸收速率和程度;治疗的持续时间;与所用的特定化合物组合使用的其它药物、化合物和/或物质;所治疗的患者的年龄、性别、重量、状况、一般健康和先前的医学史等医学领域公知的因素。The selected dosage level will depend on many factors, including the activity of the particular compound of the invention or its ester, salt or amide used; route of administration; time of administration; excretion rate of the particular compound used; rate and extent of absorption The duration of treatment; other drugs, compounds and/or substances used in combination with the specific compound used; the age, sex, weight, condition, general health and previous medical history of the patient being treated and other factors well known in the medical field.
具有本领域普通技术的医生或兽医可容易地确定并开出有效量的所需药物组合物。例如,为了达到所期望的治疗效果,医师或兽医可在低于所需的水平开始药物组合物中所用的本发明化合物的较量,并逐步增加剂量直至实现所期望的效果。通常,合适日剂量的本发明化合物将是有效产生治疗效果的最低剂量的化合物的量。此种有效剂量通常取决于上述因素。通常,口服、静脉内、脑室内和皮下剂量的用于患者的本发明化合物的范围为约0.01至约50mg/kg体重/天。如果需要的话,有效日剂量的活性化合物可以两个、三个、四个、五个、六个或更多个亚剂量在一天当中的适当的间隔分别给药,任选地呈单位剂型形式。在本发明的某些方面中,服药为每天一次给药。A doctor or veterinarian with ordinary skill in the art can easily determine and prescribe an effective amount of the required pharmaceutical composition. For example, in order to achieve the desired therapeutic effect, the physician or veterinarian can start a competition of the compound of the present invention used in the pharmaceutical composition at a level lower than the required level, and gradually increase the dosage until the desired effect is achieved. Generally, a suitable daily dose of the compound of the invention will be the amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such effective doses usually depend on the above-mentioned factors. Generally, oral, intravenous, intracerebroventricular, and subcutaneous doses of the compound of the present invention for patients range from about 0.01 to about 50 mg/kg body weight/day. If desired, the effective daily dose of the active compound can be administered separately in two, three, four, five, six or more sub-doses at appropriate intervals throughout the day, optionally in unit dosage form. In certain aspects of the invention, the medication is administered once a day.
虽然本发明化合物可单独给药,但优选以药物制剂(组合物)形式给予化合物。Although the compound of the present invention can be administered alone, it is preferable to administer the compound in the form of a pharmaceutical preparation (composition).
试剂盒/产品包装Kit/product packaging
为了用于上述适应症的治疗,试剂盒/产品包装也在此进行描述。这些试剂盒可以由输送器、药包或容器盒组成,容器盒可被划分成多格,以容纳一种或多种容器,如管形瓶、试管及类似物等,每个容器中包含所述方法中的单独一 种成分。合适的容器包括瓶子,管形瓶,注射器和试管等。容器由可接受的玻璃或塑料等材料制作而成。In order to be used for the treatment of the above-mentioned indications, the kit/product packaging is also described here. These kits can be composed of a conveyor, a medicine pack or a container box. The container box can be divided into multiple compartments to accommodate one or more containers, such as vials, test tubes, and the like. Each container contains all A single component in the method described. Suitable containers include bottles, vials, syringes and test tubes. The container is made of acceptable materials such as glass or plastic.
举例来讲,容器可装有一种或多种在此所述的化合物,化合物可能以药物组分形式存在,也可能与在本文中所述的其它成分组成混合物体存在。容器可有一个无菌输出口(例如容器可为静脉输液包或瓶,瓶塞可被皮下注射器针头刺破)。这样的试剂盒可带有一种化合物,及本文中所述的使用方法的说明、标签或操作说明。For example, the container may contain one or more of the compounds described herein. The compounds may exist in the form of pharmaceutical components, or they may exist as a mixture with other ingredients described herein. The container may have a sterile outlet (for example, the container may be an intravenous infusion bag or a bottle, and the stopper may be pierced by a hypodermic syringe needle). Such kits may contain a compound, and instructions, labels, or operating instructions for the method of use described herein.
一个典型的试剂盒可包括一种或多种容器,为适应商业推广和使用者对化合物使用的需求,每个容器装有一种或多种材料(如试剂,也可以是浓缩的母液,和/或器械)。这些材料包括但不局限于缓冲液,稀释液,滤器,针头,注射器,输送器,包,容器,瓶和/或试管,附有内容清单和/或使用说明书,内置包装也附有说明书。整套的说明都要包括在内。A typical kit may include one or more containers. In order to meet the needs of commercial promotion and the use of compounds, each container contains one or more materials (such as reagents, or concentrated mother liquor, and/ Or equipment). These materials include, but are not limited to, buffers, diluents, filters, needles, syringes, conveyors, bags, containers, bottles and/or test tubes, with a list of contents and/or instructions for use, and instructions for the built-in packaging. The entire set of instructions must be included.
标签可显示在容器上或与容器紧密相关。标签出现在容器上即指标签字母、数字或其它特征被粘贴、铸模、刻在容器上;标签也可出现在装有多种容器的容器盒或运输盒内,如在产品插页中。一个标签可用来提示内容物的某种特定治疗用途。标签也可标示内容物使用说明,诸如在上述方法中描述的。The label can be displayed on the container or closely related to the container. The appearance of a label on a container means that the label letters, numbers or other features are pasted, molded, or engraved on the container; the label can also appear in a container box or shipping box containing a variety of containers, such as in a product insert. A label can be used to indicate a specific therapeutic use of the contents. The label may also indicate instructions for use of the content, such as described in the above method.
在本说明书中被描述的所有特征(包括任何所述的权利要求、摘要和图),和/或任何方法或过程中涉及的所有步骤,均有可能以任意一种组合存在,除非某些特征或步骤在同一组合中是相互排斥的。All the features described in this specification (including any of the claims, abstracts and figures), and/or all the steps involved in any method or process, may exist in any combination, unless some features Or the steps are mutually exclusive in the same combination.
本发明提到的上述特征,或实施例提到的特征可以任意组合。本案说明书所揭示的所有特征可与任何组合物形式并用,说明书中所揭示的各个特征,可以任何可提供相同、均等或相似目的的替代性特征取代。因此除有特别说明,所揭示的特征仅为均等或相似特征的一般性例子。The above-mentioned features mentioned in the present invention or the features mentioned in the embodiments can be combined arbitrarily. All the features disclosed in the specification of this case can be used in combination with any composition form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。除非另外说明,否则所有的百分数、比率、比例、或份数按重量计。The present invention will be further explained below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and not to limit the scope of the present invention. The experimental methods that do not indicate specific conditions in the following examples are usually in accordance with conventional conditions or in accordance with the conditions recommended by the manufacturer. Unless otherwise stated, all percentages, ratios, ratios, or parts are by weight.
本发明中的重量体积百分比中的单位是本领域技术人员所熟知的,例如是指在100毫升的溶液中溶质的重量。除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。The unit of weight-volume percentage in the present invention is well known to those skilled in the art, for example, refers to the weight of the solute in a 100 ml solution. Unless otherwise defined, all professional and scientific terms used in the text have the same meaning as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to the content described can be applied to the method of the present invention. The preferred implementation methods and materials described in this article are for demonstration purposes only.
在本发明的优选例中,提供但不局限于以下化合物:In the preferred embodiment of the present invention, the following compounds are provided but not limited to:
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。The present invention will be further explained below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and not to limit the scope of the present invention. The experimental methods that do not indicate specific conditions in the following examples usually follow the conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
具体实施例Specific embodiment
当未包括制备途径时,相关中间体是市售的(例如来自Sigma Aldrich,Alfa)。When the preparation route is not included, the relevant intermediates are commercially available (for example from Sigma Aldrich, Alfa).
通用过程General process
使用市售试剂而不需进一步纯化。
1H-NMR谱在Bruker仪器上于500MHz记录。化学位移值以百万分率表示,即δ值。以下简写用于NMR信号的多重性:s=单峰,brs=宽峰,d=二重峰,t=三重峰,m=多重峰。耦合常数以J值列出,以Hz测量。NMR和质谱结果根据背景峰校正。色谱是指使用100筛目硅胶进行并在氮气压力(快速色谱)条件下完成的柱色谱。用于监测反应的TLC指使用特定流动相和来自Merck的硅胶F254作为固定相进行的TLC。
Use commercially available reagents without further purification. The 1 H-NMR spectrum was recorded on a Bruker instrument at 500 MHz. The chemical shift value is expressed in parts per million, that is, the δ value. The following abbreviations are used for the multiplicity of the NMR signal: s = singlet, brs = broad peak, d = doublet, t = triplet, m = multiplet. Coupling constants are listed as J values and measured in Hz. NMR and mass spectrometry results are corrected for background peaks. Chromatography refers to column chromatography performed using 100 mesh silica gel and completed under nitrogen pressure (flash chromatography). The TLC used to monitor the reaction refers to TLC performed using a specific mobile phase and silica gel F254 from Merck as a stationary phase.
LC-MS实验在以下条件下测量:The LC-MS experiment is measured under the following conditions:
仪器:Thermo U3000,ALLtech ELSD,MSQ,UV检测器结合ELSD和MSD(流出比为4:1)。柱:Waters X-Bridge C-18,3.5μm,4.6x50mm;柱温:30℃。梯度【时间(min)/溶剂B在A中(%)】:0.00/5.0,0.70/95,1.40/95,1.41/5,1.50/5。(溶剂A=0.01%三氟乙酸在水中;溶剂B=0.01%三氟乙酸在乙腈中)。UV检测:214/254/280/300nm;DAD检测:200-400nm;流速:4mL/min;MS:ESI,100-1500m/zInstruments: Thermo U3000, ALLtech ELSD, MSQ, UV detector combined with ELSD and MSD (the elution ratio is 4:1). Column: Waters X-Bridge C-18, 3.5μm, 4.6x50mm; column temperature: 30℃. Gradient [time (min)/solvent B in A (%)]: 0.00/5.0, 0.70/95, 1.40/95, 1.41/5, 1.50/5. (Solvent A = 0.01% trifluoroacetic acid in water; Solvent B = 0.01% trifluoroacetic acid in acetonitrile). UV detection: 214/254/280/300nm; DAD detection: 200-400nm; Flow rate: 4mL/min; MS: ESI, 100-1500m/z
制备型HPLC通常使用酸性方法(乙腈和水的梯度,各含有0.1%甲酸)用Thermo U3000 AFC-3000;柱:Globalsil C-18 12nm,250x 20mm,10μm,或相当;流速:20mL/min,进行分离。Preparative HPLC usually uses an acidic method (gradient of acetonitrile and water, each containing 0.1% formic acid) with Thermo U3000 AFC-3000; column: Globalsil C-18 12nm, 250x 20mm, 10μm, or equivalent; flow rate: 20mL/min, Separate.
中间体的合成Synthesis of intermediates
化合物INT-1的制备:Preparation of compound INT-1:
在回流条件下,将混有4-氟苯乙酮(2.5g,18mmol)和N,N-二甲基甲酰胺二甲基缩醛(2.4g,20mmol)搅拌4小时;反应液浓缩后,粗品用乙醇溶解(10mL),随后加入水合肼(1.1g,18mmol,80%w/w)。所得反应液在80℃条件下搅拌2小时,反应液浓缩后,所得粗品用硅胶柱层析(石油醚/乙酸乙酯=4/1~1/1)得到黄色固体INT-1a(1.84g,收率:62.7%)。MS(ESI):m/z 163.2(M+H)
+.
Under reflux conditions, the mixture of 4-fluoroacetophenone (2.5g, 18mmol) and N,N-dimethylformamide dimethyl acetal (2.4g, 20mmol) was stirred for 4 hours; after the reaction solution was concentrated, The crude product was dissolved in ethanol (10 mL), and then hydrazine hydrate (1.1 g, 18 mmol, 80% w/w) was added. The resulting reaction solution was stirred at 80°C for 2 hours. After the reaction solution was concentrated, the crude product obtained was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=4/1~1/1) to obtain a yellow solid INT-1a (1.84g, Yield: 62.7%). MS(ESI): m/z 163.2(M+H) + .
在室温条件下,将N-溴代丁二酰亚胺(549mg,3.1mmol)加入至溶有化合物INT-1a(500mg,3.1mmol)的N,N-二甲基甲酰胺(5mL)中,所得反应液在相同温度下搅拌1.5小时。反应液倒入水(50mL)中,并用乙酸乙酯萃取(50mL×3);合并有机相用水和饱和食盐水(各100mL)洗涤,无水硫酸钠干燥,浓缩。所得粗品用硅胶柱层析(石油醚/乙酸乙酯=4/1)得到白色固体INT-1b(553mg,收率:74.4%)。
1H NMR(500MHz,Chloroform-d)δ7.81–7.74(m,2H),7.63(s,1H),7.18–7.11(m,2H);MS(ESI):m/z 241.2(M+H)
+.
At room temperature, N-bromosuccinimide (549 mg, 3.1 mmol) was added to N, N-dimethylformamide (5 mL) in which compound INT-1a (500 mg, 3.1 mmol) was dissolved, The resulting reaction liquid was stirred at the same temperature for 1.5 hours. The reaction solution was poured into water (50 mL), and extracted with ethyl acetate (50 mL×3); the combined organic phase was washed with water and saturated brine (100 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain white solid INT-1b (553 mg, yield: 74.4%). 1 H NMR(500MHz,Chloroform-d)δ7.81–7.74(m,2H), 7.63(s,1H), 7.18–7.11(m,2H); MS(ESI): m/z 241.2(M+H ) + .
在0℃条件下,将钠氢(38mg,0.95mmol,60%w/w在煤油)加入至溶有化合物INT-1c(200mg,0.83mmol)的无水四氢呋喃(8mL)溶液中,所得反应液在相同条件下搅拌20分钟;随后加入2-(三甲基硅烷基)乙氧甲基氯(207mg,1.24mmol),所得反应液在室温条件下进一步搅拌2小时。反应液加少许水淬灭后,倒入至水(50mL)中,并用乙酸乙酯萃取(50mL×3);合并有机相用水和饱和食盐水(各100mL)洗涤,无水硫酸钠干燥,浓缩。所得粗品用硅胶柱层析(石油醚/乙酸乙酯=10/1)得到无色油状物INT-1(298mg,收率:96.7%)。Under the condition of 0℃, sodium hydrogen (38mg, 0.95mmol, 60% w/w in kerosene) was added to a solution of compound INT-1c (200mg, 0.83mmol) in anhydrous tetrahydrofuran (8mL), the resulting reaction liquid Stirred under the same conditions for 20 minutes; then 2-(trimethylsilyl)ethoxymethyl chloride (207 mg, 1.24 mmol) was added, and the resulting reaction solution was further stirred at room temperature for 2 hours. The reaction solution was quenched with a little water, poured into water (50mL), and extracted with ethyl acetate (50mL×3); the combined organic phase was washed with water and saturated brine (100mL each), dried over anhydrous sodium sulfate, and concentrated . The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=10/1) to obtain INT-1 (298 mg, yield: 96.7%) as a colorless oil.
化合物INT-2的制备:Preparation of compound INT-2:
将环丙甲基酮(160mg,1.9mmol)加入至混有钠氢(37mg,1.6mmol,60%w/w在煤油)的四氢呋喃(10mL)溶液中,所得反应液在室温条件下搅拌半小时后加热升至回流;随后滴加预先溶有4-氟苯乙酮(250mg,1.6mmol)的四氢呋喃(3mL)溶液。所得反应液在回流状态下进一步搅拌半小时。冷却至室温后, 将反应液倒入至1M盐酸水溶液,调节pH至7-8;并用乙酸乙酯萃取(30mL×2)。合并有机相用水和饱和食盐水(各50mL)洗涤,无水硫酸钠干燥,浓缩。所得粗品用硅胶柱层析(石油醚/乙酸乙酯=20/1~10/1)得到淡黄色油状物INT-2a(250mg,收率:74.8%)。MS(ESI):m/z 207.4(M+H)
+
Cyclopropyl methyl ketone (160mg, 1.9mmol) was added to a solution of sodium hydrogen (37mg, 1.6mmol, 60% w/w in kerosene) in tetrahydrofuran (10mL), and the resulting reaction solution was stirred at room temperature for half an hour After heating, it was raised to reflux; then, a solution of 4-fluoroacetophenone (250 mg, 1.6 mmol) in tetrahydrofuran (3 mL) was added dropwise. The resulting reaction solution was further stirred for half an hour under reflux. After cooling to room temperature, the reaction solution was poured into a 1M aqueous hydrochloric acid solution to adjust the pH to 7-8; and extracted with ethyl acetate (30 mL×2). The combined organic phase was washed with water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=20/1~10/1) to obtain INT-2a (250 mg, yield: 74.8%) as a pale yellow oil. MS(ESI): m/z 207.4(M+H) +
在回流条件下,将溶有化合物INT-2a(250mg,1.2mmol),水合肼(103mg,2.7mmol,80%w/w)的乙醇(5mL)溶液搅拌4小时。反应液冷却至室温后浓缩,所得粗品用二氯甲烷(30mL)溶解,并用水和饱和食盐水(各30mL)洗涤,无水硫酸钠干燥,浓缩得到白色固体INT-2b(200mg,收率:81.6%)。MS(ESI):m/z 203.5(M+H)
+
Under reflux conditions, a solution of compound INT-2a (250 mg, 1.2 mmol) and hydrazine hydrate (103 mg, 2.7 mmol, 80% w/w) dissolved in ethanol (5 mL) was stirred for 4 hours. The reaction solution was cooled to room temperature and concentrated. The resulting crude product was dissolved in dichloromethane (30 mL), washed with water and saturated brine (30 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain a white solid INT-2b (200 mg, yield: 81.6%). MS(ESI): m/z 203.5(M+H) +
在冰浴条件下,将N-碘代丁二酰亚胺(270mg,1.2mmol)加入至溶有化合物INT-2b(200mg,1.0mmol)的N,N-二甲基甲酰胺(5mL)中;所得反应液加热至90℃条件下搅拌16小时。反应液中加入二氯甲烷和饱和碳酸氢钠溶液(各30mL);有机相用水和饱和食盐水(各30mL)洗涤,无水硫酸钠干燥,浓缩得到淡黄色油状物INT-2c(300mg,收率:92.5%)。MS(ESI):m/z 329.2(M+H)
+
Under ice bath conditions, add N-iodosuccinimide (270 mg, 1.2 mmol) to N, N-dimethylformamide (5 mL) with compound INT-2b (200 mg, 1.0 mmol) dissolved ; The resulting reaction solution was heated to 90 ° C and stirred for 16 hours. Dichloromethane and saturated sodium bicarbonate solution (30 mL each) were added to the reaction solution; the organic phase was washed with water and saturated brine (30 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain a pale yellow oil INT-2c (300 mg, yield) Rate: 92.5%). MS(ESI): m/z 329.2(M+H) +
从化合物INT-2c起,参考化合物INT-1合成中的最后一步,得到化合物INT-2。MS(ESI):m/z 459.1(M+H)
+
Starting from compound INT-2c, refer to the last step in the synthesis of compound INT-1 to obtain compound INT-2. MS(ESI): m/z 459.1(M+H) +
化合物INT-3的制备:Preparation of compound INT-3:
从乙酸乙酯和4-氟苯乙酮起,参考化合物INT-2a的合成得到化合物INT-3a。Starting from ethyl acetate and 4-fluoroacetophenone, refer to the synthesis of compound INT-2a to obtain compound INT-3a.
从化合物INT-3a起,参考化合物INT-2的合成得到化合物INT-3。MS(ESI):m/z 433.0(M+H)
+。
Starting from compound INT-3a, refer to the synthesis of compound INT-2 to obtain compound INT-3. MS (ESI): m/z 433.0 (M+H) + .
化合物INT-4的制备:Preparation of compound INT-4:
将2,4-二硝基苯基羟胺(3.1g,15.4mmol)加入至溶有4-(叔丁氧羰基氨基)吡啶(3.0g,15.4mmol)的2-甲基四氢呋喃(15mL)溶液;所得反应液在40℃条件下搅拌4小时,随后冷却至室温后搅拌过夜。反应液过滤得到黄色固体INT-4a(6.1g,收率:99.6%)。2,4-Dinitrophenylhydroxylamine (3.1g, 15.4mmol) was added to a solution of 4-(tert-butoxycarbonylamino)pyridine (3.0g, 15.4mmol) in 2-methyltetrahydrofuran (15mL); The resulting reaction solution was stirred at 40°C for 4 hours, then cooled to room temperature and stirred overnight. The reaction solution was filtered to obtain a yellow solid INT-4a (6.1 g, yield: 99.6%).
将混有化合物INT-4a(1.0g,2.5mmol),丙炔酸乙酯(249mg,2.5mmol)和碳酸钾(703mg,5.0mmol)的N,N-二甲基甲酰胺(8mL)在室温条件下搅拌过夜。所得反应液倒入水(80mL)中,并用乙酸乙酯萃取(60mL×3)。合并有机相用水和饱和食盐水(各150mL)洗涤,无水硫酸钠干燥,浓缩。所得粗品用硅胶柱层析(石油醚/乙酸乙酯=4/1)得到黄色固体INT-4b(378mg,收率:48.7%)。MS(ESI):m/z 306.1(M+H)
+.
Put compound INT-4a (1.0g, 2.5mmol), ethyl propiolate (249mg, 2.5mmol) and potassium carbonate (703mg, 5.0mmol) mixed with N,N-dimethylformamide (8mL) at room temperature Stir overnight under the conditions. The resulting reaction solution was poured into water (80 mL), and extracted with ethyl acetate (60 mL×3). The combined organic phase was washed with water and saturated brine (150 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain yellow solid INT-4b (378 mg, yield: 48.7%). MS(ESI): m/z 306.1(M+H) + .
将溶有化合物INT-4b(378mg,1.24mmol)和三氟乙酸(1.41g,12.4mmol)的二氯甲烷(12mL)溶液在室温条件下搅拌过夜。所得反应液倒入水(30mL)中,用二氯甲烷萃取(20mL×2)。合并有机相用饱和碳酸氢钠,水和饱和食盐水(各50mL)洗涤,无水硫酸钠干燥,浓缩得到黄色固体INT-4c(254mg,收率:100%)。MS(ESI):m/z 206.5(M+H)
+.
A solution of compound INT-4b (378 mg, 1.24 mmol) and trifluoroacetic acid (1.41 g, 12.4 mmol) in dichloromethane (12 mL) was stirred at room temperature overnight. The resulting reaction solution was poured into water (30 mL), and extracted with dichloromethane (20 mL×2). The combined organic phase was washed with saturated sodium bicarbonate, water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain a yellow solid INT-4c (254 mg, yield: 100%). MS(ESI): m/z 206.5(M+H) + .
在冰浴条件下,将亚硝酸钠(128mg,1.86mmol)加入至溶有化合物INT-4c(254mg,1.24mmol)的溴化氢水溶液(5mL,48%w/w),并维持5分钟;随后在相同条件下加入溴化亚铜(355mg,2.48mmol),并进一步维持10分钟。所得反应液慢慢加热搅拌至50℃,反应20分钟。反应液倒入水(20mL)中,用乙酸乙酯萃取(30mL×2)。合并有机相用饱和碳酸氢钠,水和饱和食盐水(各50mL)洗涤,无水硫酸钠干燥,浓缩。所得粗品用硅胶柱层析(石油醚/乙酸乙酯=4/1)得到黄色固体INT-4(272mg,收率:81.7%)。
1H NMR(500MHz,DMSO-d
6)δ8.86(d,J=7.5Hz,1H),8.48(s,1H),8.24-8.20(m,1H),7.34(d,J=7.5Hz,1H),4.32(q,J=7.0Hz,2H),1.34(t,J=7.0Hz,3H);MS(ESI):m/z 269.3(M+H)
+.
Under ice bath conditions, sodium nitrite (128 mg, 1.86 mmol) was added to the hydrogen bromide aqueous solution (5 mL, 48% w/w) in which compound INT-4c (254 mg, 1.24 mmol) was dissolved, and maintained for 5 minutes; Subsequently, cuprous bromide (355 mg, 2.48 mmol) was added under the same conditions and maintained for a further 10 minutes. The resulting reaction solution was slowly heated and stirred to 50°C, and reacted for 20 minutes. The reaction solution was poured into water (20 mL), and extracted with ethyl acetate (30 mL×2). The combined organic phase was washed with saturated sodium bicarbonate, water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain yellow solid INT-4 (272 mg, yield: 81.7%). 1 H NMR(500MHz,DMSO-d 6 )δ8.86(d,J=7.5Hz,1H), 8.48(s,1H), 8.24-8.20(m,1H), 7.34(d,J=7.5Hz, 1H), 4.32(q,J=7.0Hz,2H),1.34(t,J=7.0Hz,3H); MS(ESI): m/z 269.3(M+H) + .
化合物INT-5的制备:Preparation of compound INT-5:
将溶有化合物INT-4(100mg,0.37mmol)的硫酸水溶液(40%w/w,5mL)在100℃条件下搅拌5小时。反应液冷却至室温后倒入水(20mL)中,并用乙酸乙酯(30mL×2)萃取。合并有机相用饱和碳酸氢钠,水和饱和食盐水(各50mL)洗涤,无水硫酸钠干燥,浓缩得到黄色油状物INT-5(77mg,收率:94.6%)。MS(ESI):m/z 197.3(M+H)
+.
An aqueous sulfuric acid solution (40% w/w, 5 mL) in which compound INT-4 (100 mg, 0.37 mmol) was dissolved was stirred at 100° C. for 5 hours. The reaction solution was cooled to room temperature, poured into water (20 mL), and extracted with ethyl acetate (30 mL×2). The combined organic phase was washed with saturated sodium bicarbonate, water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil INT-5 (77 mg, yield: 94.6%). MS(ESI): m/z 197.3(M+H) + .
化合物INT-6的制备:Preparation of compound INT-6:
在冰浴条件下,将钠氢(72mg,1.8mmol,60%w/w在煤油)加入至溶有化合物INT-1b(300mg,1.24mmol)的四氢呋喃(8mL)溶液中,并维持20分钟;随后在相同条件下加入碘甲烷(353mg,2.5mmol)。所得反应液在搅拌中缓慢升至室温,并在室温条件下搅拌过夜。反应液用少许水淬灭,倒入水(40mL)中,并用乙酸乙酯萃取(40mL×2)。合并有机相浓缩后用制备HPLC分离得到黄色固体INT-6(149mg,收率:46.9%)。
1H NMR(500MHz,Chloroform-d)δ7.88–7.81(m,2H),7.45(s,1H),7.15–7.07(m,2H),3.92(s,3H).
Under ice bath conditions, sodium hydrogen (72 mg, 1.8 mmol, 60% w/w in kerosene) was added to a solution of compound INT-1b (300 mg, 1.24 mmol) in tetrahydrofuran (8 mL) and maintained for 20 minutes; Then under the same conditions, methyl iodide (353 mg, 2.5 mmol) was added. The resulting reaction solution was slowly raised to room temperature while stirring, and stirred overnight at room temperature. The reaction solution was quenched with a little water, poured into water (40 mL), and extracted with ethyl acetate (40 mL×2). The combined organic phase was concentrated and separated by preparative HPLC to obtain yellow solid INT-6 (149 mg, yield: 46.9%). 1 H NMR (500MHz, Chloroform-d) δ 7.88-7.81 (m, 2H), 7.45 (s, 1H), 7.15-7.07 (m, 2H), 3.92 (s, 3H).
化合物INT-7的制备:Preparation of compound INT-7:
在0℃条件下,将溶有1H-吡唑-3-硼酸频哪酯(500mg,2.6mmol)和N,N-二异丙基乙胺(333mg,2.6mmol)的二氯甲烷(10mL)溶液搅拌半小时,随后加入2-(三甲基硅烷基)乙氧甲基氯(430mg,2.6mmol)。反应液在搅拌下缓慢升至室温,并在室温条件下继续搅拌过夜。反应液用二氯甲烷(40mL)稀释,并用饱和碳酸氢钠和饱和食盐水(各50mL)洗涤,无水硫酸钠干燥,浓缩。所得粗品用硅胶柱层析(二氯甲烷/甲醇=20/1)分离得到淡黄色油状物INT-7a(500 mg,收率:59.8%)。At 0℃, 1H-pyrazole-3-boronic acid pinacolate (500mg, 2.6mmol) and N,N-diisopropylethylamine (333mg, 2.6mmol) in dichloromethane (10mL) will be dissolved The solution was stirred for half an hour, and then 2-(trimethylsilyl)ethoxymethyl chloride (430 mg, 2.6 mmol) was added. The reaction solution was slowly raised to room temperature under stirring, and stirring was continued overnight at room temperature. The reaction solution was diluted with dichloromethane (40 mL), washed with saturated sodium bicarbonate and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was separated by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain INT-7a (500 mg, yield: 59.8%) as a pale yellow oil.
在氮气气氛下,将混有化合物INT-7a(150mg,0.46mmol),2-溴-6-甲基吡啶(88mg,0.51mmol),Pd(PPh
3)
4(53mg,0.046mmol)和碳酸钾(192mg,1.38mmol)的1,4-二氧六环和水的混合溶液(3.3mL,v/v=10/1)在90℃条件下搅拌16小时。反应液冷却后用乙酸乙酯(30mL)稀释,硅藻土过滤。滤液浓缩后用硅胶柱层析(石油醚/乙酸乙酯=5/1)分离得到黄色油状物INT-7b(120mg,收率:89.6%)。MS(ESI):m/z 290.5(M+H)
+
Under a nitrogen atmosphere, the compound INT-7a (150mg, 0.46mmol), 2-bromo-6-methylpyridine (88mg, 0.51mmol), Pd(PPh 3 ) 4 (53mg, 0.046mmol) and potassium carbonate will be mixed A mixed solution (3.3 mL, v/v=10/1) of 1,4-dioxane and water (192 mg, 1.38 mmol) was stirred at 90°C for 16 hours. The reaction solution was cooled and diluted with ethyl acetate (30 mL), and filtered through Celite. The filtrate was concentrated and separated by silica gel column chromatography (petroleum ether/ethyl acetate=5/1) to obtain a yellow oily INT-7b (120 mg, yield: 89.6%). MS(ESI): m/z 290.5(M+H) +
从化合物INT-7b起,参照化合物INT-1b的合成得到化合物INT-7。MS(ESI):m/z 368.3(M+H)
+
Starting from compound INT-7b, refer to the synthesis of compound INT-1b to obtain compound INT-7. MS(ESI): m/z 368.3(M+H) +
化合物INT-8的制备:Preparation of compound INT-8:
从化合物INT-7a和2-溴-6-三氟甲基吡啶起,参照化合物INT-7的合成得到化合物INT-8。MS(ESI):m/z 422.1(M+H)
+
Starting from compound INT-7a and 2-bromo-6-trifluoromethylpyridine, referring to the synthesis of compound INT-7, compound INT-8 was obtained. MS(ESI): m/z 422.1(M+H) +
化合物INT-9的制备:Preparation of compound INT-9:
从化合物INT-7a和2-溴-6-二氟甲基吡啶起,参照化合物INT-7的合成得到化合物INT-9。MS(ESI):m/z 404.1(M+H)
+
Starting from compound INT-7a and 2-bromo-6-difluoromethylpyridine, referring to the synthesis of compound INT-7, compound INT-9 was obtained. MS(ESI): m/z 404.1(M+H) +
化合物INT-10的制备:Preparation of compound INT-10:
从6-三氟甲基吡啶-2-甲酸甲酯起,参照化合物INT-2的合成得到化合物 INT-10。MS(ESI):m/z 510.2(M+H)
+
Starting from methyl 6-trifluoromethylpyridine-2-carboxylate, the compound INT-10 was obtained by referring to the synthesis of compound INT-2. MS(ESI): m/z 510.2(M+H) +
化合物INT-11的制备:Preparation of compound INT-11:
从6-甲基吡啶-2-甲酸甲酯起,参照化合物INT-2的合成得到化合物INT-11。MS(ESI):m/z 456.1(M+H)
+
Starting with methyl 6-picoline-2-carboxylate, the compound INT-11 was obtained by referring to the synthesis of compound INT-2. MS(ESI): m/z 456.1(M+H) +
化合物INT-12的制备:Preparation of compound INT-12:
从4-氟苯乙酮和环戊甲基酮起,参照化合物INT-2的合成得到化合物INT-12。MS(ESI):m/z 487.0(M+H)
+
Starting from 4-fluoroacetophenone and cyclopentyl methyl ketone, the compound INT-12 was obtained by referring to the synthesis of compound INT-2. MS(ESI): m/z 487.0(M+H) +
化合物INT-13的制备:Preparation of compound INT-13:
从化合物INT-4a和3-炔基-2-丁酮起,参照化合物INT-4的合成得到化合物INT-13。MS(ESI):m/z 239.0(M+H)
+
Starting from compound INT-4a and 3-alkynyl-2-butanone, referring to the synthesis of compound INT-4, compound INT-13 was obtained. MS(ESI): m/z 239.0(M+H) +
化合物INT-14的制备:Preparation of compound INT-14:
将草酸二乙酯(554mg,3.8mmol)加入至混有钠氢(74mg,3.2mmol,60%w/w在煤油)的四氢呋喃(20mL)溶液中,所得反应液在室温条件下搅拌半小时后加热升至回流;随后滴加预先溶有4-氟苯乙酮(500mg,3.6mmol)的四氢呋喃(6mL)溶液。所得反应液在回流状态下进一步搅拌半小时。冷却至室温后,将反应液倒入至1M盐酸水溶液,调节pH至7-8;并用乙酸乙酯萃取(30mL×2)。合并有机相用水和饱和食盐水(各50mL)洗涤,无水硫酸钠干燥,浓缩。所得粗品用硅胶柱层析(石油醚/乙酸乙酯=20/1~10/1)得到淡黄色油状物INT-14a(386mg,收率:45.1%)。MS(ESI):m/z 239.3(M+H)
+
Diethyl oxalate (554mg, 3.8mmol) was added to a tetrahydrofuran (20mL) solution mixed with sodium hydrogen (74mg, 3.2mmol, 60% w/w in kerosene), and the resulting reaction solution was stirred at room temperature for half an hour. Heat to reflux; then add dropwise a solution of 4-fluoroacetophenone (500 mg, 3.6 mmol) in tetrahydrofuran (6 mL) previously dissolved. The resulting reaction solution was further stirred for half an hour under reflux. After cooling to room temperature, the reaction solution was poured into a 1M aqueous hydrochloric acid solution to adjust the pH to 7-8; and extracted with ethyl acetate (30 mL×2). The combined organic phase was washed with water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=20/1~10/1) to obtain INT-14a (386 mg, yield: 45.1%) as a pale yellow oil. MS(ESI): m/z 239.3(M+H) +
从化合物INT-14a起,参照化合物INT-2的合成得到化合物INT-14。MS(ESI):m/z 491.2(M+H)
+
Starting from compound INT-14a, referring to the synthesis of compound INT-2, compound INT-14 was obtained. MS(ESI): m/z 491.2(M+H) +
化合物INT-15的制备Preparation of compound INT-15
从4-氟苯乙酮和1,1-二氟乙酸乙酯起,参照化合物INT-14的合成得到化合物INT-15。MS(ESI):m/z 469.4(M+H)
+
From 4-fluoroacetophenone and 1,1-difluoroethyl acetate, refer to the synthesis of compound INT-14 to obtain compound INT-15. MS(ESI): m/z 469.4(M+H) +
实施例化合物的合成Synthesis of Example Compound
实施例1:Example 1:
在氮气氛围下,将混有化合物INT-4(10mg,37μmol),联硼酸频那醇酯(9.9mg,39μmol),Pd(PPh
3)
2Cl
2(2.6mg,3.7μmol)和醋酸钾(10.9mg,111μmol)的1,4-二氧六环溶液(5mL)在90℃条件下搅拌2小时。随后在反应液中加入化合物INT-1(15mg,40μmol),Pd(PPh
3)
4(4.7mg,4.0μmol)磷酸钾(25.7mg,121μmol)和水(0.5mL);所得混合液用氮气置换三次,并在100℃条件和氮气气氛下搅拌过夜。反应液冷却至室温,硅藻土过滤,浓缩。所得粗品用制备型薄层层析板(石油醚/乙酸乙酯=3/1)得到黄色油状物1a(16.7mg,收率:86.0%)。 MS(ESI):m/z 481.0(M+H)
+.
Under a nitrogen atmosphere, the compound INT-4 (10mg, 37μmol), pinacol diborate (9.9mg, 39μmol), Pd(PPh 3 ) 2 Cl 2 (2.6mg, 3.7μmol) and potassium acetate ( 10.9 mg, 111 μmol) of 1,4-dioxane solution (5 mL) was stirred at 90°C for 2 hours. Subsequently, compound INT-1 (15 mg, 40 μmol), Pd(PPh 3 ) 4 (4.7 mg, 4.0 μmol) potassium phosphate (25.7 mg, 121 μmol) and water (0.5 mL) were added to the reaction solution; the resulting mixture was replaced with nitrogen Three times, and stirred overnight at 100°C under nitrogen atmosphere. The reaction solution was cooled to room temperature, filtered through Celite, and concentrated. The obtained crude product was used with a preparative thin-layer chromatography plate (petroleum ether/ethyl acetate=3/1) to obtain a yellow oil 1a (16.7 mg, yield: 86.0%). MS(ESI): m/z 481.0(M+H) + .
将溶有化合物1a(16.7mg,35μmol)的三氟乙酸和二氯甲烷的混合溶液(2mL,v/v=1/1)溶液在室温下搅拌2小时。反应液中加入乙酸乙酯和水(各15mL),然后分液;有机相进一步用饱和碳酸氢钠和饱和食盐水洗涤(各10mL),浓缩。所得粗品用制备HPLC分离得到白色固体1(2.0mg,收率:16.4%)。
1H NMR(500MHz,DMSO-d6)δ13.33(s,1H),8.78(d,J=7.3Hz,1H),8.37(s,1H),7.84(s,1H),7.57–7.45(m,3H),7.38–7.16(m,3H),7.09–7.02(m,1H),4.15(q,J=7.1Hz,2H),1.15(t,J=7.1Hz,3H);MS(ESI):m/z 351.2(M+H)
+.
A mixed solution (2 mL, v/v=1/1) of trifluoroacetic acid and dichloromethane in which compound 1a (16.7 mg, 35 μmol) was dissolved was stirred at room temperature for 2 hours. Ethyl acetate and water (15 mL each) were added to the reaction solution, followed by liquid separation; the organic phase was further washed with saturated sodium bicarbonate and saturated brine (10 mL each), and concentrated. The obtained crude product was separated by preparative HPLC to obtain a white solid 1 (2.0 mg, yield: 16.4%). 1 H NMR(500MHz,DMSO-d6)δ13.33(s,1H), 8.78(d,J=7.3Hz,1H), 8.37(s,1H), 7.84(s,1H), 7.57–7.45(m ,3H),7.38–7.16(m,3H),7.09–7.02(m,1H),4.15(q,J=7.1Hz,2H),1.15(t,J=7.1Hz,3H); MS(ESI) :m/z 351.2(M+H) + .
实施例2:Example 2:
从化合物INT-5起,参照化合物1的合成得到化合物2。
1H NMR(500MHz,DMSO-d6)δ13.25(s,1H),8.57(d,J=7.2Hz,1H),8.03(brs,1H),7.93(d,J=2.0Hz,1H),7.58–7.43(m,3H),7.30–7.17(m,2H),6.66–6.62(m,1H),6.51–6.48(m,1H);MS(ESI):m/z 279.3(M+H)
+.
Starting from compound INT-5, referring to the synthesis of compound 1, compound 2 is obtained. 1 H NMR(500MHz,DMSO-d6)δ13.25(s,1H), 8.57(d,J=7.2Hz,1H), 8.03(brs,1H), 7.93(d,J=2.0Hz,1H), 7.58–7.43(m,3H),7.30–7.17(m,2H),6.66–6.62(m,1H),6.51–6.48(m,1H); MS(ESI): m/z 279.3(M+H) + .
实施例3:Example 3:
将氢氧化钠水溶液(3M,1mL)加入至溶有化合物1a(147mg,0.31mmol)的甲醇(5mL)溶液;所得反应液在60℃条件下搅拌2小时。反应液冷却至室温后,用1M盐酸水溶液调节pH至3-4,并用乙酸乙酯萃取(20mL×2)。合并有机相用饱和碳酸氢钠和饱和食盐水洗涤(各30mL),无水硫酸钠干燥,浓缩后得到黄色油状物3a(122mg,收率:88.1%)。MS(ESI):m/z 453.2(M+H)
+.
Aqueous sodium hydroxide solution (3M, 1 mL) was added to a solution of compound 1a (147 mg, 0.31 mmol) in methanol (5 mL); the resulting reaction solution was stirred at 60° C. for 2 hours. After the reaction solution was cooled to room temperature, the pH was adjusted to 3-4 with 1M aqueous hydrochloric acid, and extracted with ethyl acetate (20 mL×2). The combined organic phase was washed with saturated sodium bicarbonate and saturated brine (30 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil 3a (122 mg, yield: 88.1%). MS(ESI): m/z 453.2(M+H) + .
在溶有化合物3a(122mg,0.27mmol)的1,4-二氧六环(4mL)溶液中加入 N,N-二异丙基乙胺(70mg,0.54mmol),HATU(123mg,0.32mmol)和氨(0.4M在1,4-二氧六环中,5mL);所得反应液在50℃条件下搅拌4小时。反应液浓缩,所得粗品用硅胶柱层析(石油醚/乙酸乙酯=1/1)得到淡黄色油状物3b(100mg,收率:82.2%)。Add N,N-diisopropylethylamine (70mg, 0.54mmol), HATU (123mg, 0.32mmol) to 1,4-dioxane (4mL) solution with compound 3a (122mg, 0.27mmol) dissolved And ammonia (0.4M in 1,4-dioxane, 5mL); the resulting reaction solution was stirred at 50°C for 4 hours. The reaction solution was concentrated, and the obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate = 1/1) to obtain a pale yellow oil 3b (100 mg, yield: 82.2%).
从化合物3b起,参照化合物1的最后一步反应得到化合物3。
1H NMR(500MHz,Chloroform-d)δ8.32–8.27(m,1H),8.27–8.23(m,1H),8.20(d,J=2.6Hz,1H),7.84(brs,1H),7.45–7.37(m,2H),7.28–7.24(m,2H),7.09–7.00(m,2H),6.71–6.65(m,1H);MS(ESI):m/z 322.3(M+H)
+.
Starting from compound 3b, refer to the last step of compound 1 to obtain compound 3. 1 H NMR(500MHz, Chloroform-d) δ8.32–8.27(m,1H), 8.27–8.23(m,1H), 8.20(d,J=2.6Hz,1H), 7.84(brs,1H), 7.45 –7.37(m,2H),7.28–7.24(m,2H),7.09–7.00(m,2H),6.71–6.65(m,1H); MS(ESI): m/z 322.3(M+H) + .
实施例4:Example 4:
从化合物INT-5和化合物INT-7起,参照化合物2的合成得到化合物4。
1H NMR(500MHz,DMSO-d6)δ8.61-8.56(m,1H),8.30(s,1H),7.95(s,1H),7.81(s,1H),7.73(t,J=7.5Hz,1H),7.27–7.22(m,1H),6.90–6.83(m,1H),6.53(s,1H),2.44(s,3H);MS(ESI):m/z 276.3(M+H)
+.
Starting from compound INT-5 and compound INT-7, referring to the synthesis of compound 2, compound 4 is obtained. 1 H NMR(500MHz,DMSO-d6)δ8.61-8.56(m,1H),8.30(s,1H),7.95(s,1H),7.81(s,1H),7.73(t,J=7.5Hz ,1H),7.27–7.22(m,1H),6.90–6.83(m,1H),6.53(s,1H),2.44(s,3H); MS(ESI): m/z 276.3(M+H) + .
实施例5:Example 5:
从化合物INT-5和化合物INT-8起,参照化合物2的合成得到化合物5。
1H NMR(500MHz,DMSO-d6)δ8.57(d,J=7.5Hz,1H),8.22(s,1H),8.16(t,J=8.0Hz,1H),8.11(d,J=8.0Hz,1H),7.98–7.94(m,1H),7.89–7.84(m,2H),6.89(d,J=7.5Hz,1H),6.50(s,1H);MS(ESI):m/z 330.3(M+H)
+.
Starting from compound INT-5 and compound INT-8, referring to the synthesis of compound 2, compound 5 is obtained. 1 H NMR(500MHz,DMSO-d6)δ8.57(d,J=7.5Hz,1H), 8.22(s,1H), 8.16(t,J=8.0Hz,1H), 8.11(d,J=8.0 Hz,1H),7.98–7.94(m,1H),7.89–7.84(m,2H),6.89(d,J=7.5Hz,1H),6.50(s,1H); MS(ESI): m/z 330.3(M+H) + .
实施例6:Example 6:
从化合物INT-4和化合物6a起,参照化合物1a的合成得到化合物6a。MS(ESI):m/z 365.3(M+H)
+.
Starting from compound INT-4 and compound 6a, referring to the synthesis of compound 1a, compound 6a is obtained. MS(ESI): m/z 365.3(M+H) + .
从化合物6a起,参照化合物3b的合成得到化合物6。
1H NMR(500MHz,DMSO-d6)δ8.67(d,J=7.1Hz,1H),8.49(s,1H),8.20(s,1H),8.11(s,1H),7.64(brs,1H),7.51–7.41(m,2H),7.26–7.16(m,2H),7.03(brs,1H),6.78–6.72(m,1H),3.93(s,3H);MS(ESI):m/z 336.3(M+H)
+.
Starting from compound 6a, referring to the synthesis of compound 3b, compound 6 is obtained. 1 H NMR(500MHz,DMSO-d6)δ8.67(d,J=7.1Hz,1H), 8.49(s,1H), 8.20(s,1H), 8.11(s,1H), 7.64(brs,1H) ),7.51–7.41(m,2H),7.26–7.16(m,2H),7.03(brs,1H),6.78–6.72(m,1H),3.93(s,3H); MS(ESI): m/ z 336.3(M+H) + .
实施例7:Example 7:
从化合物INT-4和化合INT-2起,参照化合物1a的合成得到化合物7a。MS(ESI):m/z 521.5(M+H)
+.
Starting from compound INT-4 and compound INT-2, referring to the synthesis of compound 1a, compound 7a is obtained. MS(ESI): m/z 521.5(M+H) + .
从化合物7a起,参照化合物3的合成得到化合物7。
1H NMR(500MHz,DMSO-d6)δ12.88(brs,1H),8.70(d,J=7.0Hz,1H),8.52(s,1H),8.20(s,1H),7.69(s,1H),7.48–7.38(m,2H),7.19(t,J=9.0Hz,2H),7.02(s,1H),6.81–6.73(m,1H),1.95–1.83(m,1H),0.98–0.83(m,4H);MS(ESI):m/z 362.0(M+H)
+.
Starting from compound 7a, referring to the synthesis of compound 3, compound 7 is obtained. 1 H NMR(500MHz,DMSO-d6)δ12.88(brs,1H), 8.70(d,J=7.0Hz,1H), 8.52(s,1H), 8.20(s,1H), 7.69(s,1H) ),7.48–7.38(m,2H),7.19(t,J=9.0Hz,2H),7.02(s,1H),6.81-6.73(m,1H),1.95-1.83(m,1H),0.98- 0.83(m,4H); MS(ESI): m/z 362.0(M+H) + .
实施例8:Example 8:
从化合物INT-4和化合INT-3起,参照化合物7的合成得到化合物8。
1H NMR(500MHz,Methanol-d4)δ8.51(d,J=7.2Hz,1H),8.44(s,1H),8.15(s,1H),7.45–7.38(m,2H),7.07(s,2H),6.73(s,1H),4.62(s,2H),2.40(s,3H);MS(ESI):m/z336.2(M+H)
+.
Starting from compound INT-4 and compound INT-3, refer to the synthesis of compound 7 to obtain compound 8. 1 H NMR(500MHz,Methanol-d4)δ8.51(d,J=7.2Hz,1H),8.44(s,1H),8.15(s,1H),7.45-7.38(m,2H),7.07(s ,2H),6.73(s,1H),4.62(s,2H),2.40(s,3H); MS(ESI): m/z336.2(M+H) + .
实施例9:Example 9:
从化合物INT-4和化合INT-7起,参照化合物7的合成得到化合物9。
1H NMR(500MHz,DMSO-d6)δ13.35(brs,1H),8.66(s,1H),8.48(s,1H),8.40-8.24(m,1H),7.73(t,J=7.5Hz,1H),7.63(s,1H),7.22(s,1H),7.15-6.92(m,2H),2.39(s,3H);MS(ESI):m/z 319.1(M+H)
+.
From compound INT-4 and compound INT-7, refer to the synthesis of compound 7 to obtain compound 9. 1 H NMR(500MHz,DMSO-d6)δ13.35(brs,1H),8.66(s,1H),8.48(s,1H),8.40-8.24(m,1H),7.73(t,J=7.5Hz ,1H),7.63(s,1H),7.22(s,1H),7.15-6.92(m,2H),2.39(s,3H); MS(ESI): m/z 319.1(M+H) + .
实施例10:Example 10:
从化合物INT-4和化合INT-8起,参照化合物7的合成得到化合物10。
1H NMR(500MHz,methanol-d4)δ8.51(d,J=7.0Hz,1H),8.42(s,1H),8.21(s,1H),8.10–7.98(m,3H),7.75–7.70(m,1H),7.14(d,J=7.0Hz,1H);MS(ESI):m/z 373.2(M+H)
+.
From compound INT-4 and compound INT-8, refer to the synthesis of compound 7 to obtain compound 10. 1 H NMR(500MHz, methanol-d4)δ8.51(d,J=7.0Hz,1H), 8.42(s,1H), 8.21(s,1H), 8.10–7.98(m,3H), 7.75–7.70 (m,1H),7.14(d,J=7.0Hz,1H); MS(ESI): m/z 373.2(M+H) + .
实施例11:Example 11:
从化合物INT-4和化合INT-9起,参照化合物7的合成得到化合物11。
1H NMR(500MHz,Methanol-d4)δ8.52(d,J=7.0Hz,1H),8.42(s,1H),8.38(s,1H),8.05(s,1H),8.00(t,J=8.0Hz,1H),7.90–7.83(m,1H),7.65(d,J=7.5Hz,1H),7.12–7.08(m,1H),6.65(t,J=45Hz,1H);MS(ESI):m/z 355.0(M+H)
+.
From compound INT-4 and compound INT-9, refer to the synthesis of compound 7 to obtain compound 11. 1 H NMR(500MHz,Methanol-d4)δ8.52(d,J=7.0Hz,1H),8.42(s,1H),8.38(s,1H),8.05(s,1H),8.00(t,J =8.0Hz,1H),7.90–7.83(m,1H), 7.65(d,J=7.5Hz,1H), 7.12–7.08(m,1H), 6.65(t,J=45Hz,1H); MS( ESI): m/z 355.0(M+H) + .
实施例12:Example 12:
从化合物INT-4和化合INT-10起,参照化合物7的合成得到化合物12。
1H NMR(500MHz,Methanol-d4)δ8.54(d,J=7.5Hz,1H),8.45(s,1H),8.27(s,1H),7.98(t,J=7.5Hz,1H),7.65(d,J=7.5Hz,1H),7.04–6.99(m,1H),2.02–1.93(m,1H),1.04–0.95(m,2H),0.91–0.85(m,2H);MS(ESI):m/z 413.3(M+H)
+.
From compound INT-4 and compound INT-10, refer to the synthesis of compound 7 to obtain compound 12. 1 H NMR(500MHz,Methanol-d4)δ8.54(d,J=7.5Hz,1H),8.45(s,1H),8.27(s,1H),7.98(t,J=7.5Hz,1H), 7.65(d,J=7.5Hz,1H),7.04–6.99(m,1H),2.02–1.93(m,1H),1.04–0.95(m,2H),0.91–0.85(m,2H); MS( ESI): m/z 413.3(M+H) + .
实施例13:Example 13:
从化合物INT-4和化合INT-11起,参照化合物7的合成得到化合物13。
1H NMR(500MHz,Methanol-d4)δ8.70–8.42(m,2H),8.33(s,1H),7.72–7.55(m,1H),7.49–7.07(m,2H),7.01–6.85(m,1H),2.59–2.30(m,3H),2.09–1.81(m,1H),1.08–0.85(m,4H);MS(ESI):m/z 359.3(M+H)
+.
From compound INT-4 and compound INT-11, refer to the synthesis of compound 7 to obtain compound 13. 1 H NMR(500MHz,Methanol-d4)δ8.70–8.42(m,2H), 8.33(s,1H), 7.72–7.55(m,1H), 7.49–7.07(m,2H), 7.01–6.85( m,1H),2.59–2.30(m,3H),2.09–1.81(m,1H),1.08–0.85(m,4H); MS(ESI): m/z 359.3(M+H) + .
实施例14:Example 14:
从化合物INT-4和化合INT-10起,参照化合物12的合成,将氨换成二甲胺得到化合物14。
1H NMR(500MHz,Methanol-d4)δ8.53(s,1H),8.26(s,1H),8.12-7.93(m,3H),7.64(s,1H),7.03-7.00(m,1H),3.20(s,6H),2.05-1.97(m,1H),1.05-0.95(m,2H),0.92-0.85(m,2H);MS(ESI):m/z 441.2(M+H)
+.
Starting from compound INT-4 and compound INT-10, referring to the synthesis of compound 12, the ammonia is replaced with dimethylamine to obtain compound 14. 1 H NMR(500MHz,Methanol-d4)δ8.53(s,1H), 8.26(s,1H), 8.12-7.93(m,3H), 7.64(s,1H), 7.03-7.00(m,1H) ,3.20(s,6H),2.05-1.97(m,1H),1.05-0.95(m,2H),0.92-0.85(m,2H); MS(ESI): m/z 441.2(M+H) + .
实施例15:Example 15:
从化合物INT-4和化合INT-10起,参照化合物12的合成,将氨换成甲胺得到化合物15。
1H NMR(500MHz,Methanol-d4)δ8.52(s,1H),8.36(s,1H),8.27(s,1H),8.06-7.94(m,2H),7.64(d,J=7.5Hz,1H),7.00(dd,J=7.0,2.0Hz,1H),2.90(s,3H),1.99(s,1H),1.00(s,2H),0.91-0.84(m,2H);MS(ESI):m/z 427.2(M+H)
+.
Starting from compound INT-4 and compound INT-10, referring to the synthesis of compound 12, the ammonia is replaced with methylamine to obtain compound 15. 1 H NMR(500MHz,Methanol-d4)δ8.52(s,1H),8.36(s,1H),8.27(s,1H),8.06-7.94(m,2H),7.64(d,J=7.5Hz ,1H),7.00(dd,J=7.0,2.0Hz,1H),2.90(s,3H),1.99(s,1H),1.00(s,2H),0.91-0.84(m,2H); MS( ESI): m/z 427.2(M+H) + .
实施例16:Example 16:
从化合物INT-4和化合INT-2起,参照化合物7的合成,将氨换成乙醇胺得到化合物16。
1H NMR(500MHz,Methanol-d4)δ8.50(d,J=7.0Hz,1H),8.42(s,1H),8.31(s,1H),7.44-7.39(m,2H),7.08(t,J=8.5Hz,2H),6.78(d,J=7.0Hz,1H),3.71(t,J=6.0Hz,2H),3.49(t,J=6.0Hz,2H),2.04-1.96(m,1H),1.05-0.96(m,2H),0.92-0.85(m,2H);m/z 405.7(M+H)
+.
Starting from compound INT-4 and compound INT-2, referring to the synthesis of compound 7, the ammonia is replaced with ethanolamine to obtain compound 16. 1 H NMR(500MHz,Methanol-d4)δ8.50(d,J=7.0Hz,1H),8.42(s,1H),8.31(s,1H),7.44-7.39(m,2H),7.08(t ,J=8.5Hz,2H), 6.78(d,J=7.0Hz,1H), 3.71(t,J=6.0Hz,2H), 3.49(t,J=6.0Hz,2H),2.04-1.96(m ,1H),1.05-0.96(m,2H),0.92-0.85(m,2H); m/z 405.7(M+H) + .
实施例17:Example 17:
从化合物INT-4和化合INT-2起,参照化合物7的合成得到化合物17。
1H NMR(500MHz,Methanol-d4)δ8.51(d,J=7.0Hz,1H),8.44(s,1H),8.17(s,1H),7.42–7.38(m,2H),7.05(t,J=8.5Hz,2H),6.73(d,J=8.0Hz,1H),2.13–2.01(m,2H),1.89–1.71(m,5H),1.71–1.63(m,2H);m/z 389.7(M+H)
+.
From compound INT-4 and compound INT-2, refer to the synthesis of compound 7 to obtain compound 17. 1 H NMR(500MHz,Methanol-d4)δ8.51(d,J=7.0Hz,1H),8.44(s,1H),8.17(s,1H),7.42-7.38(m,2H),7.05(t ,J=8.5Hz,2H),6.73(d,J=8.0Hz,1H),2.13-2.01(m,2H),1.89-1.71(m,5H),1.71-1.63(m,2H); m/ z 389.7(M+H) + .
实施例18:Example 18:
从化合物INT-13和化合物INT-2起,参照化合物1的合成得到化合物18。
1H NMR(500MHz,Methanol-d4)δ8.60(d,J=7.2Hz,1H),8.55(s,1H),8.38(s,1H),7.42(m,2H),7.15-7.05(m,2H),6.96(s,1H),2.55(s,3H),2.12-1.96(m,1H),0.99(m,4H);m/z 361.2(M+H)
+.
Starting from compound INT-13 and compound INT-2, referring to the synthesis of compound 1, compound 18 was obtained. 1 H NMR(500MHz,Methanol-d4)δ8.60(d,J=7.2Hz,1H),8.55(s,1H),8.38(s,1H),7.42(m,2H),7.15-7.05(m ,2H),6.96(s,1H),2.55(s,3H),2.12-1.96(m,1H),0.99(m,4H); m/z 361.2(M+H) + .
实施例19:Example 19:
从化合物7a起,参照化合物1合成中的最后一步得到化合物19a。m/z 391.2(M+H)
+.
Starting from compound 7a, refer to the last step in the synthesis of compound 1 to obtain compound 19a. m/z 391.2(M+H) + .
在冰浴条件下,将二异丁基氢化铝(83μL,2M在甲苯中)滴加至溶有化合物19a(40mg,0.10mmol)的二氯甲烷(1mL)溶液中;所得混合液液在相同条件下搅拌半小时。反应液随后加入到酒石酸钾钠溶液中(5mL,1M水溶液),经乙酸乙酯萃取;有机相减压浓缩后,所得粗品用制备HPLC分离得到白色固体19(5.2mg,收率:14.6%)。
1H NMR(500MHz,Methanol-d4)δ8.44(d,J=7.2Hz,1H),7.95(s,1H),7.70(s,1H),7.44(dd,J=8.5,5.4Hz,2H),7.08(m,2H),6.71(m,1H),4.76(s,2H),2.01(m,1H),0.94(m,4H);m/z 349.3(M+H)
+.
Under ice bath conditions, diisobutylaluminum hydride (83μL, 2M in toluene) was added dropwise to a solution of compound 19a (40mg, 0.10mmol) in dichloromethane (1mL); the resulting mixture was in the same Stir under the conditions for half an hour. The reaction solution was then added to potassium sodium tartrate solution (5mL, 1M aqueous solution), and extracted with ethyl acetate; after the organic phase was concentrated under reduced pressure, the crude product obtained was separated by preparative HPLC to obtain a white solid 19 (5.2mg, yield: 14.6%) . 1 H NMR(500MHz,Methanol-d4)δ8.44(d,J=7.2Hz,1H),7.95(s,1H),7.70(s,1H),7.44(dd,J=8.5,5.4Hz,2H ),7.08(m,2H),6.71(m,1H),4.76(s,2H),2.01(m,1H),0.94(m,4H); m/z 349.3(M+H) + .
实施例20:Example 20:
从化合物INT-14和化合物INT-4起,参照化合物1和化合物3的合成得到化合物20a。m/z 394.3(M+H)
+.
Starting from compound INT-14 and compound INT-4, referring to the synthesis of compound 1 and compound 3, compound 20a is obtained. m/z 394.3(M+H) + .
从化合物20a起,参照化合物19的最后一步合成得到化合物20。
1H NMR(500MHz,Methanol-d4)δ13.31(s,1H),8.69(d,J=7.0Hz,1H),8.53–8.48(m,1H),8.09(s,1H),7.49–7.38(m,2H),7.29–7.13(m,2H),7.01–6.75(m,1H),4.49(s,2H);m/z 352.2(M+H)
+.
Starting from compound 20a, refer to the last step of compound 19 to obtain compound 20. 1 H NMR(500MHz,Methanol-d4)δ13.31(s,1H),8.69(d,J=7.0Hz,1H),8.53-8.48(m,1H),8.09(s,1H),7.49-7.38 (m,2H),7.29–7.13(m,2H),7.01–6.75(m,1H),4.49(s,2H); m/z 352.2(M+H) + .
实施例21:Example 21:
从化合物INT-15和化合物INT-4起,参照化合物1和化合物3的合成得到化合物21。
1HNMR(500MHz,Methanol-d4)δ8.56(d,J=7.0Hz,1H),8.44(s,1H),8.23(s,1H),7.42(dd,J=8.5,5.0Hz,2H),7.13(t,J=8.5Hz,2H),6.90–6.83(m,1H),1.36–1.19(m,1H);m/z 372.3(M+H)
+.
Starting from compound INT-15 and compound INT-4, referring to the synthesis of compound 1 and compound 3, compound 21 was obtained. 1 HNMR(500MHz,Methanol-d4)δ8.56(d,J=7.0Hz,1H),8.44(s,1H),8.23(s,1H),7.42(dd,J=8.5,5.0Hz,2H) ,7.13(t,J=8.5Hz,2H),6.90–6.83(m,1H),1.36–1.19(m,1H); m/z 372.3(M+H) + .
测试实施例Test example
化合物对TGFβRI激酶(ALK5)活性抑制作用的测定:Determination of compound's inhibitory effect on TGFβRI kinase (ALK5) activity:
TGFβRI激酶购买自Carna(Cat#09-141)。在384孔板(Greiner,Cat#784075)中加入2μl用激酶缓冲液(40mM Tris PH 7.5,20mM MgCl
2,1mM DTT,1mg/ml BSA)配制的酶溶液(TGFβRI激酶在最终反应体系中为25nM)。对于阴性对照则加入2μl激酶缓冲液。将化合物用DMSO配制成10mM的储存液,在检测化合物之前根据起始浓度的需要,用DMSO对化合物进行二次稀释。取2.5μl化合物加入47.5μl ddH
2O中,按照3倍稀释方法进行稀释,每个化合物设置10个浓度点。化合物稀释完成后,取1μl加入酶溶液中。充分混匀后室温孵育10min(最终反应体系中DMSO浓度为1%)。对于阴性对照和阳性对照,则加入1μl含5%DMSO的水溶液。最后加入2μl含有ATP以及TGFβRI激酶多肽底物(Signalchem,Cat#T36-58)的混合液(ATP最终浓度为3.5μM,底物最终浓度为0.1μg/ul),充分混匀后置于28度反应120min。最后使用ADP-Glo Kinase Assay Kit(Promega,Cat#V9102)进行检测。使用Molecular Devices,SpectraMax i3x.读取最终化学发光信号。采用XLFIT对所得到的数据进行4参数曲线拟合并计算IC
50。
TGFβRI kinase was purchased from Carna (Cat#09-141). Add 2μl of enzyme solution prepared with kinase buffer (40mM Tris PH 7.5, 20mM MgCl 2 , 1mM DTT, 1mg/ml BSA) into a 384-well plate (Greiner, Cat#784075) (TGFβRI kinase is 25nM in the final reaction system) ). For the negative control, 2μl kinase buffer was added. The compound was prepared as a 10 mM stock solution with DMSO, and the compound was diluted twice with DMSO according to the requirement of the initial concentration before the compound was detected. Take 2.5 μl of the compound and add it to 47.5 μl of ddH 2 O, and dilute according to the 3-fold dilution method, with 10 concentration points for each compound. After the compound was diluted, 1 μl was added to the enzyme solution. After mixing thoroughly, incubate at room temperature for 10 min (the concentration of DMSO in the final reaction system is 1%). For the negative control and the positive control, add 1 μl of an aqueous solution containing 5% DMSO. Finally, add 2μl of a mixture containing ATP and TGFβRI kinase peptide substrate (Signalchem, Cat#T36-58) (the final concentration of ATP is 3.5μM, the final concentration of substrate is 0.1μg/ul), mix well and place at 28°C Reaction for 120min. Finally, use ADP-Glo Kinase Assay Kit (Promega, Cat#V9102) for detection. Use Molecular Devices, SpectraMax i3x. to read the final chemiluminescence signal. XLFIT data obtained using the 4-parameter curve fitting is performed aggregated IC 50.
化合物对p38α激酶活性抑制作用的测定:Determination of compound's inhibitory effect on p38α kinase activity:
p38α激酶购买自SignalChem(Cat#M39-10BG)。在384孔板(Greiner,Cat#784075)中加入2μl用激酶缓冲液(40mM Tris PH 7.5,20mM MgCl
2,0.05mM DTT,0.1mg/ml BSA)配制的酶溶液(p38α激酶在最终反应体系中为0.8ng/ul)。对于阴性对照则加入2μl激酶缓冲液。将化合物用DMSO配制成10mM的储存液,在检测化合物之前根据起始浓度的需要,用DMSO对化合物进行二次稀释。 取2.5μl化合物加入47.5μl ddH
2O中,按照3倍稀释方法进行稀释,每个化合物设置10个浓度点。化合物稀释完成后,取1μl加入酶溶液中。充分混匀后室温孵育10min(最终反应体系中DMSO浓度为1%)。对于阴性对照和阳性对照,则加入1μl含5%DMSO的水溶液。最后加入2μl含有ATP以及p38激酶多肽底物(Signalchem,Cat#P03-58)的混合液(ATP最终浓度为50μM,底物最终浓度为0.125μg/μl),充分混匀后置于25度反应120min。最后使用ADP-Glo Kinase Assay Kit(Promega,Cat#V9102)进行检测。使用Molecular Devices,SpectraMax i3x.读取最终化学发光信号。采用XLFIT对所得到的数据进行4参数曲线拟合并计算IC
50。
p38α kinase was purchased from SignalChem (Cat#M39-10BG). Add 2μl of enzyme solution (p38α kinase in the final reaction system) prepared with kinase buffer (40mM Tris PH 7.5, 20mM MgCl 2 , 0.05mM DTT, 0.1mg/ml BSA) into a 384-well plate (Greiner, Cat#784075) 0.8ng/ul). For the negative control, 2μl kinase buffer was added. The compound was prepared as a 10 mM stock solution with DMSO, and the compound was diluted twice with DMSO according to the requirement of the initial concentration before the compound was detected. Take 2.5 μl of the compound and add it to 47.5 μl of ddH 2 O, and dilute according to the 3-fold dilution method, with 10 concentration points for each compound. After the compound was diluted, 1 μl was added to the enzyme solution. After mixing thoroughly, incubate at room temperature for 10 min (the concentration of DMSO in the final reaction system is 1%). For the negative control and the positive control, add 1 μl of an aqueous solution containing 5% DMSO. Finally, add 2μl of a mixture containing ATP and p38 kinase peptide substrate (Signalchem, Cat#P03-58) (the final concentration of ATP is 50μM, the final concentration of substrate is 0.125μg/μl), mix well and place in a 25 degree reaction 120min. Finally, use ADP-Glo Kinase Assay Kit (Promega, Cat#V9102) for detection. Use Molecular Devices, SpectraMax i3x. to read the final chemiluminescence signal. XLFIT data obtained using the 4-parameter curve fitting is performed aggregated IC 50.
实施例中所列化合物对于ALK5和p38α的激酶活性抑制作用的结果:The results of the inhibitory effects of the compounds listed in the examples on the kinase activity of ALK5 and p38α:
*参比化合物是LY2157299(即galunisertib)*The reference compound is LY2157299 (i.e. galunisertib)
化合物对TGFβRI受体Smad信号通路的抑制活性的测定:Determination of the inhibitory activity of the compound on the TGFβRI receptor Smad signaling pathway:
收集HEK-Blue TGFβcells(Invivogen,Cat#hkb-tgfb),并用10%FBS的DMEM调整细胞密度为1.25×10
6cells/ml,并以每孔40μl加入96孔板中。将化合物用DMSO配制成10mM的储存液,在检测化合物之前根据起始浓度的需要,用DMSO对化合物进行二次稀释。取2.5μl化合物加入1ml完全培养基中,吹 打混匀,用含0.25%DMSO的DMEM培养基对化合物进行3倍稀释(100μl体系中DMSO浓度为0.1%)。取40μl配制好的化合物至96孔细胞板中,阳性对照以及阴性对照中加入40ul含0.25%DMSO的培养基,于37℃5%CO
2培养箱中孵育2小时。每孔加入20μl人重组TGFβ1(Invivogen,cat#Rcyc-htgfb1),其最终浓度为0.1ng/ml。置于37℃5%CO
2中培养24小时。24小时后取60μl上清用于分泌型碱性磷酸酶(SEAP)检测,细胞板中补加60ul/well的培养基用于细胞活性检测。SEAP检测采用Great EscApe SEAP chemiluminescence KIT(Clontech,Cat#631738)进行检测,细胞活性检测采用CellTiter-Glo Luminescent Cell Viability Assay(Promega,Cat#G7573)进行检测。使用Molecular Devices,SpectraMax i3x.读取最终化学发光信号。采用XLFIT对所得到的数据进行4参数曲线拟合并计算IC
50。
Collect HEK-Blue TGFβcells (Invivogen, Cat#hkb-tgfb), adjust the cell density to 1.25×10 6 cells/ml with 10% FBS DMEM, and add 40 μl per well to a 96-well plate. The compound was prepared as a 10 mM stock solution with DMSO, and the compound was diluted twice with DMSO according to the requirement of the initial concentration before the compound was detected. Add 2.5 μl of the compound to 1 ml of complete medium, mix by pipetting, and dilute the compound 3-fold with DMEM medium containing 0.25% DMSO (the DMSO concentration in a 100 μl system is 0.1%). Take 40 μl of the prepared compound into a 96-well cell plate, add 40 μl of medium containing 0.25% DMSO to the positive control and the negative control, and incubate for 2 hours in a 5% CO 2 incubator at 37°C. Add 20μl of human recombinant TGFβ1 (Invivogen, cat#Rcyc-htgfb1) to each well, the final concentration of which is 0.1ng/ml. Incubate in 5% CO 2 at 37°C for 24 hours. After 24 hours, 60μl of supernatant was used for secreted alkaline phosphatase (SEAP) detection, and 60ul/well of medium was added to the cell plate for cell viability detection. SEAP detection uses Great EscApe SEAP chemiluminescence KIT (Clontech, Cat#631738) for detection, and cell viability detection uses CellTiter-Glo Luminescent Cell Viability Assay (Promega, Cat#G7573) for detection. Use Molecular Devices, SpectraMax i3x. to read the final chemiluminescence signal. XLFIT data obtained using the 4-parameter curve fitting is performed aggregated IC 50.
实施例中所列化合物对于TGFβRI受体Smad信号通路的抑制活性的结果:The results of the inhibitory activity of the compounds listed in the examples on the TGFβRI receptor Smad signaling pathway:
*参比化合物是LY2157299(即galunisertib)*The reference compound is LY2157299 (i.e. galunisertib)
Claims (9)
- 式(I)化合物或其药学上可接受的盐、前药、同位素衍生物、异构体、溶剂化物、或其代谢产物:The compound of formula (I) or a pharmaceutically acceptable salt, prodrug, isotope derivative, isomer, solvate, or metabolite thereof:其中,Cy表示被0、1、2、3个取代基所取代的C 6-C 10芳基或者5-10元杂芳基,其中所述的取代基选自:卤素、C 1-C 6烷基、C 3-C 6环烷基、卤代C 1-C 6烷基、-OR a、氰基、硝基、NR aR b、-SO 2R a、-C(O)R a、-C(O)OR a、-C(O)NR aR b、-P(O)R aR b; Wherein, Cy represents a C 6 -C 10 aryl group or a 5-10 membered heteroaryl group substituted by 0, 1, 2, 3 substituents, wherein the substituents are selected from: halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl, -OR a, cyano, nitro, NR a R b, -SO 2 R a, -C (O) R a , -C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;R 1表示氢、卤素、C 1-C 6烷基、C 3-C 6环烷基、羟基(C 1-C 6烷基)、卤代C 1-C 6烷基; R 1 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl;R 2表示氢、C 1-C 6烷基、C 3-C 6环烷基、羟基(C 1-C 6烷基)、卤代C 1-C 6烷基、-OR a、氰基、硝基、NR aR b、-SO 2R a、-C(O)R a、-C(O)OR a、-C(O)NR aR b、-NR aC(O)R b、-SO 2NR aR b、-NR aSO 2R b; R 2 represents hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl, -OR a , cyano, Nitro, NR a R b , -SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -NR a C(O)R b , -SO 2 NR a R b , -NR a SO 2 R b ;R 3表示氢、卤素、C 1-C 6烷基、C 3-C 6环烷基、羟基(C 1-C 6烷基)、卤代C 1-C 6烷基、-OR a、氰基、硝基、NR aR b、-SO 2R a、-C(O)R a、-C(O)OR a、-C(O)NR aR b、-NR aC(O)R b、-SO 2NR aR b、-NR aSO 2R b; R 3 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl, -OR a , cyanide Group, nitro group, NR a R b , -SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -NR a C(O)R b , -SO 2 NR a R b , -NR a SO 2 R b ;R 4表示氢、C 1-C 6烷基、C 2-C 6烯基、C 3-C 6环烷基、卤代C 1-C 6烷基、-OR a、-C(O)R a、-C(O)OR a、-C(O)NR aR b、羟基(C 1-C 6烷基); R 4 represents hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, halogenated C 1 -C 6 alkyl, -OR a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , hydroxyl (C 1 -C 6 alkyl);R 5表示氢、C 1-C 6烷基、C 2-C 6烯基、C 3-C 6环烷基、卤代C 1-C 6烷基;或者R 4、R 5与其所连接的原子一起形成5-8元饱和或不饱和环,该环中还可以任意地含有0、1或2个选自N、O、S的杂原子; R 5 represents hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl; or R 4 , R 5 and the connected The atoms together form a 5-8 membered saturated or unsaturated ring, which may optionally contain 0, 1, or 2 heteroatoms selected from N, O, and S;其中,R a、R b分别各自独立地表示氢、C 1-C 6烷基、C 2-C 6烯基、C 3-C 6环烷基、卤代C 1-C 6烷基;或者R a、R b与其所连接的原子一起形成5-8元环,该环中还可以任意地含有0、1或2个选自N、O、S的杂原 子; Wherein, R a and R b each independently represent hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, or halogenated C 1 -C 6 alkyl; or R a, R b form together with the atoms to which they are attached a 5-8 membered ring which may also optionally contain 1 or 2 heteroatoms selected from N, O, S, heteroatoms;n表示0、1、2或3。n represents 0, 1, 2 or 3.
- 如权利要求1所述的式(I)化合物或其药学上可接受的盐、前药、同位素衍生物、异构体、溶剂化物、或其代谢产物,其中所述式(I)化合物具有以下式(II)结构:The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt, prodrug, isotope derivative, isomer, solvate, or metabolite thereof, wherein the compound of formula (I) has the following Structure of formula (II):其中,R 1、R 3、R 4、R 5、R a、R b和n具有如权利要求1所述的定义; Wherein, R 1, R 3, R 4, R 5, R a, R b and n have the meanings according to claim 1;R 2表示氢、C 1-C 6烷基、C 3-C 6环烷基、羟基(C 1-C 6烷基)、卤代C 1-C 6烷基; R 2 represents hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, hydroxy (C 1 -C 6 alkyl), halogenated C 1 -C 6 alkyl;W表示CR L或者N; W represents CR L or N;R 6表示氢、卤素、C 1-C 6烷基、C 3-C 6环烷基、卤代C 1-C 6烷基、-OR a、氰基、硝基、NR aR b、-SO 2R a、-C(O)R a、-C(O)OR a、-C(O)NR aR b、-P(O)R aR b; R 6 represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl, -OR a , cyano, nitro, NR a R b ,- SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;其中,R L表示氢、卤素、C 1-C 6烷基、C 3-C 6环烷基、卤代C 1-C 6烷基、-OR a、氰基、硝基、NR aR b、-SO 2R a、-C(O)R a、-C(O)OR a、-C(O)NR aR b、-P(O)R aR b; Wherein, R L represents hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halogenated C 1 -C 6 alkyl, -OR a , cyano, nitro, NR a R b , -SO 2 R a , -C(O)R a , -C(O)OR a , -C(O)NR a R b , -P(O)R a R b ;其中,o表示0、1、2或3。Among them, o represents 0, 1, 2 or 3.
- 一种药物组合物,其包含权利要求1至3任一项所述的式(I)化合物或其药学上可接受的盐、前药、同位素衍生物、异构体、溶剂化物、或其代谢产物,以及任选的药学上可接受的载体。A pharmaceutical composition comprising the compound of formula (I) according to any one of claims 1 to 3 or a pharmaceutically acceptable salt, prodrug, isotope derivative, isomer, solvate, or metabolism thereof The product, and optionally a pharmaceutically acceptable carrier.
- 如权利要求4所述的药物组合物,其进一步包含另外的治疗剂和/或检查点抑制剂,所述另外的治疗剂优选地选自苯丁酸氮芥、美法仑、环磷酰胺、异环磷酰胺、白消安、卡莫司汀、洛莫司汀、链脲佐菌素、 顺铂、卡铂、奥沙利铂、达卡巴嗪、替莫唑胺、丙卡巴肼、甲氨蝶呤、氟尿嘧啶、阿糖胞苷、吉西他滨、巯基嘌呤、氟达拉滨、长春碱、长春新碱、长春瑞滨、紫杉醇、多西紫杉醇、拓扑替康、伊立替康、依托泊苷、曲贝替定、更生霉素、多柔比星、表柔比星、道诺霉素、米托蒽醌、博来霉素、丝裂霉素C、伊沙匹隆、他莫昔芬、氟他胺、戈那瑞林类似物、甲地孕酮、强的松、地塞米松、甲泼尼龙、沙利度胺、干扰素α、亚叶酸钙、西罗莫司、西罗莫司脂化物、依维莫司、阿法替尼、alisertib、amuvatinib、阿帕替尼、阿西替尼、硼替佐米、波舒替尼、布立尼布、卡博替尼、西地尼布、crenolanib、克卓替尼、达拉菲尼、达可替尼、达努塞替、达沙替尼、多维替尼、厄洛替尼、foretinib、ganetespib、吉非替尼、依鲁替尼、埃克替尼、伊马替尼、iniparib、拉帕替尼、lenvatinib、linifanib、linsitinib、马赛替尼、momelotinib、莫替沙尼、来那替尼、尼罗替尼、niraparib、oprozomib、olaparib、帕唑帕尼、pictilisib、普纳替尼、quizartinib、瑞格菲尼、rigosertib、rucaparib、鲁索利替尼、塞卡替尼、saridegib、索拉非尼、舒尼替尼、替拉替尼、tivantinib、替沃扎尼、托法替尼、曲美替尼、凡德他尼、维利帕尼、威罗菲尼、维莫德吉、volasertib、阿仑单抗、贝伐单抗、贝伦妥单抗维多汀、卡妥索单抗、西妥昔单抗、地诺单抗、吉妥珠单抗、伊匹单抗、尼妥珠单抗、奥法木单抗、帕尼单抗、利妥昔单抗、托西莫单抗、曲妥珠单抗;所述的检查点抑制剂优选地选自抗PD-1抗体、抗PD-L1抗体、LAG3抗体、TIM-3抗体及抗CTLA-4抗体。The pharmaceutical composition according to claim 4, further comprising an additional therapeutic agent and/or a checkpoint inhibitor, the additional therapeutic agent is preferably selected from the group consisting of chlorambucil, melphalan, cyclophosphamide, Ifosfamide, busulfan, carmustine, lomustine, streptozotocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate , Fluorouracil, Cytarabine, Gemcitabine, Mercaptopurine, Fludarabine, Vinblastine, Vincristine, Vinorelbine, Paclitaxel, Docetaxel, Topotecan, Irinotecan, Etoposide, Trabatin Dactin, dactinomycin, doxorubicin, epirubicin, daunomycin, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide , Gonarelin analogs, megestrol, prednisone, dexamethasone, methylprednisolone, thalidomide, interferon alpha, leucovorin, sirolimus, sirolimus, Everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brinib, cabotinib, cediranib, crenolanib, Crototinib, dabrafenib, dacomitinib, danusetin, dasatinib, dovetinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, ectinib Ni, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motisani, lenatinib, nilotinib, niraparib, oprozomib, olaparib, pazopa Ni, pictilisib, punatinib, quizartinib, rigorfinib, rigosertib, rucaparib, ruxolitinib, secatinib, saridegib, sorafenib, sunitinib, tilatinib, tivantinib, Tivozani, tofacitinib, trametinib, vandetanib, veripanib, veirofenib, vermodil, volasertib, alemtuzumab, bevacizumab, berento Monoclonal antibodies: Vidotin, Catuxomab, Cetuximab, Denosumab, Gemtuzumab, Ipilimumab, Nituzumab, Ofatumumab, Panitumumab , Rituximab, tositumomab, trastuzumab; the checkpoint inhibitor is preferably selected from anti-PD-1 antibody, anti-PD-L1 antibody, LAG3 antibody, TIM-3 antibody and Anti-CTLA-4 antibody.
- 如权利要求1-3任一项所述的式(I)化合物或其药学上可接受的盐、前药、同位素衍生物、异构体、溶剂化物、或其代谢产物或者如权利要求4-5任一项所述的药物组合物在制备用于通过抑制TGF-β受体来预防或治疗的肿瘤、癌症、病毒感染、器官移植排斥、神经退行性疾病、注意力缺陷相关疾病或自身免疫性疾病的药物中的用途,其中所述TGF-β受体优选选自TGFβRI(ALK5)受体。The compound of formula (I) according to any one of claims 1-3 or a pharmaceutically acceptable salt, prodrug, isotope derivative, isomer, solvate, or metabolite thereof, or a pharmaceutically acceptable salt, prodrug, isotope derivative, isomer, solvate, or metabolite thereof, or as claimed in claim 4- 5 The pharmaceutical composition described in any one is prepared for the prevention or treatment of tumors, cancers, viral infections, organ transplant rejections, neurodegenerative diseases, attention deficit related diseases or autoimmune diseases by inhibiting TGF-β receptors. For use in drugs for sexual diseases, wherein the TGF-β receptor is preferably selected from the TGFβRI (ALK5) receptor.
- 如权利要求6所述的用途,其中,所述肿瘤或癌症选自皮肤癌、膀胱癌、卵巢癌、乳腺癌、胃癌、胰腺癌、前列腺癌、结肠癌、肺癌、骨癌、脑癌、神经细胞瘤、直肠癌、结肠癌、家族性腺瘤性息肉性癌、遗传性非息肉性结直肠癌、食管癌、唇癌、喉癌、下咽癌、舌癌、唾 液腺癌、胃癌、腺癌、甲状腺髓样癌、乳头状甲状腺癌、肾癌、肾实质癌、卵巢癌、宫颈癌、子宫体癌、子宫内膜癌、绒毛膜癌、睾丸癌、泌尿癌、黑素瘤、脑肿瘤诸如成胶质细胞瘤、星形细胞瘤、脑膜瘤、成神经管细胞瘤和外周神经外胚层肿瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、伯基特淋巴瘤、急性淋巴性白血病(ALL)、慢性淋巴性白血病(CLL)、急性骨髓性白血病(AML)、慢性粒细胞白血病(CML)、成人T细胞白血病淋巴瘤、弥漫性大B细胞淋巴瘤(DLBCL)、肝细胞癌、胆囊癌、支气管癌、小细胞肺癌、非小细胞肺癌、多发性骨髓瘤、基底细胞瘤、畸胎瘤、成视网膜细胞瘤、脉络膜黑素瘤、精原细胞瘤、横纹肌肉瘤、颅咽管瘤、骨肉瘤、软骨肉瘤、肌肉瘤、脂肪肉瘤、纤维肉瘤、尤因肉瘤和浆细胞瘤。The use according to claim 6, wherein the tumor or cancer is selected from skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, pancreatic cancer, prostate cancer, colon cancer, lung cancer, bone cancer, brain cancer, nerve Cell tumor, rectal cancer, colon cancer, familial adenomatous polyposis cancer, hereditary non-polyposis colorectal cancer, esophagus cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, stomach cancer, adenocarcinoma, Medullary thyroid cancer, papillary thyroid cancer, kidney cancer, renal parenchymal cancer, ovarian cancer, cervical cancer, uterine body cancer, endometrial cancer, choriocarcinoma, testicular cancer, urinary cancer, melanoma, brain tumors such as adult Glioma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, acute lymphatic leukemia (ALL ), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, gallbladder cancer , Bronchial carcinoma, small cell lung cancer, non-small cell lung cancer, multiple myeloma, basal cell tumor, teratoma, retinoblastoma, choroidal melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma Tumor, chondrosarcoma, sarcoma, liposarcoma, fibrosarcoma, Ewing's sarcoma and plasmacytoma.
- 一种预防或治疗肿瘤、癌症、病毒感染、器官移植排斥、神经退行性疾病、注意力缺陷相关疾病或自身免疫性疾病的方法,其包括向有此需要的哺乳动物施用权利要求1-3任一项所述的化合物或其药学上可接受的盐、前药、同位素衍生物、异构体、溶剂化物、或其代谢产物或者权利要求4或5所述的药物组合物。A method for preventing or treating tumors, cancers, viral infections, organ transplant rejection, neurodegenerative diseases, attention deficit-related diseases or autoimmune diseases, which comprises administering any of claims 1 to 3 to mammals in need thereof One of the compound or a pharmaceutically acceptable salt, prodrug, isotope derivative, isomer, solvate, or metabolite thereof, or the pharmaceutical composition of claim 4 or 5.
- 一种抑制TGF-β受体活性的方法,其包括使TGF-β受体暴露于如权利要求1-3任一项所述的式(I)化合物或其药学上可接受的盐、前药、同位素衍生物、异构体、溶剂化物、或其代谢产物,其中所述TGF-β受体优选选自TGFβRI(ALK5)受体。A method for inhibiting the activity of TGF-β receptor, which comprises exposing TGF-β receptor to the compound of formula (I) according to any one of claims 1 to 3 or a pharmaceutically acceptable salt or prodrug thereof , Isotope derivatives, isomers, solvates, or metabolites thereof, wherein the TGF-β receptor is preferably selected from the TGFβRI (ALK5) receptor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010212752 | 2020-03-24 | ||
CN202010212752.X | 2020-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021190425A1 true WO2021190425A1 (en) | 2021-09-30 |
Family
ID=77891775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/081965 WO2021190425A1 (en) | 2020-03-24 | 2021-03-22 | TRANSFORMING GROWTH FACTOR-β RECEPTOR INHIBITOR |
Country Status (2)
Country | Link |
---|---|
TW (1) | TWI768781B (en) |
WO (1) | WO2021190425A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114853754B (en) * | 2022-05-23 | 2023-04-18 | 云白药征武科技(上海)有限公司 | Thioamide derivative and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017215506A1 (en) * | 2016-06-13 | 2017-12-21 | 南京明德新药研发股份有限公司 | Benzotriazole-derived α and β unsaturated amide compound used as tgf-βr1 inhibitor |
WO2018017633A1 (en) * | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
CN107663206A (en) * | 2016-07-29 | 2018-02-06 | 上海璎黎药业有限公司 | Nitrogenous heteroaromatic compound, its preparation method, pharmaceutical composition and application |
CN110066277A (en) * | 2018-01-24 | 2019-07-30 | 上海璎黎药业有限公司 | Aromatic heterocycle substituted olefine compound, preparation method, pharmaceutical composition and application |
-
2021
- 2021-03-22 TW TW110110282A patent/TWI768781B/en not_active IP Right Cessation
- 2021-03-22 WO PCT/CN2021/081965 patent/WO2021190425A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017215506A1 (en) * | 2016-06-13 | 2017-12-21 | 南京明德新药研发股份有限公司 | Benzotriazole-derived α and β unsaturated amide compound used as tgf-βr1 inhibitor |
WO2018017633A1 (en) * | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
CN107663206A (en) * | 2016-07-29 | 2018-02-06 | 上海璎黎药业有限公司 | Nitrogenous heteroaromatic compound, its preparation method, pharmaceutical composition and application |
CN110066277A (en) * | 2018-01-24 | 2019-07-30 | 上海璎黎药业有限公司 | Aromatic heterocycle substituted olefine compound, preparation method, pharmaceutical composition and application |
Non-Patent Citations (2)
Title |
---|
LI XINGZHOU, LIU FENG, LI SONG: "Research Progress on Transforming Growth Factor β Signal and its Signal Pathway Blockers", FOREIGN MEDICAL SCIENCES SECTION OF PHARMACY, MILITARY MEDICAL SCIENCES, INSTITUT FÜR PHARMAKOLOGIE UND TOXIKOLOGIE, CN, vol. 33, no. 5, 31 October 2006 (2006-10-31), CN, pages 331 - 335, XP055853037, ISSN: 1001-0971, DOI: 10.13220/j.cnki.jipr.2006.05.005 * |
SUN LI-QIAN, MENG LI-QIANG, YAN CHAO-QUN, CUI DONG-XIAO, MIAO JUN-QIU, CHEN JING-RUN, LIANG TAI-GANG, LI QING-SHAN: "3D-QSAR Studies on 4-([1,2,4]Triazolo[1,5-α] pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole Analogues as Potent Inhibitors of Transforming Growth Factor-β Type Ⅰ Receptor Kinase", JIEGOU HUAXUE - CHINESE JOURNAL OF STRUCTURAL CHEMISTRY, ZHONGGUO KEXUEYUAN FUJIAN WUZHI JIEGOU YANJIUSUO, CN, vol. 37, no. 4, 15 April 2018 (2018-04-15), CN, pages 517 - 530, XP055853038, ISSN: 0254-5861, DOI: 10.14102/j.cnki.0254-5861.2011-1766 * |
Also Published As
Publication number | Publication date |
---|---|
TWI768781B (en) | 2022-06-21 |
TW202144347A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019158070A1 (en) | A2a and/or a2b receptor antagonist | |
CN111548343B (en) | Preparation method of high-activity CSF1R inhibitor compound | |
CN110914277B (en) | Imidazo [1,2-b ] pyrimido [4,5-d ] pyridazin-5 (6H) -one compounds and application thereof | |
KR20150090044A (en) | Azaquinazoline carboxamide derivatives | |
JP2024513538A (en) | Substituted fused bicyclic compounds and their use as PARP inhibitors | |
WO2022089398A1 (en) | High activity hpk1 kinase inhibitor | |
CN112028891B (en) | Adenosine receptor antagonists | |
CN112313220B (en) | PD-L1 antagonist compounds | |
WO2021190425A1 (en) | TRANSFORMING GROWTH FACTOR-β RECEPTOR INHIBITOR | |
WO2021129584A1 (en) | Pd-l1 antagonist compound | |
CN112592354B (en) | Preparation method of isoxazolo-pyrimidine heterocyclic compound | |
CN111440148B (en) | Preparation method of adenosine receptor antagonist | |
JP2018536692A (en) | Novel dihydropyranopyrimidinone derivatives and uses thereof {Novel dihydropyranopyrimidinone derivatives, and use thereof} | |
LU505117B1 (en) | A pan-KRAS inhibitor compound | |
WO2023025225A1 (en) | Cyclin k degradation agent | |
WO2024022365A1 (en) | Wnt pathway inhibitor compound | |
WO2022199561A1 (en) | Hpk1 kinase inhibitor compound | |
WO2022214008A1 (en) | Highly active hpk1 kinase inhibitor | |
WO2023143546A1 (en) | Wnt pathway inhibitor compounds | |
BR112018009880B1 (en) | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS MODULATING CHEMOKIN RECEPTORS AND THEIR USES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21775613 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21775613 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06/07/2023) |